FORM 10-Q Quarterly Report

0001078782-14-001938.txt : 20141106 0001078782-14-001938.hdr.sgml : 20141106 20141106133152 ACCESSION NUMBER: 0001078782-14-001938 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20140930 FILED AS OF DATE: 20141106 DATE AS OF CHANGE: 20141106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VOLITIONRX LTD CENTRAL INDEX KEY: 0000093314 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 911949078 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-30402 FILM NUMBER: 141199905 BUSINESS ADDRESS: STREET 1: 150 ORCHARD ROAD CITY: ORCHARD PLAZA 08-02 STATE: U0 ZIP: 238841 BUSINESS PHONE: 000-000-0000 MAIL ADDRESS: STREET 1: 150 ORCHARD ROAD CITY: ORCHARD PLAZA 08-02 STATE: U0 ZIP: 238841 FORMER COMPANY: FORMER CONFORMED NAME: STANDARD CAPITAL CORP DATE OF NAME CHANGE: 19990812 10-Q 1 f10q093014_10q.htm FORM 10-Q QUARTERLY REPORT FORM 10-Q Quarterly Report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

X .QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

.TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from __________ to __________

Commission File Number: 000-30402

VOLITIONRX LIMITED

[f10q093014_10q001.jpg]

(Exact name of registrant as specified in its charter)


Delaware		91-1949078
(State of incorporation)		(I.R.S. Employer Identification No.)

1 Scotts Road

#24-05 Shaw Centre

Singapore 228208

(Address of principal executive offices)

Telephone: (212) 618-1750

Facsimile: +65 6333 7235

(Registrant’s Telephone and Facsimile Number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X . No .

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes X . No . (Not required)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer	.	Accelerated filer	.
Non-accelerated filer	. (Do not check if a smaller reporting company)	Smaller reporting company	X .

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes . No X .

As of November 6, 2014, there were 14,450,717 shares of the registrant’s $0.001 par value common stock issued and outstanding.

VOLITIONRX LIMITED *

TABLE OF CONTENTS


		PAGE
PART I - FINANCIAL INFORMATION

ITEM 1.	FINANCIAL STATEMENTS	3

ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	14

ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	17

ITEM 4.	CONTROLS AND PROCEDURES	18

PART II - OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS	18

ITEM 1A.	RISK FACTORS	18

ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	18

ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	20

ITEM 4.	MINE SAFETY DISCLOSURES	20

ITEM 5.	OTHER INFORMATION	20

ITEM 6.	EXHIBITS	20

Special Note Regarding Forward-Looking Statements

Information included in this Form 10-Q contains forward-looking statements. This information may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of VolitionRX Limited (the “Company”), to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe future plans, strategies and expectations of the Company, are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. These forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that these projections included in these forward-looking statements will come to pass. Actual results of the Company could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, the Company has no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

*Please note that throughout this Quarterly Report, and unless otherwise noted, the words "we," "our," "us," the "Company," or "VNRX" refers to VolitionRX Limited.

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS


		Index
Condensed Consolidated Balance Sheets		4

Condensed Consolidated Statements of Operations and Comprehensive Loss		5

Condensed Consolidated Statements of Cash Flows		6

Condensed Consolidated Notes to the Financial Statements		7

VOLITIONRX LIMITED

(A Development Stage Company)

Condensed Consolidated Balance Sheets

(Expressed in US dollars)


	September 30, 2014	December 31, 2013
	$	$
	(unaudited)
ASSETS
Cash	2,419,667	888,704
Prepaid expenses	133,848	82,135
Other current assets	117,409	34,612

Total Current Assets	2,670,924	1,005,451

Property and equipment, net	315,777	63,265
Intangible assets, net	862,753	1,002,043

Total Assets	3,849,454	2,070,759

LIABILITIES
Accounts payable and accrued liabilities	693,646	518,086
Management and directors’ fees payable	240,978	222,294
Derivative liability	6,446,068	–
Deferred grant income	199,862	216,894

Total Current Liabilities	7,580,554	957,274

Grant repayable	367,112	432,811

Total Liabilities	7,947,666	1,390,085

STOCKHOLDERS’ (DEFICIT) EQUITY
Preferred Stock
Authorized: 1,000,000 shares of preferred stock, at $0.001 par value
Issued and outstanding: Nil shares and Nil shares, respectively	–	–
Common Stock
Authorized: 100,000,000 shares of common stock, at $0.001 par value
Issued and outstanding: 14,308,960 shares and 11,679,757 shares, respectively	14,309	11,680
Additional paid-in capital	14,548,494	12,024,711
Accumulated other comprehensive loss	(93,526)	(59,795)
Accumulated Deficit	(18,567,489)	(11,295,922)

Total Stockholders’ (Deficit) Equity	(4,098,212)	680,674

Total Liabilities and Stockholders’ (Deficit) Equity	3,849,454	2,070,759

(The accompanying notes are an integral part of these condensed consolidated financial statements)

VOLITIONRX LIMITED

(A Development Stage Company)

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Expressed in US dollars)

(unaudited)


	For the three months ended September 30, 2014	For the three months ended September 30, 2013	For the nine months ended September 30, 2014	For the nine months ended September 30, 2013
	$	$	$	$
Revenue	14,785	–	14,785	–

Expenses
General and administrative	129,318	67,961	249,986	242,660
Professional fees	119,510	153,226	412,532	310,585
Salaries and office administrative fees	457,355	179,846	670,518	569,238
Research and development	1,071,984	524,534	2,733,742	1,758,372

Total Operating Expenses	1,778,167	925,567	4,066,778	2,880,855

Net Operating Loss	(1,763,382)	(925,567)	(4,051,993)	(2,880,855)

Other Income/(Expenses)
Grants received	–	–	143,987	–
Loss on derivative remeasurement	(4,130,562)	–	(3,363,561)	–

Net Other Expenses	(4,130,562)	–	(3,219,574)	–

Provision for income taxes	–	–	–	–

Net Loss	(5,893,944)	(925,567)	(7,271,567)	(2,880,855)

Other Comprehensive Loss
Foreign currency translation adjustments	(19,893)	(6,478)	(33,731)	(18,336)

Total Other Comprehensive Loss	(19,893)	(6,478)	(33,731)	(18,336)

Net Comprehensive Loss	(5,913,837)	(932,045)	(7,305,298)	(2,899,191)

Net Loss per Share – Basic and Diluted	(0.44)	(0.08)	(0.56)	(0.27)

Weighted Average Shares Outstanding – Basic and Diluted	13,524,998	11,086,237	13,057,866	10,649,152

(The accompanying notes are an integral part of these condensed consolidated financial statements)

VOLITIONRX LIMITED

(A Development Stage Company)

Condensed Consolidated Statements of Cash Flows

(Expressed in US dollars)

(unaudited)


	For the nine months ended September 30,	For the nine months ended September 30,
	2014	2013
	$	$
Operating Activities
Net loss	(7,271,567)	(2,880,855)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	99,904	109,044
Stock based compensation	311,907	236,966
Common stock and warrants issued to settle liabilities for services	403,483	348,172
Amortization of stock issued in advance of services	–	52,500
Non-operating income – grants received	(143,987)	–
Loss on derivative re-measurement	3,363,561	–

Changes in operating assets and liabilities:
Prepaid expenses	(61,483)	(81,965)
Other current assets	(88,422)	7,292
Accounts payable and accrued liabilities	238,446	(166,093)

Net Cash Used In Operating Activities	(3,148,158)	(2,374,939)

Investing Activities
Purchases of property and equipment	(297,607)	(713)

Net Cash Used in Investing Activities	(297,607)	(713)

Financing Activities
Proceeds from issuance of common shares	4,893,529	1,871,500
Grants received	143,987	605,154
Grants repaid	(33,166)	–
Repayment of notes payable	–	(1,321)

Net Cash Provided By Financing Activities	5,004,350	2,475,333

Effect of foreign exchange on cash	(27,622)	(2,627)

Increase in Cash	1,530,963	97,054

Cash – Beginning of Period	888,704	376,421

Cash – End of Period	2,419,667	473,475

Supplemental Disclosures of Cash Flow Information
Interest paid	10,274	–
Income tax paid	–	–

Non Cash Financing Activities::
Common stock issued for debt	–	77,333

(The accompanying notes are an integral part of these condensed consolidated financial statements)

VOLITIONRX LIMITED

(A Development Stage Company)

Notes to the Condensed Consolidated Financial Statements

September 30, 2014 and December 31, 2013

(Unaudited)

Note 1 - Condensed Financial Statements

The accompanying unaudited financial statements have been prepared by VolitionRX Limited (the “Company”) without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2014, and for all periods presented herein, have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed unaudited financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2013 audited financial statements. The results of operations for the periods ended September 30, 2014 and 2013 are not necessarily indicative of the operating results for the full years.

Note 2 - Going Concern

The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred losses since inception of $18,661,015 and currently has very limited revenues, which creates substantial doubt about its ability to continue as a going concern.

The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions and/or financing as may be required to sustain its operations. Management's plan to address this need includes, (a) continued exercise of tight cost controls to conserve cash, (b) receiving additional grant funds, and (c) obtaining additional financing through debt or equity financing.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

Note 3 - Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with US generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

Principles of Consolidation

The accompanying condensed consolidated financial statements for the period ended September 30, 2014 include the accounts of the Company and its wholly-owned subsidiaries, Singapore Volition Pte Ltd, Belgian Volition SA, and Hypergenomics Pte. Ltd. All significant intercompany balances and transactions have been eliminated in consolidation.

Note 3 - Summary of Significant Accounting Policies (continued)

Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As at September 30, 2014 and December 31, 2013, the Company had $2,419,667 and $888,704, respectively in cash and cash equivalents.

Basic and Diluted Net Loss Per Share

The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. For the three months ended September 30, 2014, 543,275 dilutive warrants and 2,357,275 potentially dilutive warrants and options were excluded from the Diluted EPS calculation as their effect is anti dilutive. For the nine months ended September 30, 2014, 592,204 dilutive warrants and 2,112,995 potentially dilutive warrants and options were excluded from the Diluted EPS calculation as their effect is anti dilutive.

Foreign Currency Translation

The Company’s functional currency is the Euro and its reporting currency is the United States dollar. Management has adopted ASC 830-20, “Foreign Currency Matters – Foreign Currency Transactions”. All assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. For revenues and expenses, the weighted average exchange rate for the period is used. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in other comprehensive loss.

Recent Accounting Pronouncements

Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s consolidated financial statements.

The Company has limited operations and is considered to be in the development stage. In the quarterly period ended September 30, 2014, the Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the Company to remove the inception to date information and all references to the development stage.

Note 4 - Intangible Assets

The Company’s intangible assets consist of intellectual property, principally patents, acquired in the acquisition of ValiBio SA. The patents are being amortized over their remaining lives, which are 9 years and 17 years.


			December 31,
			2013
		Accumulated	Net Carrying
	Cost	Amortization	Value
	$	$	$

Patents	1,314,559	312,516	1,002,043

	1,314,559	312,516	1,002,043

Note 4 - Intangible Assets (continued)


			September 30,
			2014
		Accumulated	Net Carrying
	Cost	Amortization	Value
	$	$	$

Patents	1,219,969	357,216	862,753

	1,219,969	357,216	862,753

During the nine month period ended September 30, 2014, and the year ended December 31, 2013, the Company recognized $72,646 and $114,879 in amortization expense respectively. During the year ended December 31, 2013 the Company also recognized impairment losses of $350,000. No impairment losses were recognized during the nine month period ended September 30, 2014.

The Company amortizes the long-lived assets on a straight line basis with terms ranging from 13 to 20 years. The annual estimated amortization schedule over the next five years is as follows:


2014 - remaining	$	22,721
2015	$	90,882
2016	$	90,882
2017	$	90,882
2018	$	90,882

The Company periodically reviews its long lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 as of December 31, 2013. The result of this review confirmed that the fair value of the patents exceeded their carrying value as of December 31, 2013.

Note 5 - Related Party Transactions

The Company contracts with a related party to rent office space, be provided with office support staff, and have consultancy services provided on behalf of the Company. See Note 8 for obligation under the contract.

Note 6 - Common Stock

On February 26, 2014, the Company issued 1,500,000 shares of common stock for a total of $3,000,000 at a price of $2.00 per share. Attached to these share issuances were 1,500,000 warrants, immediately exercisable for a period of five years at $2.20 per share. The warrants were valued at $3,955,546 using the Black-Scholes Option Pricing model using the following assumptions: Five year term, $2.68 stock price, $2.20 exercise price, 239% volatility, 1.50% risk free rate. Agents received 30,975 warrants, exercisable on the same terms as the warrants issued for cash subscriptions, and valued at $82,507 on the same basis as above. Due to a ratchet provision in the warrant agreement effective for the twelve months to February 26, 2015, all the foregoing warrants have been treated as a derivative liability in accordance with ASC 815. Other fees and expenses directly attributable to agents in respect of these issuances were $147,186 in cash, and $25,900 settled by the issue of shares of common stock. Legal expenses directly attributable to the issuances amounted to $84,879.

On February 26, 2014, the Company issued 16,667 shares of common stock to settle liabilities for services valued at $35,000, at a price of $2.10 per share.

On March 25, 2014, the Company issued 12,334 shares of common stock to settle liabilities for services valued at $25,900, at a price of $2.10 per share.

On March 26, 2014, the Company issued 99,178 shares of common stock to the subscribers for the 297,500 shares of common stock issued on June 10, 2013. These additional shares were issued for no additional consideration under the terms of the Private Placement Memorandum because certain subsequent fundraising targets had not been met.

Note 6 - Common Stock (continued)

On June 5, 2014, the Company issued 160,228 shares of common stock for cash of $352,500, at a price of $2.20 per share.

On September 24, 2014, the Company issued 21,250 shares of common stock at a price of $2.20 per share to settle liabilities for services valued at $46,748. In addition, on that date, the Company issued 492,316 shares of common stock at a price of $2.20 for cash of $1,083,094 and 27,230 shares of common stock at a price of $2.20 to an agent in settlement of their debt of $59,906.

On September 26, 2014, the Company issued 300,000 shares of common stock at a price of $2.50 per share for cash of $688,970. The amount received was the net proceeds, after fees of $60,000 had been paid to an agent and $1,030 paid in other fees and bank charges.

In addition, on that date, the Company issued 24,000 warrants to the same agent, immediately exercisable over a period of three years at $3 per share. The warrants were valued at $103,223 using the Black-Scholes Option Pricing model using the following assumptions: Three year term, $4.45 stock price, $3 exercise price, 235% volatility, 1.08% risk free rate.

Note 7 - Warrants and Options

Warrants

On January 28, 2014, the Company issued 10,000 warrants to a consultant for services at an exercise price of $2.40, exercisable immediately for three years. The warrants were valued at $21,500 using the Black-Scholes Option Pricing model using the following assumptions: Three-year term, $2.26 stock price, $2.40 exercise price, 229% volatility, 0.75% risk free rate.

On February 26, 2014, the Company issued 1,500,000 warrants attached to the issue of 1,500,000 shares for cash totaling $3,000,000. The Company has valued these warrants at $3,995,546 and treated this amount as a derivative liability, in accordance with ASC 815. The warrants are exercisable immediately for five years at an exercise price of $2.20.

On February 26, 2014, the Company issued 30,975 warrants to agents as part remuneration in respect of the issuance of 1,500,000 shares for cash totaling $3,000,000. The warrants were valued at $82,507 using the Black-Scholes Option Pricing model using the following assumptions: Five-year term, $2.68 stock price, $2.20 exercise price, 241% volatility, 1.5% risk free rate. The Company has treated this amount as a derivative liability, in accordance with ASC 815. Each warrant is exercisable immediately for five years at an exercise price of $2.20 per share.

On September 5, 2014, the Company issued 10,000 warrants to a consultant for services. These warrants were valued at $20,092 using the Black-Scholes Option Pricing model using the following assumptions: Three year term, $2.10 stock price, $2.40 exercise price, 236% volatility, 0.99% risk free rate. Each warrant is exercisable immediately for three years at an exercise price of $2.40 per share.

On September 26, 2014, the Company issued 24,000 warrants to an agent as part remuneration in respect of the issuance of 300,000 shares for net proceeds of $688,970. These warrants were valued at $103,223 using the Black-Scholes Option Pricing model using the following assumptions: Three year term, $4.45 stock price, $3 exercise price, 235% volatility, 1.08% risk free rate. Each warrant is exercisable immediately for three years at an exercise price of $3 per share.

All of the 1,530,975 warrants issued on February 26, 2014, have been treated as a derivative liability, in accordance with ASC 815, owing to a ratchet provision in the warrant agreement being effective for the twelve months to February 26, 2015. The derivative liability was measured at $4,078,054 as at February 26, 2014. It was re-measured as of March 31, 2014, and revalued at $4,182,748. The derivative liability was further re-measured as of June 30, 2014, and revalued at $2,315,506, resulting in a gain of $1,867,241 for the three months ended June 30, 2014. At September 30, 2014, the derivative liability was re-measured and revalued at $6,446,068, resulting in a loss of $4,130,562 for the three months ended September 30, 2014.

Note 7 - Warrants and Options (continued)

Below is a table summarizing the warrants issued and outstanding as of September 30, 2014.


Date	Number	Exercise	Contractual	Expiration	Value if
Issued	Outstanding	Price $	Life (Years)	Date	Exercised $
03/15/11	200,000	0.50	5	3/15/2016	100,000
03/24/11	100,000	0.50	5	3/24/2016	50,000
04/01/11	100,000	0.50	5	4/1/2016	50,000
06/21/11	100,000	0.50	5	6/21/2016	50,000
07/13/11	250,000	1.05	5	07/13/16	262,500
05/11/12	344,059	2.60	4	05/10/16	894,553
05/11/12	26,685	1.75	3	05/10/15	46,699
03/20/13	200,000	2.47	3	03/20/16	494,000
				-12/20/19
06/10/13	29,750	2.00	5.5	12/10/18	59,500
08/07/13	45,000	2.40	3	08/07/16	108,000
11/25/13	456,063	2.40	5	11/25/18	1,094,551
12/31/13	64,392	2.40	5	12/31/18	154,541
01/28/14	10,000	2.40	3	01/28/17	24,000
02/26/14	1,530,975	2.20	5	02/26/19	3,368,145
09/05/14	10,000	2.40	3	09/05/17	24,000
09/26/14	24,000	3.00	3	09/26/17	72,000
09/30/14	3,490,924	1.96	4.7	–	6,852,489

Options

On November 17, 2011, the Company adopted and approved the 2011 Equity Incentive Plan for the directors, officers, employees and key consultants of the Company. Pursuant to the Plan, the Company was authorized to issue 900,000 restricted shares, $0.001 par value, of the Company’s common stock.

Options to purchase 25,000 shares were granted on May 16, 2014. These options vest in equal six monthly installments over three years from the date of grant, and expire three years after the vesting dates. The exercise prices are $3.00 for options vesting in the first year, $4.00 for options vesting in the second year, and $5.00 for options vesting in the third year. The Company has calculated the estimated fair market value of these options using the Black-Scholes Option Pricing model and the following assumptions: term 3 to 5.5 years, stock price $2.01, exercise prices $3.00-$5.00, 235% volatility, 0.80% risk free rate.

On August 5, 2014, it was approved at the Company’s Annual General Meeting to increase the number of restricted shares that the Company is authorized to issue under the 2011 Equity Incentive Plan to 2,000,000.

On August 18, 2014, The Company granted options to purchase 670,000 shares. These options vest in two equal tranches, the first tranche vests on February 18, 2015. The second tranche vests on February 18, 2016. All the options expire four years after their vesting dates. The exercise prices are $2.50 for options vesting in the first year and $3.00 for options vesting in the second year. The Company has calculated the estimated fair market value of these options using the Black-Scholes Option Pricing model and the following assumptions: term 4.5 to 5.5 years, stock price $1.85, exercise prices $2.50-$3.00, 237% volatility, 1.58% risk free rate.

On August 18, 2014, The Company granted options to purchase 60,000 shares. These options vest in six equal monthly installments over three years, starting six months after the date of grant, and expire three years after the vesting dates. The exercise prices are $3.00 for options vesting in the first year, $4.00 for options vesting in the second year, and $5.00 for options vesting in the third year. The Company has calculated the estimated fair market value of these options using the Black-Scholes Option Pricing model and the following assumptions: term 3.5 to 6 years, stock price $1.85, exercise prices $3.00-$5.00, 237% volatility, 0.89% risk free rate.

During the nine month period ended September 30, 2014, 10,000 options expired following the cessation of a consultant’s contract.

Note 7 - Warrants and Options (continued)

Below is a table summarizing the options issued and outstanding as of September 30, 2014.


Date	Number	Exercise	Contractual		Value if
Issued	Outstanding	Price $	Life (Years)	Expiration Date	Exercised $
11/25/11	680,000	3.00-5.00	3	05/25/15-11/25/17	2,710,000
09/01/12	30,000	4.31-6.31	3	03/01/16-09/01/18	159,300
12/13/12	100,000	3.01	3	12/13/15	301,000
03/20/13	37,000	2.35-4.35	3	09/20/16-03/20/19	123,950
09/02/13	16,300	2.35-4.35	3	03/02/14-09/02/16	54,605
05/16/14	25,000	3.00-5.00	3-5.5	11/16/17-05/16/20	100,000
08/18/14	670,000	2.50-3.00	4.5-5.5	02/18/19-02/18/20	1,842,500
08/18/14	60,000	3.00-5.00	3.5-6.0	02/18/18-08/18/20	240,000
09/30/14	1,618,300	3.89	3	–	5,531,355

Total remaining unrecognized compensation cost related to non-vested stock options is approximately $1,209,924 and is expected to be recognized over a period of three years.

Note 8 - Commitments and Contingencies

Walloon Region Grant

On March 16, 2010, the Company entered into an agreement with the Walloon Region government in Belgium wherein the Walloon Region would fund up to a maximum of $1,329,413 (€1,048,020) to help fund the research endeavors of the Company in the area of colorectal cancer. The Company had received the entirety of these funds in respect of approved expenditures as of March 31, 2014. Under the terms of the agreement, the Company is due to repay $398,824 (€314,406) of this amount by installments over the period June 30, 2014 to June 30, 2023. The Company has recorded the balance of $1,009,610 (€733,614) to other income as there is no obligation to repay this amount. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 6 percent royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of $398,824 (€314,406) and the 6 percent royalty on revenue, is twice the amount of funding received.

Administrative Support Agreement

On August 6, 2010, the Company entered into an agreement with a related party to rent office space, contract for office support staff, and have consulting services provided on behalf of the Company. The agreement requires the Company to pay $6,270 per month for office space and staff services as well as approximately $16.000 per month in fees for two senior executives. The Company is also required to pay for all reasonable expenses incurred. The contract is in force for 12 months with automatic extensions of 12 months with a 3 month notice required for termination of the contract.

Leases

The Company leases premises and facilities under operating leases with terms ranging from 12 months to 24 months. The annual non-cancelable operating lease payments on these leases are as follows:


2014	$	84,251
2015	$	2,458
Thereafter		Nil

Bonn University Agreement

On July 11, 2012, the Company entered into an agreement with Bonn University, Germany, relating to a program of samples testing. The agreement was for a period of two years from June 1, 2012 to May 31, 2014. The total payments made by the Company in accordance with the agreement were $494,715 (€390,000). On April 16, 2014, the Company entered into an extension of this agreement, for a period of a further two years from June 1, 2014 to May 31, 2016. The total payments to be made by the Company in accordance with the extension of the agreement are $494,715 (€390,000).

Note 8 - Commitments and Contingencies (continued)

Hvidovre Hospital, Denmark Agreement

On August 8, 2014, Belgium Volition SA entered into an agreement with Hvidovre Hospital, University of Copenhagen in Denmark, relating to a program of samples testing associated with colorectal cancer. It will run for a period of two years to August 8, 2016. Total payments (inclusive of local taxes) to be made under the agreement are $1,745,920 (DKR 10,245,000).

Legal Proceedings

There are no legal proceedings which the Company believes will have a material adverse effect on its financial position.

Note 9 - Subsequent Events

Common Stock

On October 3, 2014, 50,000 warrants were exercised for total proceeds of $123,500. As a result, an aggregate total of 50,000 shares of common stock were issued.

On October 9, 2014, the Company issued 91,757 shares of common stock for a total of $229,393

Warrants

On October 31, 2014, the Company amended the terms of 1,121,225 warrants of the 1,530,975 that had been issued on February 26, 2014 (See note 6). The aforementioned warrants had a ratchet provision effective until February 26, 2015 and have been treated as a derivative liability. As a result of the amendment, the ratchet provision is now effective until October 31, 2014.

END NOTES TO FINANCIALS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF PLAN OF OPERATION

This Management’s Discussion and Analysis of Plan of Operation contains forward-looking statements. These forward-looking statements are not historical facts but rather are based on current expectations, estimates and projections. We may use words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “foresee,” “estimate” and variations of these words and similar expressions to identify forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted. You should read this report completely and with the understanding that actual future results may be materially different from what we expect. The forward-looking statements included in this report are made as of the date of this report and should be evaluated with consideration of any changes occurring after the date of this Report. We will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Liquidity and Capital Resources

As of September 30, 2014, the Company had cash of $2,419,667, other current assets and prepayments of $251,257, and current liabilities of $7,580,554. This represents a working capital deficit of $4,909,630. Current liabilities include an amount of $6,446,068 in respect of a derivative liability. After excluding this liability there is an operating working capital surplus of $1,536,438.

We intend to use our cash reserves to fund further research and development activities. We do not currently have any substantial source of revenues and expect to rely on additional financing. We are pursuing plans to seek further capital through the sale of additional stock by way of private placement, but there is no assurance that we will be successful in raising further funds.

In the event that additional financing is delayed, the Company will prioritize the maintenance of its research and development personnel and facilities, primarily in Belgium, and the maintenance of its patent rights. However the completion of clinical validation studies and regulatory approval processes for the purpose of bringing products to the IVD market would be delayed. In the event of an ongoing lack of financing, we may be obliged to discontinue operations, which will adversely affect the value of our common stock.

Overview of Operations

Management has identified the specific processes and resources required to achieve the near and medium term objectives of the business plan, including personnel, facilities, equipment, research and testing materials including antibodies and clinical samples, and the protection of intellectual property. To date, operations have proceeded satisfactorily in relation to the business plan. However it is possible that some resources will not readily become available in a suitable form or on a timely basis or at an acceptable cost. It is also possible that the results of some processes may not be as expected and that modifications of procedures and materials may be required. Such events could result in delays to the achievement of the near and medium term objectives of the business plan, in particular the progression of clinical validation studies and regulatory approval processes for the purpose of bringing products to the IVD market. However, at this point, the most significant risk to the Company is that it will not succeed in obtaining additional financing in the medium term.

On October 31, 2014, the Company amended the terms of 1,121,225 warrants of the 1,530,975 that had been issued on February 26, 2014 (See note 6 to The Financial Statements.) The aforementioned warrants had a ratchet provision effective until February 26, 2015 and have been treated as a derivative liability. As a result of the amendment, the ratchet provision is now effective until October 31, 2014. If the ratchet provision had been changed in these warrants to give an effective date prior to September 30, 2014, then the derivative liability in the balance sheet would have been $1,725,226, as opposed to $6,446,068 disclosed on the balance sheet as at September 30, 2014 (See note 7a to The Financial Statements.)

Results of Operations

Three Months Ended September 30, 2014

The following table sets forth the Company’s results of operations for the three months ended September 30, 2014 and the comparative period for the three months ended September 30, 2013.


	Three Months	Three Months
	Ended	Ended		Percentage
	September 30, 2014	September 30, 2013	Increase/ Decrease	Increase/ Decrease
	($)	($)	($)	(%)
Revenues	14,785	−	14,785	−

Operating Expenses	(1,778,167)	(925,567)	(852,600)	92.1%
Net Other Expense	(4,130,562)	−	(4,130,562)	−
Income Taxes	−	−	−	−

Net Loss	(5,893,944)	(925,567)	(4,968,377)	536.8%

Basic and Diluted Loss Per Share	(0.44)	(0.08)	(0.36)	450.0%

Weighted Average Basic and Diluted Shares Outstanding	13,524,998	11,086,237	2,438,761	22.0%

Revenues

The Company had revenues of $14,785 from operations in the three months ended September 30, 2014, and no revenues from operations in the comparative period for the three months ended September 30, 2013. The Company’s operations are still predominantly in the development stage.

Operating Expenses

For the three months ended September 30, 2014, the Company’s operating expenses increased by $852,600, or 92.1%. Operating expenses are comprised of salaries and office administrative fees, research and development expenses, professional fees, and other general and administrative expenses. Salaries and office administrative fees increased by $277,509, due principally to an increase in costs on a warrants revaluation of $155,654. In addition, there was an extra $78,548 of costs generated from the amortization of share options, following additional share options being granted in August 2014. Research and development expenses increased by $547,450. This is mainly explained by additional costs of $90,219 for the purchases of antibodies and samples, and $213,367 in staff and consultancy costs. $151,914 was also spent on a new Danish Study in 2014, and an additional $65,214 on share option amortization for staff in R&D. These increases all reflect a higher level of research and development activity. Professional fees decreased by $33,716, due principally to decreases in fees for public relations and investor relations services, as services were rationalized. General and administrative expenses increased by $61,357. This increase is in part explained by an increase in fundraising services costs of $35,906, associated with fees paid to placement agents and a $17,321 increase in travel, subsistence and conference costs.

Net Other Expenses

For the three months ended September 30, 2014, the Company recorded other expenses of $4,130,562 in relation to the revaluation of a derivative liability resulting from the issue of 1,500,000 warrants attached to the issuance of 1,500,000 shares, together with 30,975 warrants issued to agents.

Net Loss

For the three months ended September 30, 2014, the Company recorded a net loss of $5,893,944, a negative change of $4,968,377 or 536.8% in relation to the comparative period loss of $925,567 for the three months ended September 30, 2013. The change is a result of the changes described above.

Nine Months Ended September 30, 2014

The following table sets forth the Company’s results of operations for the nine months ended September 30, 2014 and the comparative period for the nine months ended September 30, 2013.


	Nine Months	Nine Months
	Ended	Ended		Percentage
	September 30, 2014	September 30, 2013	Increase/ Decrease	Increase/ Decrease
	($)	($)	($)	(%)
Revenues	14,785	−	14,785	−

Operating Expenses	(4,066,778)	(2,880,855)	(1,185,923)	41.2%
Net Other Expense	(3,219,574)	−	(3,219,574)	−
Income Taxes	−	−	−	−

Net Loss	(7,271,567)	(2,880,855)	(4,390,712)	152.4%

Basic and Diluted Loss Per Share	(0.56)	(0.27)	(0.29)	105.8%

Weighted Average Basic and Diluted Shares Outstanding	13,057,866	10,649,152	2,408,714	22.6%

Revenues

The Company had $14,785 of revenues from operations in the nine months ended September 30, 2014, and no revenues from operations in the comparative period for the nine months ended September 30, 2013. The Company’s operations are still predominantly in the development stage.

Operating Expenses

For the nine months ended September 30, 2014, the Company’s operating expenses increased by $1,185,923, or 41.2%. Operating expenses are comprised of salaries and office administrative fees, research and development expenses, professional fees, and other general and administrative expenses. Salaries and office administrative fees increased by $101,280, due to an increase of $41,230 in share options amortization, a $21,316 increase in warrants costs and an extra $28,129, as a result of the handover to, and overlap with the new CFO. Research and development expenses increased by $975,370, mainly due to increases of $208,425 in patent filing costs, $166,297 in purchases of antibodies and samples, and $336,368 in staff and consultancy costs. An additional $151,914 was also spent on a new Danish Study in 2014. These increases all reflect a higher level of research and development and patent activity. Professional fees increased by $101,947, due principally to increases of $39,493 in legal fees, with additional fund raising activities in 2014 and $58,429 in fees for investor relations services , as a result of the issue of warrants and additional resource being taken on in this area. General and administrative expenses increased by $7,326.

Net Other Expenses

For the nine months ended September 30, 2014, the Company recorded other income of $143,987, representing grant funds received from public bodies in respect of approved expenditures, where there is no obligation to repay. There were no grant funds that met these criteria in respect of the nine months ended September 30, 2013. The Company also recorded a loss of $3,363,561, in relation to the revaluation of a derivative liability, resulting from the issuance of 1,500,000 warrants attached to the issuance of 1,500,000 shares, together with 30,975 warrants issued to agents.

Net Loss

For the nine months ended September 30, 2014, the Company had a net loss of $7,271,567, which is an increase of $4,390,712 or 152.4% over the comparative period for the nine months ended September 30, 2013. The change is a result of the changes described above.

Going Concern

We have not attained profitable operations and are dependent upon obtaining financing to pursue any extensive activities. For these reasons, our auditors stated in their report on our audited financial statements that they have substantial doubt that we will be able to continue as a going concern without further financing.

Off-Balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

Future Financings

We will continue to rely on equity sales of our common shares in order to continue to fund our business operations. Issuances of additional shares will result in dilution to existing stockholders. There is no assurance that we will achieve any additional sales of equity securities or arrange for debt or other financing to fund our operations and other activities.

Critical Accounting Policies

Our financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. A complete summary of these policies is included in the notes to our financial statements. In general, management's estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

Contractual Obligations

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

Recently Issued Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by our company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management carried out an evaluation under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 ("Exchange Act"). Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures were not effective as of September 30, 2014, due to the material weakness resulting from no member of our Board of Directors qualifying as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-K. On November 5, 2014, the Board of Directors formed an Audit Committee and adopted its Charter. Mr. Guy Innes is a Chartered Accountant and qualifies as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-K. Please refer to our Annual Report for the year ended December 31, 2013 on Form 10-K as filed with the SEC on March 28, 2014, for a complete discussion relating to the foregoing evaluation of Disclosures and Procedures.

Changes in Internal Control over Financial Reporting

Our management has also evaluated our internal control over financial reporting, and there have been no significant changes in our internal controls or in other factors that could significantly affect those controls subsequent to the date of our last evaluation.

The Company is not required by current SEC rules to include, and does not include, an auditor's attestation report. The Company's registered public accounting firm has not attested to Management's reports on the Company's internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our director, officer or any affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Quarterly Issuances:

On or about September 24, 2014, the Company issued 540,796 shares of common stock to 10 non-U.S. investors and 7 U.S. Investors at a price of $2.20 per share, for an aggregate amount of $1,189,749.

On or about September 26, 2014, the Company issued 300,000 shares of common stock to 23 U.S. Investors at a price of $2.50 per share, for an aggregate amount of $750,000. The net proceeds received by the Company after commissions were $677,970.

Subsequent Issuances:

On or about October 3, 2014, 50,000 warrants were exercised for total proceeds of $123,500. As a result, an aggregate total of 50,000 shares of common stock were issued to 1 U.S. Investor.

On or about October 9, 2014, the Company issued 91,757 shares of common stock to 7 non-U.S. investors and 10 U.S. Investors at a price of $2.50 per share, for an aggregate amount of $229,393.

Exemption From Registration. The shares of Common Stock referenced herein were issued in reliance upon one of the following exemptions:

(a) The shares of Common Stock referenced herein were issued in reliance upon the exemption from securities registration afforded by the provisions of Section 4(2) of the Securities Act of 1933, as amended, ("Securities Act"), based upon the following: (a) each of the persons to whom the shares of Common Stock were issued (each such person, an "Investor") confirmed to the Company that it or he is an "accredited investor," as defined in Rule 501 of Regulation D promulgated under the Securities Act and has such background, education and experience in financial and business matters as to be able to evaluate the merits and risks of an investment in the securities, (b) there was no public offering or general solicitation with respect to the offering of such shares, (c) each Investor was provided with certain disclosure materials and all other information requested with respect to the Company, (d) each Investor acknowledged that all securities being purchased were being purchased for investment intent and were "restricted securities" for purposes of the Securities Act, and agreed to transfer such securities only in a transaction registered under the Securities Act or exempt from registration under the Securities Act and (e) a legend has been, or will be, placed on the certificates representing each such security stating that it was restricted and could only be transferred if subsequently registered under the Securities Act or transferred in a transaction exempt from registration under the Securities Act.

(b) The shares of common stock referenced herein were issued pursuant to and in accordance with Rule 506 of Regulation D and Section 4(2) of the Securities Act. We made this determination in part based on the representations of the Investor(s), which included, in pertinent part, that such Investor(s) was an “accredited investor” as defined in Rule 501(a) under the Securities Act, and upon such further representations from the Investor(s) that (a) the Investor is acquiring the securities for his, her or its own account for investment and not for the account of any other person and not with a view to or for distribution, assignment or resale in connection with any distribution within the meaning of the Securities Act, (b) the Investor agrees not to sell or otherwise transfer the purchased securities unless they are registered under the Securities Act and any applicable state securities laws, or an exemption or exemptions from such registration are available, (c) the Investor either alone or together with its representatives has knowledge and experience in financial and business matters such that he, she or it is capable of evaluating the merits and risks of an investment in us, and (d) the Investor has no need for the liquidity in its investment in us and could afford the complete loss of such investment. Our determination is made based further upon our action of (a) making written disclosure to each Investor prior to the closing of sale that the securities have not been registered under the Securities Act and therefore cannot be resold unless they are registered or unless an exemption from registration is available, (b) making written descriptions of the securities being offered, the use of the proceeds from the offering and any material changes in the Company’s affairs that are not disclosed in the documents furnished, and (c) placement of a legend on the certificate that evidences the securities stating that the securities have not been registered under the Securities Act and setting forth the restrictions on transferability and sale of the securities, and upon such inaction of the Company of any general solicitation or advertising for securities herein issued in reliance upon Rule 506 of Regulation D and Section 4(2) of the Securities Act.

(c) The shares of Common Stock referenced herein were issued pursuant to and in accordance with Rule 903 of Regulation S of the Act. We completed the offering of the shares pursuant to Rule 903 of Regulation S of the Act on the basis that the sale of the shares was completed in an "offshore transaction", as defined in Rule 902(h) of Regulation S. We did not engage in any directed selling efforts, as defined in Regulation S, in the United States in connection with the sale of the shares. Each investor represented to us that the investor was not a "U.S. person", as defined in Regulation S, and was not acquiring the shares for the account or benefit of a U.S. person. The agreement executed between us and each investor included statements that the securities had not been registered pursuant to the Act and that the securities may not be offered or sold in the United States unless the securities are registered under the Act or pursuant to an exemption from the Act. Each investor agreed by execution of the agreement for the shares: (i) to resell the securities purchased only in accordance with the provisions of Regulation S, pursuant to registration under the Act or pursuant to an exemption from registration under the Act; (ii) that we are required to refuse to register any sale of the securities purchased unless the transfer is in accordance with the provisions of Regulation S, pursuant to registration under the Act or pursuant to an exemption from registration under the Act; and (iii) not to engage in hedging transactions with regards to the securities purchased unless in compliance with the Act. All certificates representing the shares were or upon issuance will be endorsed with a restrictive legend confirming that the securities had been issued pursuant to Regulation S of the Act and could not be resold without registration under the Act or an applicable exemption from the registration requirements of the Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

Subsequent Events

On November 5, 2014, the Board of Directors formed and adopted Charters for its Audit Committee, Nominations and Governance Committee, and Compensation Committee.

ITEM 6. EXHIBITS


Exhibit Number	Description	Filing
2.01	Share Purchase Agreement by and between Singapore Volition and ValiRX PLC dated September 22, 2010	Filed with the SEC on May 8, 2012 as part of our Amended Current Report on Form 8-K/A.
2.02	Supplementary Agreement to the Share Purchase Agreement by and between Singapore Volition and ValiRX PLC dated June 9, 2011	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
3.01	Certificate of Incorporation	Filed with the SEC on December 6, 1999 as part of our Registration Statement on Form 10-SB.
3.01(a)	Amendment to Certificate of Incorporation	Filed with the SEC on November 10, 2005 as part of our Registration Statement on Form SB-2.
3.01(b)	Certificate for Renewal and Revival of Charter	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
3.01 (c)	Amended & Restated Certificate of Incorporation	Filed with the SEC on October 7, 2013 as part of our Current Report on Form 8-K.
3.02	Bylaws	Filed with the SEC on December 6, 1999 as part of our Registration Statement on Form 10-SB.
4.01	2011 Equity Incentive Plan dated November 17, 2011	Filed with the SEC on November 18, 2011 as part of our Current Report on Form 8-K.
4.02	Sample Stock Option Agreement	Filed with the SEC on November 18, 2011 as part of our Current Report on Form 8-K.
4.03	Sample Stock Award Agreement for Restricted Stock	Filed with the SEC on November 18, 2011 as part of our Current Report on Form 8-K.
10.01	Patent License Agreement by and between Cronos Therapeutics Limited and Imperial College Innovations Limited dated October 19, 2005	Filed with the SEC on February 24, 2012 as part of our Amended Current Report on Form 8-K/A.
10.02	Amended Patent License Agreement by and between Cronos Therapeutics Limited and Imperial College Innovations Limited dated July 31, 2006	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
10.03	Extension Letter Agreement by and between Cronos Therapeutics Limited and Imperial College Innovations Limited dated September 4, 2006	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
10.04	Patent License Agreement by and between ValiRX PLC and Chroma Therapeutics Limited dated October 3, 2007	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
10.05	Contract Repayable Grant Advance on the Diagnosis of Colorectal Cancer by “Nucleosomics^TM” by and between ValiBio SA and The Walloon Region dated December 17, 2009	Filed with the SEC on February 24, 2012 as part of our Amended Current Report on Form 8-K/A.
10.06	Non-Exploitation and Third Party Patent License Agreement by and among ValiBio SA, ValiRX PLC and The Walloon Region dated December 17, 2009	Filed with the SEC on February 24, 2012 as part of our Amended Current Report on Form 8-K/A.
10.07	Agreement by and between Singapore Volition and PB Commodities Pte Limited dated August 6, 2010	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
10.08	Employment Agreement by and between PB Commodities Pte Ltd and Cameron Reynolds dated September 4, 2010	Filed with the SEC on February 24, 2012 as part of our Amended Current Report on Form 8-K/A.
10.09	Employment Agreement by and between PB Commodities Pte Ltd and Rodney Rootsaert dated September 4, 2010	Filed with the SEC on February 24, 2012 as part of our Amended Current Report on Form 8-K/A.
10.10	Deed of Novation by and among Singapore Volition Pte Limited, ValiRX PLC, ValiBio SA and Chroma Therapeutics Limited dated September 22, 2010	Filed with the SEC on February 24, 2012 as part of our Amended Current Report on Form 8-K/A.


10.11	Letter of Appointment as Non-Executive Director by and between Singapore Volition Pte Limited and Guy Archibald Innes dated September 23, 2010	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
10.12	Employment Agreement by and between Singapore Volition and Dr. George S. Morris dated September 29, 2010	Filed with the SEC on February 24, 2012 as part of our Amended Current Report on Form 8-K/A.
10.13	Master Consultancy Services Agreement by and between Singapore Volition Pte Limited and OncoLytika Ltd dated October 1, 2010	Filed with the SEC on April 1, 2013 as part of our Annual Report on Form 10-K.
10.14	Consultancy Agreement by and between PB Commodities Pte Ltd and Kendall Life Sciences Consultants Ltd dated October 4, 2010	Filed with the SEC on February 24, 2012 as part of our Amended Current Report on Form 8-K/A.
10.15	Patent License Agreement by and between Singapore Volition and Belgian Volition dated November 2, 2010	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
10.16	Consultancy Agreement by and between Belgian Volition S.A. and Borlaug Limited dated January 1, 2011	Filed with the SEC on April 1, 2013 as part of our Annual Report on Form 10-K.
10.17	Letter of Appointment as Non-Executive Director by and between Singapore Volition Pte Limited and Dr. Alan Colman dated May 25, 2011	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
10.18	License Agreement by and between Singapore Volition and the European Molecular Biology Laboratory dated June 6, 2011	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
10.19	Deed of Novation by and among Imperial College Innovations Limited, Valipharma Limited and Hypergenomics Pte Limited dated June 9, 2011	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
10.20	Patent License Agreement by and between Hypergenomics Pte Limited and Valipharma Limited dated June 9, 2011	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
10.21	Consultancy Agreement by and between Singapore Volition Pte Limited and Malcolm Lewin dated July 10, 2011	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
10.22	Letter of Appointment as Executive Chairman by and between Singapore Volition and Dr. Martin Faulkes dated July 13, 2011	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
10.23	Service Agreement by and between Singapore Volition and Volition Research Limited dated August 10, 2011	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
10.24	Settlement Agreement by and between Singapore Volition and Volition Research Limited dated August 11, 2011	Filed with the SEC on January 11, 2012 as part of our Amended Current Report on Form 8-K/A.
10.25	Share Exchange Agreement by and between the Company and Singapore Volition Pte Limited dated September 26, 2011	Filed with the SEC on September 29, 2011 as part of our Current Report on Form 8-K.
10.26	Agreement, Consent and Waiver by and between Standard Capital Corporation and its Shareholders dated September 27, 2011	Filed with the SEC on April 5, 2012 as part of our Amended Current Report on Form 8-K/A.
10.27	Agreement by and between Hypergenomics Pte Limited and PB Commodities Pte Ltd dated October 1, 2011	Filed with the SEC on February 24, 2012 as part of our Amended Current Report on Form 8-K/A.
10.28	Agreement by and between Belgian Volition SA and the Biobank of CHU UCL Mont-Godinne dated August 6, 2012	Filed with the SEC on October 4, 2012 as part of our Amended Registration Statement on Form S-1/A.
10.29	Common Stock Purchase Agreement by and among the Company and the purchasers thereto dated February 26, 2014	Filed with the SEC on February 28, 2014 as part of our Current Report on Form 8-K.
14.01	Code of Ethics	Filed with the SEC on November 10, 2005 as part of our Registration Statement on Form SB-2.
16.01	Letter from Madsen & Associates, CPA's Inc. dated November 29, 2011	Filed with the SEC on November 30, 2011 as part of our Current Report on Form 8-K.
21.01	List of Subsidiaries	Filed with the SEC on October 13, 2011 as part of our Current Report on Form 8-K.
31.01	Certification of Principal Executive Officer Pursuant to Rule 13a-14	Filed herewith.
31.02	Certification of Principal Financial Officer Pursuant to Rule 13a-14	Filed herewith.
32.01	CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act	Filed herewith.
32.02	CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act	Filed herewith.
101.INS*	XBRL Instance Document	Filed herewith.
101.SCH*	XBRL Taxonomy Extension Schema Document	Filed herewith.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document	Filed herewith.
101.LAB*	XBRL Taxonomy Extension Labels Linkbase Document	Filed herewith.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document	Filed herewith.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document	Filed herewith.

Pursuant to Regulation S-T, this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


		VOLITIONRX LIMITED

Dated: November 6, 2014		/s/ Cameron Reynolds
		By: Cameron Reynolds
		Its: President, Principal Executive Officer and Director


Dated: November 6, 2014		/s/ Michael O’Connell
		By: Michael O’Connell
		Its: Principal Financial Officer, Principal Accounting Officer, & Treasurer

Pursuant to the requirement of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated:


Dated: November 6, 2014		/s/ Cameron Reynolds
		Cameron Reynolds – President, CEO & Director


Dated: November 6, 2014		/s/ Dr. Martin Faulkes
		Dr. Martin Faulkes – Director


Dated: November 6, 2014		/s/ Guy Archibald Innes
		Guy Archibald Innes – Director


Dated: November 6, 2014		/s/ Dr. Alan Colman
		Dr. Alan Colman – Director


Dated: November 6, 2014		/s/ Dr. Habib Skaff
		Dr. Habib Skaff – Director


Dated: November 6, 2014		/s/ Rodney Gerard Rootsaert
		Rodney Gerard Rootsaert – Secretary

EX-31.01 2 f10q063014_ex31z01.htm EXHIBIT 31.01 SECTION 302 CERTIFICATION Exhibit 31.01 Section 302 Certification

EXHIBIT 31.01

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13a-14

I, Cameron Reynolds, certify that:

I have reviewed this quarterly report on Form 10-Q of VolitionRX Limited;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 6, 2014

/s/ Cameron Reynolds

By: Cameron Reynolds

Its: Chief Executive Officer

EX-31.02 3 f10q063014_ex31z02.htm EXHIBIT 31.02 SECTION 302 CERTIFICATION Exhibit 31.02 Section 302 Certification

EXHIBIT 31.02

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13a-14

I, Michael O’Connell, certify that:

I have reviewed this quarterly report on Form 10-Q of VolitionRX Limited;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 6, 2014

/s/ Michael O’Connell

By: Michael O’Connell

Its: Chief Financial Officer

EX-32.01 4 f10q063014_ex32z01.htm EXHIBIT 32.01 SECTION 906 CERTIFICATION Exhibit 32.01 Section 906 Certification

EXHIBIT 32.01

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of VolitionRX Limited (the “Company”) on Form 10-Q for the period ending September 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Cameron Reynolds, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Cameron Reynolds

By: Cameron Reynolds

Chief Executive Officer

Dated: November 6, 2014

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.02 5 f10q063014_ex32z02.htm EXHIBIT 32.02 SECTION 906 CERTIFICATION Exhibit 32.02 Section 906 Certification

EXHIBIT 32.02

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of VolitionRX Limited (the “Company”) on Form 10-Q for the period ending September 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael O’Connell, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Michael O’Connell

By: Michael O’Connell

Chief Financial Officer

Dated: November 6, 2014

EX-101.CAL 6 vnrx-20140930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 vnrx-20140930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.INS 8 vnrx-20140930.xml XBRL INSTANCE DOCUMENT 0000093314 2013-12-31 0000093314 2013-01-01 2013-12-31 0000093314 us-gaap:PatentsMember 2013-12-31 0000093314 2014-01-01 2014-09-30 0000093314 2010-08-05 2014-09-30 0000093314 2014-09-30 0000093314 us-gaap:PatentsMember 2014-09-30 0000093314 us-gaap:MinimumMember 2014-01-01 2014-09-30 0000093314 us-gaap:MaximumMember 2014-01-01 2014-09-30 0000093314 2012-12-31 0000093314 us-gaap:WarrantMember VNRX:DateTwoMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateThreeMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateFourMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateFiveMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateSixMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateSevenMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateEightMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateTenMember us-gaap:MinimumMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateNineMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateTwelveMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateElevenMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateThirteenMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateFourteenMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateFifteenMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateSixteenMember 2014-09-30 0000093314 VNRX:DateIssuanceOneMember 2014-09-30 0000093314 VNRX:DateIssuanceOneMember us-gaap:MinimumMember 2014-09-30 0000093314 VNRX:DateIssuanceOneMember us-gaap:MaximumMember 2014-09-30 0000093314 VNRX:DateIssuanceTwoMember 2014-09-30 0000093314 VNRX:DateIssuanceTwoMember us-gaap:MinimumMember 2014-09-30 0000093314 VNRX:DateIssuanceTwoMember us-gaap:MaximumMember 2014-09-30 0000093314 VNRX:DateIssuanceThreeMember 2014-09-30 0000093314 2014-07-01 2014-09-30 0000093314 2013-09-30 0000093314 VNRX:DilutiveWarrantsMember 2014-07-01 2014-09-30 0000093314 us-gaap:EmployeeStockOptionMember 2014-07-01 2014-09-30 0000093314 VNRX:DilutiveWarrantsAndOptionsMember 2014-01-01 2014-09-30 0000093314 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceFourMember 2014-09-30 0000093314 VNRX:DateIssuanceFourMember us-gaap:MinimumMember 2014-09-30 0000093314 VNRX:DateIssuanceFourMember us-gaap:MaximumMember 2014-09-30 0000093314 VNRX:DateIssuenceFiveMember 2014-09-30 0000093314 VNRX:DateIssuenceFiveMember us-gaap:MinimumMember 2014-09-30 0000093314 VNRX:DateIssuenceFiveMember us-gaap:MaximumMember 2014-09-30 0000093314 VNRX:DateIssuenceSixMember 2014-09-30 0000093314 VNRX:DateIssuenceSixMember us-gaap:MinimumMember 2014-09-30 0000093314 VNRX:DateIssuenceSixMember us-gaap:MaximumMember 2014-09-30 0000093314 VNRX:DateIssuanceSevenMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateTwoMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateThreeMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateFourMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateFiveMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateSixMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateSevenMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateEightMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateTenMember us-gaap:MinimumMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateTenMember us-gaap:MaximumMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateNineMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateTwelveMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateElevenMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateThirteenMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateFourteenMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateFifteenMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateSixteenMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceOneMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceOneMember us-gaap:MinimumMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceTwoMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceTwoMember us-gaap:MinimumMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceTwoMember us-gaap:MaximumMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceThreeMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceOneMember us-gaap:MaximumMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceFourMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceFourMember us-gaap:MinimumMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceFourMember us-gaap:MaximumMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceFiveMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceFiveMember us-gaap:MinimumMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceFiveMember us-gaap:MaximumMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceSixMember us-gaap:MinimumMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceSixMember us-gaap:MaximumMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateSeventeenMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateEighteenMember 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateSeventeenMember 2014-01-01 2014-09-30 0000093314 us-gaap:WarrantMember VNRX:DateEighteenMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceSevenMember us-gaap:MinimumMember 2014-09-30 0000093314 VNRX:DateIssuanceSevenMember us-gaap:MaximumMember 2014-09-30 0000093314 VNRX:DateIssuanceSevenOneMember 2014-09-30 0000093314 VNRX:DateIssuanceSevenOneMember us-gaap:MinimumMember 2014-09-30 0000093314 VNRX:DateIssuanceSevenOneMember us-gaap:MaximumMember 2014-09-30 0000093314 VNRX:DateIssuanceSevenMember us-gaap:MinimumMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceSevenMember us-gaap:MaximumMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceSevenOneMember us-gaap:MinimumMember 2014-01-01 2014-09-30 0000093314 VNRX:DateIssuanceSevenOneMember us-gaap:MaximumMember 2014-01-01 2014-09-30 0000093314 2013-07-01 2013-09-30 0000093314 2013-01-01 2013-09-30 0000093314 2014-11-06 xbrli:shares iso4217:USD iso4217:USD xbrli:shares

-4051993

-1763382

-925567

-2880855

4066778

1778167

925567

2880855

2733742

1071984

524534

1758372

670518

457355

179846

569238

412532

119510

153226

310585

249986

129318

67961

242660

14785

-143987

-33731

-19893

-6478

-18336

-33731

-19893

-6478

-18336

-7305298

-5913837

-932045

-2899191

-0.56

-0.44

-0.08

-0.27

13057866

13524998

11086237

10649152

-7271567

-18661015

-5893944

-925567

-2880855

311907

236966

99904

109044

61483

81965

88422

-7292

238446

-166093

-3148158

-2374939

403483

348172

52500 143987

-297607

-713

297607

713

888704

2419667

376421

473475

1530963

97054

-27622

-2627

5004350

2475333

1321

143987 605154

4893529

1871500

77333

10274

888704

2419667

1314559

1219969

312516

357216

1002043

862753

22721

90882

P9Y P17Y

114879

72646

350000

P13Y P20Y

1618300

680000

30000

100000

37000

16300

25000

670000

60000

3.89

3.00

5.00

4.31

6.31

3.01

2.35

4.35

2.35

4.35

3.00

5.00

2.50

3.00

5.00

5531355

2710000

159300

301000

123950

54605

100000

1842500

240000

4130562

84251

2458

6446068 2357275 2112995

-3219574

-4130562

3363561 4130562 543275 592204 P3Y P3Y P3Y P3Y P3Y P3Y P3Y P5Y6M P4Y6M P5Y6M P3Y6M P6Y 2015-05-25 2016-03-01 2018-09-01 2015-12-13 2017-11-25 2016-09-20 2019-03-20 2014-03-02 2016-09-02 2017-11-16 2020-05-16 2019-02-18 2020-02-18 2018-02-18 2020-08-18 10000

82135

133848

34612

117409

1005451

2670924

63265

315777

1002043

862753

2070759

3849454

518086

693646

222294

240978

6446068

216894

199862

957274

7580554

432811 367112

1390085

7947666

0.001

1000000

0.001

100000000

11679757

14308960

11679757

14308960

3363561 33166 VOLITIONRX LTD 0000093314 10-Q 2014-09-30 false --12-31 No No Yes Smaller Reporting Company 14450717 Q3 2014

11680

14309

12024711

14548494

-59795

-93526

11295922

18567489

680674

-4098212

2070759

3849454

The accompanying unaudited financial statements have been prepared by VolitionRX Limited (the Company) without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2014, and for all periods presented herein, have been made.   Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed unaudited financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2013 audited financial statements. The results of operations for the periods ended September 30, 2014 and 2013 are not necessarily indicative of the operating results for the full years.

The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred losses since inception of $18,661,015 and currently has very limited revenues, which creates substantial doubt about its ability to continue as a going concern.   The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions and/or financing as may be required to sustain its operations. Management's plan to address this need includes, (a) continued exercise of tight cost controls to conserve cash, (b) receiving additional grant funds, and (c) obtaining additional financing through debt or equity financing.   The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

Use of Estimates The preparation of financial statements in conformity with US generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Companys estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.   Principles of Consolidation The accompanying condensed consolidated financial statements for the period ended September 30, 2014 include the accounts of the Company and its wholly-owned subsidiaries, Singapore Volition Pte Ltd, Belgian Volition SA, and Hypergenomics Pte. Ltd. All significant intercompany balances and transactions have been eliminated in consolidation.   Cash and Cash Equivalents The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As at September 30, 2014 and December 31, 2013, the Company had $2,419,667 and $888,704, respectively in cash and cash equivalents.   Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. For the three months ended September 30, 2014, 543,275 dilutive warrants and 2,357,275 potentially dilutive warrants and options were excluded from the Diluted EPS calculation as their effect is anti dilutive. For the nine months ended September 30, 2014, 592,204 dilutive warrants and 2,112,995 potentially dilutive warrants and options were excluded from the Diluted EPS calculation as their effect is anti dilutive.   Foreign Currency Translation The Companys functional currency is the Euro and its reporting currency is the United States dollar. Management has adopted ASC 830-20, Foreign Currency Matters Foreign Currency Transactions. All assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. For revenues and expenses, the weighted average exchange rate for the period is used. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in other comprehensive loss.   Recent Accounting Pronouncements Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Companys management believes that these recent pronouncements will not have a material effect on the Companys consolidated financial statements.   The Company has limited operations and is considered to be in the development stage. In the quarterly period ended September 30, 2014, the Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the Company to remove the inception to date information and all references to the development stage.

The Companys intangible assets consist of intellectual property, principally patents, acquired in the acquisition of ValiBio SA. The patents are being amortized over their remaining lives, which are 9 years and 17 years.   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">December 31,</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">2013</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Accumulated</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Net Carrying</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Cost</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Amortization</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Value</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">$</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">$</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">$</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%">Patents</td> <td style="width: 1%"> </td> <td style="width: 1%; border-bottom: black 1pt solid"> </td> <td style="width: 8%; border-bottom: black 1pt solid; text-align: right">1,314,559</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%; border-bottom: black 1pt solid"> </td> <td style="width: 8%; border-bottom: black 1pt solid; text-align: right">312,516</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%; border-bottom: black 1pt solid"> </td> <td style="width: 8%; border-bottom: black 1pt solid; text-align: right">1,002,043</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,314,559</td> <td nowrap="nowrap"> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">312,516</td> <td nowrap="nowrap"> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,002,043</td> <td nowrap="nowrap"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">September 30,</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">2014</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Accumulated</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Net Carrying</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Cost</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Amortization</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Value</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">$</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">$</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">$</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%">Patents</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">1,219,969</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">357,216</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">862,753</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,219,969</td> <td nowrap="nowrap"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">357,216</td> <td nowrap="nowrap"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">862,753</td> <td nowrap="nowrap"> </td></tr> </table>   During the nine month period ended September 30, 2014, and the year ended December 31, 2013, the Company recognized $72,646 and $114,879 in amortization expense respectively. During the year ended December 31, 2013 the Company also recognized impairment losses of $350,000. No impairment losses were recognized during the nine month period ended September 30, 2014.   The Company amortizes the long-lived assets on a straight line basis with terms ranging from 13 to 20 years. The annual estimated amortization schedule over the next five years is as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%">2014 - remaining</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">22,721</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2015</td> <td> </td> <td>$</td> <td style="text-align: right">90,882</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2016</td> <td> </td> <td>$</td> <td style="text-align: right">90,882</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2017</td> <td> </td> <td>$</td> <td style="text-align: right">90,882</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2018</td> <td> </td> <td>$</td> <td style="text-align: right">90,882</td> <td nowrap="nowrap"> </td></tr> </table>   The Company periodically reviews its long lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 as of December 31, 2013. The result of this review confirmed that the fair value of the patents exceeded their carrying value as of December 31, 2013.

The Company contracts with a related party to rent office space, be provided with office support staff, and have consultancy services provided on behalf of the Company. See Note 8 for obligation under the contract.

On February 26, 2014, the Company issued 1,500,000 shares of common stock for a total of $3,000,000 at a price of $2.00 per share. Attached to these share issuances were 1,500,000 warrants, immediately exercisable for a period of five years at $2.20 per share. The warrants were valued at $3,955,546 using the Black-Scholes Option Pricing model using the following assumptions: Five year term, $2.68 stock price, $2.20 exercise price, 239% volatility, 1.50% risk free rate. Agents received 30,975 warrants, exercisable on the same terms as the warrants issued for cash subscriptions, and valued at $82,507 on the same basis as above. Due to a ratchet provision in the warrant agreement effective for the twelve months to February 26, 2015, all the foregoing warrants have been treated as a derivative liability in accordance with ASC 815. Other fees and expenses directly attributable to agents in respect of these issuances were $147,186 in cash, and $25,900 settled by the issue of shares of common stock. Legal expenses directly attributable to the issuances amounted to $84,879.   On February 26, 2014, the Company issued 16,667 shares of common stock to settle liabilities for services valued at $35,000, at a price of $2.10 per share.   On March 25, 2014, the Company issued 12,334 shares of common stock to settle liabilities for services valued at $25,900, at a price of $2.10 per share.   On March 26, 2014, the Company issued 99,178 shares of common stock to the subscribers for the 297,500 shares of common stock issued on June 10, 2013. These additional shares were issued for no additional consideration under the terms of the Private Placement Memorandum because certain subsequent fundraising targets had not been met.   On June 5, 2014, the Company issued 160,228 shares of common stock for cash of $352,500, at a price of $2.20 per share.   On September 24, 2014, the Company issued 21,250 shares of common stock at a price of $2.20 per share to settle liabilities for services valued at $46,748. In addition, on that date, the Company issued 492,316 shares of common stock at a price of $2.20 for cash of $1,083,094 and 27,230 shares of common stock at a price of $2.20 to an agent in settlement of their debt of $59,906.   On September 26, 2014, the Company issued 300,000 shares of common stock at a price of $2.50 per share for cash of $688,970. The amount received was the net proceeds, after fees of $60,000 had been paid to an agent and $1,030 paid in other fees and bank charges.   In addition, on that date, the Company issued 24,000 warrants to the same agent, immediately exercisable over a period of three years at $3 per share. The warrants were valued at $103,223 using the Black-Scholes Option Pricing model using the following assumptions: Three year term, $4.45 stock price, $3 exercise price, 235% volatility, 1.08% risk free rate.

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; font: 10pt Times New Roman, Times, Serif; text-align: right; text-indent: -40pt">a)  </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warrants</td></tr> </table>   On January 28, 2014, the Company issued 10,000 warrants to a consultant for services at an exercise price of $2.40, exercisable immediately for three years. The warrants were valued at $21,500 using the Black-Scholes Option Pricing model using the following assumptions: Three-year term, $2.26 stock price, $2.40 exercise price, 229% volatility, 0.75% risk free rate.   On February 26, 2014, the Company issued 1,500,000 warrants attached to the issue of 1,500,000 shares for cash totaling $3,000,000. The Company has valued these warrants at $3,995,546 and treated this amount as a derivative liability, in accordance with ASC 815. The warrants are exercisable immediately for five years at an exercise price of $2.20.   On February 26, 2014, the Company issued 30,975 warrants to agents as part remuneration in respect of the issuance of 1,500,000 shares for cash totaling $3,000,000. The warrants were valued at $82,507 using the Black-Scholes Option Pricing model using the following assumptions: Five-year term, $2.68 stock price, $2.20 exercise price, 241% volatility, 1.5% risk free rate. The Company has treated this amount as a derivative liability, in accordance with ASC 815. Each warrant is exercisable immediately for five years at an exercise price of $2.20 per share.   On September 5, 2014, the Company issued 10,000 warrants to a consultant for services. These warrants were valued at $20,092 using the Black-Scholes Option Pricing model using the following assumptions: Three year term, $2.10 stock price, $2.40 exercise price, 236% volatility, 0.99% risk free rate. Each warrant is exercisable immediately for three years at an exercise price of $2.40 per share.   On September 26, 2014, the Company issued 24,000 warrants to an agent as part remuneration in respect of the issuance of 300,000 shares for net proceeds of $688,970. These warrants were valued at $103,223 using the Black-Scholes Option Pricing model using the following assumptions: Three year term, $4.45 stock price, $3 exercise price, 235% volatility, 1.08% risk free rate. Each warrant is exercisable immediately for three years at an exercise price of $3 per share.   All of the 1,530,975 warrants issued on February 26, 2014, have been treated as a derivative liability, in accordance with ASC 815, owing to a ratchet provision in the warrant agreement being effective for the twelve months to February 26, 2015. The derivative liability was measured at $4,078,054 as at February 26, 2014. It was re-measured as of March 31, 2014, and revalued at $4,182,748. The derivative liability was further re-measured as of June 30, 2014, and revalued at $2,315,506, resulting in a gain of $1,867,241 for the three months ended June 30, 2014. At September 30, 2014, the derivative liability was re-measured and revalued at $6,446,068, resulting in a loss of $4,130,562 for the three months ended September 30, 2014.   Below is a table summarizing the warrants issued and outstanding as of September 30, 2014.   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>Date</td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2" style="text-align: center">Contractual</td> <td nowrap="nowrap"> </td> <td style="text-align: center">Expiration</td> <td> </td> <td colspan="2" style="text-align: center">Value if</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Issued</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Outstanding</td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price $</td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Date</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercised $</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%">03/15/11</td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">200,000</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">0.50</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">5</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 10%; text-align: right">3/15/2016</td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">100,000</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>03/24/11</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">100,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">0.50</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">3/24/2016</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">50,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>04/01/11</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">100,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">0.50</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">4/1/2016</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">50,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>06/21/11</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">100,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">0.50</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">6/21/2016</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">50,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>07/13/11</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">250,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">1.05</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">07/13/16</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">262,500</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>05/11/12</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">344,059</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.60</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">4</td> <td nowrap="nowrap"> </td> <td style="text-align: right">05/10/16</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">894,553</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>05/11/12</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">26,685</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">1.75</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">05/10/15</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">46,699</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>03/20/13</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">200,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.47</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">03/20/16</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">494,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td style="text-align: right">-12/20/19</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>06/10/13</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">29,750</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.00</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5.5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">12/10/18</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">59,500</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>08/07/13</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">45,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.40</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">08/07/16</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">108,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>11/25/13</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">456,063</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.40</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">11/25/18</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">1,094,551</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>12/31/13</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">64,392</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.40</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">12/31/18</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">154,541</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>01/28/14</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">10,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.40</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">01/28/17</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">24,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>02/26/14</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">1,530,975</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.20</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">02/26/19</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3,368,145</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>09/05/14</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">10,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.40</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">09/05/17</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">24,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>09/26/14</td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">24,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3.00</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">09/26/17</td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">72,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>09/30/14</td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,490,924</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1.96</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4.7</td> <td nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">6,852,489</td> <td nowrap="nowrap"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: right">b)  </td> <td>Options</td></tr> </table>   On November 17, 2011, the Company adopted and approved the 2011 Equity Incentive Plan for the directors, officers, employees and key consultants of the Company. Pursuant to the Plan, the Company was authorized to issue 900,000 restricted shares, $0.001 par value, of the Companys common stock.   Options to purchase 25,000 shares were granted on May 16, 2014. These options vest in equal six monthly installments over three years from the date of grant, and expire three years after the vesting dates. The exercise prices are $3.00 for options vesting in the first year, $4.00 for options vesting in the second year, and $5.00 for options vesting in the third year. The Company has calculated the estimated fair market value of these options using the Black-Scholes Option Pricing model and the following assumptions: term 3 to 5.5 years, stock price $2.01, exercise prices $3.00-$5.00, 235% volatility, 0.80% risk free rate.   On August 5, 2014, it was approved at the Companys Annual General Meeting to increase the number of restricted shares that the Company is authorized to issue under the 2011 Equity Incentive Plan to 2,000,000.   On August 18, 2014, The Company granted options to purchase 670,000 shares. These options vest in two equal tranches, the first tranche vests on February 18, 2015. The second tranche vests on February 18, 2016. All the options expire four years after their vesting dates. The exercise prices are $2.50 for options vesting in the first year and $3.00 for options vesting in the second year. The Company has calculated the estimated fair market value of these options using the Black-Scholes Option Pricing model and the following assumptions: term 4.5 to 5.5 years, stock price $1.85, exercise prices $2.50-$3.00, 237% volatility, 1.58% risk free rate.   On August 18, 2014, The Company granted options to purchase 60,000 shares. These options vest in six equal monthly installments over three years, starting six months after the date of grant, and expire three years after the vesting dates. The exercise prices are $3.00 for options vesting in the first year, $4.00 for options vesting in the second year, and $5.00 for options vesting in the third year. The Company has calculated the estimated fair market value of these options using the Black-Scholes Option Pricing model and the following assumptions: term 3.5 to 6 years, stock price $1.85, exercise prices $3.00-$5.00, 237% volatility, 0.89% risk free rate.   During the nine month period ended September 30, 2014, 10,000 options expired following the cessation of a consultants contract.   Below is a table summarizing the options issued and outstanding as of September 30, 2014.   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>Date</td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Number</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Exercise</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Contractual</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center">Expiration</td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Value if</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Issued</td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Outstanding</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price $</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Date</td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercised $</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 33%">11/25/11</td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">680,000</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">3.00-5.00</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">3</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 11%; text-align: right">05/25/15-11/25/17</td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2,710,000</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>09/01/12</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">30,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">4.31-6.31</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">03/01/16-09/01/18</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">159,300</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>12/13/12</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">100,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3.01</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">12/13/15</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">301,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>03/20/13</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">37,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.35-4.35</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">09/20/16-03/20/19</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">123,950</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>09/02/13</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">16,300</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.35-4.35</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">03/02/14-09/02/16</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">54,605</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>05/16/14</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">25,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3.00-5.00</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3-5.5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">11/16/17-05/16/20</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">100,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>08/18/14</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">670,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.50-3.00</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">4.5-5.5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">02/18/19-02/18/20</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">1,842,500</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>08/18/14</td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">60,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3.00-5.00</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3.5-6.0</td> <td nowrap="nowrap"> </td> <td style="text-align: right">02/18/18-08/18/20</td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">240,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>09/30/14</td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,618,300</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">3.89</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">5,531,355</td> <td nowrap="nowrap"> </td></tr> </table>   Total remaining unrecognized compensation cost related to non-vested stock options is approximately $1,209,924 and is expected to be recognized over a period of three years.

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; font: 10pt Times New Roman, Times, Serif; text-align: right">a)  </td> <td style="font: 10pt Times New Roman, Times, Serif">Walloon Region Grant</td></tr> </table>   On March 16, 2010, the Company entered into an agreement with the Walloon Region government in Belgium wherein the Walloon Region would fund up to a maximum of $1,329,413 (1,048,020) to help fund the research endeavors of the Company in the area of colorectal cancer. The Company had received the entirety of these funds in respect of approved expenditures as of March 31, 2014. Under the terms of the agreement, the Company is due to repay $398,824 (314,406) of this amount by installments over the period June 30, 2014 to June 30, 2023. The Company has recorded the balance of $1,009,610 (733,614) to other income as there is no obligation to repay this amount. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 6 percent royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of $398,824 (314,406) and the 6 percent royalty on revenue, is twice the amount of funding received.   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; font: 10pt Times New Roman, Times, Serif; text-align: right">b)  </td> <td style="font: 10pt Times New Roman, Times, Serif">Administrative Support Agreement</td></tr> </table>   On August 6, 2010, the Company entered into an agreement with a related party to rent office space, contract for office support staff, and have consulting services provided on behalf of the Company. The agreement requires the Company to pay $6,270 per month for office space and staff services as well as approximately $16.000 per month in fees for two senior executives. The Company is also required to pay for all reasonable expenses incurred. The contract is in force for 12 months with automatic extensions of 12 months with a 3 month notice required for termination of the contract.   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; font: 10pt Times New Roman, Times, Serif; text-align: right">c)  </td> <td style="font: 10pt Times New Roman, Times, Serif"> Leases</td></tr> </table>   The Company leases premises and facilities under operating leases with terms ranging from 12 months to 24 months. The annual non-cancelable operating lease payments on these leases are as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%">2014 </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">84,251</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>2015 </td> <td> </td> <td>$</td> <td style="text-align: right">2,458</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Thereafter </td> <td> </td> <td colspan="2" style="text-align: right">Nil</td> <td nowrap="nowrap"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: right">d)  </td> <td>Bonn University Agreement</td></tr> </table>                                                   On July 11, 2012, the Company entered into an agreement with Bonn University, Germany, relating to a program of samples testing. The agreement was for a period of two years from June 1, 2012 to May 31, 2014. The total payments made by the Company in accordance with the agreement were $494,715 (390,000). On April 16, 2014, the Company entered into an extension of this agreement, for a period of a further two years from June 1, 2014 to May 31, 2016. The total payments to be made by the Company in accordance with the extension of the agreement are $494,715 (390,000).   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: right">e)  </td> <td>Hvidovre Hospital, Denmark Agreement</td></tr> </table>   On August 8, 2014, Belgium Volition SA entered into an agreement with Hvidovre Hospital, University of Copenhagen in Denmark, relating to a program of samples testing associated with colorectal cancer. It will run for a period of two years to August 8, 2016. Total payments (inclusive of local taxes) to be made under the agreement are $1,745,920 (DKR 10,245,000).   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: right">f)  </td> <td>Legal Proceedings</td></tr> </table>   There are no legal proceedings which the Company believes will have a material adverse effect on its financial position.

The preparation of financial statements in conformity with US generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Companys estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

The accompanying condensed consolidated financial statements for the period ended September 30, 2014 include the accounts of the Company and its wholly-owned subsidiaries, Singapore Volition Pte Ltd, Belgian Volition SA, and Hypergenomics Pte. Ltd. All significant intercompany balances and transactions have been eliminated in consolidation.

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As at September 30, 2014 and December 31, 2013, the Company had $2,419,667 and $888,704, respectively in cash and cash equivalents.

The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. For the three months ended September 30, 2014, 543,275 dilutive warrants and 2,357,275 potentially dilutive warrants and options were excluded from the Diluted EPS calculation as their effect is anti dilutive. For the nine months ended September 30, 2014, 592,204 dilutive warrants and 2,112,995 potentially dilutive warrants and options were excluded from the Diluted EPS calculation as their effect is anti dilutive.

The Companys functional currency is the Euro and its reporting currency is the United States dollar. Management has adopted ASC 830-20, Foreign Currency Matters Foreign Currency Transactions. All assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. For revenues and expenses, the weighted average exchange rate for the period is used. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in other comprehensive loss.

Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Companys management believes that these recent pronouncements will not have a material effect on the Companys consolidated financial statements.   The Company has limited operations and is considered to be in the development stage. In the quarterly period ended September 30, 2014, the Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the Company to remove the inception to date information and all references to the development stage.

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">December 31,</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">2013</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Accumulated</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Net Carrying</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Cost</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Amortization</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Value</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">$</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">$</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">$</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%">Patents</td> <td style="width: 1%"> </td> <td style="width: 1%; border-bottom: black 1pt solid"> </td> <td style="width: 8%; border-bottom: black 1pt solid; text-align: right">1,314,559</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%; border-bottom: black 1pt solid"> </td> <td style="width: 8%; border-bottom: black 1pt solid; text-align: right">312,516</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%; border-bottom: black 1pt solid"> </td> <td style="width: 8%; border-bottom: black 1pt solid; text-align: right">1,002,043</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,314,559</td> <td nowrap="nowrap"> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">312,516</td> <td nowrap="nowrap"> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,002,043</td> <td nowrap="nowrap"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">September 30,</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">2014</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Accumulated</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Net Carrying</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Cost</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Amortization</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Value</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">$</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">$</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">$</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%">Patents</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">1,219,969</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">357,216</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">862,753</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,219,969</td> <td nowrap="nowrap"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">357,216</td> <td nowrap="nowrap"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">862,753</td> <td nowrap="nowrap"> </td></tr> </table>

The annual estimated amortization schedule over the next five years is as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%">2014 - remaining</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">22,721</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2015</td> <td> </td> <td>$</td> <td style="text-align: right">90,882</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2016</td> <td> </td> <td>$</td> <td style="text-align: right">90,882</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2017</td> <td> </td> <td>$</td> <td style="text-align: right">90,882</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2018</td> <td> </td> <td>$</td> <td style="text-align: right">90,882</td> <td nowrap="nowrap"> </td></tr> </table>

Below is a table summarizing the warrants issued and outstanding as of September 30, 2014.   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>Date</td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2" style="text-align: center">Contractual</td> <td nowrap="nowrap"> </td> <td style="text-align: center">Expiration</td> <td> </td> <td colspan="2" style="text-align: center">Value if</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Issued</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Outstanding</td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price $</td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Date</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercised $</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 38%">03/15/11</td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">200,000</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">0.50</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">5</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 10%; text-align: right">3/15/2016</td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">100,000</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>03/24/11</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">100,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">0.50</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">3/24/2016</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">50,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>04/01/11</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">100,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">0.50</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">4/1/2016</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">50,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>06/21/11</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">100,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">0.50</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">6/21/2016</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">50,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>07/13/11</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">250,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">1.05</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">07/13/16</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">262,500</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>05/11/12</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">344,059</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.60</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">4</td> <td nowrap="nowrap"> </td> <td style="text-align: right">05/10/16</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">894,553</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>05/11/12</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">26,685</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">1.75</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">05/10/15</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">46,699</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>03/20/13</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">200,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.47</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">03/20/16</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">494,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td style="text-align: right">-12/20/19</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>06/10/13</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">29,750</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.00</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5.5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">12/10/18</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">59,500</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>08/07/13</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">45,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.40</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">08/07/16</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">108,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>11/25/13</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">456,063</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.40</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">11/25/18</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">1,094,551</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>12/31/13</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">64,392</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.40</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">12/31/18</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">154,541</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>01/28/14</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">10,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.40</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">01/28/17</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">24,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>02/26/14</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">1,530,975</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.20</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">02/26/19</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3,368,145</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>09/05/14</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">10,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.40</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">09/05/17</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">24,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>09/26/14</td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">24,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3.00</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">09/26/17</td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">72,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>09/30/14</td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,490,924</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1.96</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4.7</td> <td nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">6,852,489</td> <td nowrap="nowrap"> </td></tr> </table>

Below is a table summarizing the options issued and outstanding as of September 30, 2014.   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>Date</td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Number</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Exercise</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Contractual</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center">Expiration</td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Value if</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Issued</td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Outstanding</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price $</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td nowrap="nowrap" style="text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Date</td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercised $</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 33%">11/25/11</td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">680,000</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">3.00-5.00</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">3</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 11%; text-align: right">05/25/15-11/25/17</td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2,710,000</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>09/01/12</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">30,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">4.31-6.31</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">03/01/16-09/01/18</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">159,300</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>12/13/12</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">100,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3.01</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">12/13/15</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">301,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>03/20/13</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">37,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.35-4.35</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">09/20/16-03/20/19</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">123,950</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>09/02/13</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">16,300</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.35-4.35</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="text-align: right">03/02/14-09/02/16</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">54,605</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>05/16/14</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">25,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3.00-5.00</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">3-5.5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">11/16/17-05/16/20</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">100,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>08/18/14</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">670,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">2.50-3.00</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">4.5-5.5</td> <td nowrap="nowrap"> </td> <td style="text-align: right">02/18/19-02/18/20</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">1,842,500</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>08/18/14</td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">60,000</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3.00-5.00</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3.5-6.0</td> <td nowrap="nowrap"> </td> <td style="text-align: right">02/18/18-08/18/20</td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">240,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>09/30/14</td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,618,300</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">3.89</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3</td> <td nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="text-align: right"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">5,531,355</td> <td nowrap="nowrap"> </td></tr> </table>

The annual non-cancelable operating lease payments on these leases are as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%">2014 </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">84,251</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>2015 </td> <td> </td> <td>$</td> <td style="text-align: right">2,458</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Thereafter </td> <td> </td> <td colspan="2" style="text-align: right">Nil</td> <td nowrap="nowrap"> </td></tr> </table>

P5Y P5Y P5Y P5Y P5Y P4Y P3Y P3Y P5Y6M P3Y P5Y P5Y P3Y P5Y P3Y P3Y P4Y8M12D 2016-03-15 2016-03-24 2016-04-01 2016-06-21 2016-07-13 2016-05-10 2015-05-10 2016-03-20 2019-12-20 2018-12-10 2016-08-07 2018-11-25 2018-12-31 2017-01-28 2019-02-26 2017-09-05 2017-09-26 100000 50000 50000 50000 262500 894553 46699 494000 59500 108000 1094551 154541 24000 3368145 24000 72000 6852489 200000 100000 100000 100000 250000 344059 26685 200000 29750 45000 456063 64392 10000 1530975 10000 24000 3490924 0.50 0.50 0.50 0.50 1.05 2.60 1.75 2.47 2.00 2.40 2.40 2.40 2.40 2.20 2.40 3.00 1.96

EX-101.LAB 9 vnrx-20140930_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Patents [Member] Finite-Lived Intangible Assets by Major Class [Axis] Dilutive Warrants [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Potentially dilutive warrants and options [Member] Minimum [Member] Range [Axis] Maximum [Member] Warrant [Member] Equity Components [Axis] On 03/15/11 [Member] Report Date [Axis] On 03/24/11 [Member] On 04/01/11 [Member] On 06/21/11 [Member] On 07/13/11 [Member] On 05/11/12 [Member] On 05/11/12 One [Member] On 03/20/13 [Member] On 06/10/13 [Member] On 08/07/13 [Member] On 11/25/13 [Member] On 12/31/13 [Member] On 01/28/14 [Member] On 02/26/14 [Member] On 09/05/14 [Member] Issued On 11/25/11 [Member] Issued On 09/01/12 [Member] Issued On 12/13/12 [Member] Issued on 09/02/13 [Member] Issued on 09/02/13 [Member] Issued on 03/31/14 [Member] Dilutive Warrants [Member] Issued On 03/20/13 [Member] Issued on 09/02/13 [Member] Issued on 05/16/14 [Member] Issued on 08/18/14 [Member] Issued on 05/16/14 [Member] On 09/26/14 [Member] On 09/30/14 [Member] Issued on 08/18/14 [Member] Issued on 09/30/14 [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Condensed Consolidated Balance Sheets ASSETS Cash Prepaid expenses Other current assets Total Current Assets Property and equipment, net Intangible assets, net Total Assets LIABILITIES Accounts payable and accrued liabilities Management and directors' fees payable Derivative liability Deferred grant income Total Current Liabilities Grant repayable Total Liabilities STOCKHOLDERS' (DEFICIT) EQUITY Preferred Stock Authorized: 1,000,000 shares of preferred stock, at $0.001 par value Issued and outstanding: Nil shares and Nil shares, respectively Common Stock Authorized: 100,000,000 shares of common stock, at $0.001 par value Issued and outstanding: 14,308,960 shares and 11,679,757 shares, respectively Additional paid-in capital Accumulated other comprehensive loss Accumulated Deficit Total Stockholders' (Deficit) Equity Total Liabilities and Stockholders' (Deficit) Equity Condensed Consolidated Balance Sheets Parenthetical Preferred Stock, par value Peferred Stock, shares authorized Preferred Stock, shares issued Preferred Stock, shares outstanding Common Stock, par value Common Stock, shares authorized Common Stock, shares issued Common Stock, shares outstanding Condensed Consolidated Statements Of Operations And Comprehensive Loss Revenue Expenses General and administrative Professional fees Salaries and office administrative fees Research and development Total Operating Expenses Net Operating Loss Other Income Grants received Loss on derivative remeasurement Net Other Expenses Provision for income taxes Net Loss Other Comprehensive Loss Foreign currency translation adjustments Total Other Comprehensive Loss Net Comprehensive Loss Net Loss per Share - Basic and Diluted Weighted Average Shares Outstanding - Basic and Diluted Condensed Consolidated Statements Of Cash Flows Operating Activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Stock based compensation Common stock and warrants issued to settle liabilities for services Amortization of stock issued in advance of services Non-operating income - grants received Loss on derivative re-measurement Changes in operating assets and liabilities: Prepaid expenses Other current assets Accounts payable and accrued liabilities Net Cash Used In Operating Activities Investing Activities Purchases of property and equipment Net Cash Used in Investing Activities Financing Activities Proceeds from issuance of common shares Grants received Grants repaid Repayment of notes payable Net Cash Provided By Financing Activities Effect of foreign exchange on cash Increase in Cash Cash - Beginning of Period Cash - End of Period Supplemental Disclosures of Cash Flow Information Interest paid Income tax paid Non Cash Financing Activities:: Common stock issued for debt Notes to Financial Statements Note 1. Condensed Financial Statements Note 2. Going Concern Note 3. Summary of Significant Accounting Policies Note 4. Intangible Assets Note 5. Related Party Transactions Note 6. Common Stock Note 7. Warrants And Options Note 8. Commitments and Contingencies Note 9. Subsequent Events Summary Of Significant Accounting Policies Policies Use of Estimates Principles of Consolidation Cash and Cash Equivalents Basic and Diluted Net Income (Loss) Per Share Foreign Currency Translation Recent Accounting Pronouncements Intangible Assets Tables Patents amortized over their remaining lives Annual estimated amortization schedule Warrants And Options Tables Summary of Warrants Issued And Outstanding Summary of options issued and outstanding Commitments And Contingencies Tables Operating lease payments Going Concern Details Narrative Net Loss Statement [Table] Statement [Line Items] Antidilutive Securities [Axis] Cash and Cash Equivalents Dilutive warrants Potentially dilutive warrants and options Cost Accumulated Amortization Net Carrying Value Intangible Assets Details 1 2014 - Remaining 2015 2016 2017 2018 Intangible Assets Remaining amortized life Amortization expense Impairment loss Amortization of long-lived asset on straight line basis Number Outstanding Exercise Price Contractual Life (Years) Expiration Date EX-101.PRE 10 vnrx-20140930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 11 vnrx-20140930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Condensed Financial Statements link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Warrants And Options link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Warrants and Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Intangible Assets (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Warrants And Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Warrants And Options (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Warrants And Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink GRAPHIC 12 f10q093014_10q001.jpg IMAGE begin 644 f10q093014_10q001.jpg M_]C_X``02D9)1@`!`0$`2`!(``#_X@OX24-#7U!23T9)3$4``0$```OH```` M``(```!M;G1R4D="(%A96B`'V0`#`!L`%0`D`!]A8W-P```````````````` M``````````$`````````````]M8``0````#3+0`````I^#W>K_)5KGA"^N3* M@SD-`````````````````````````````````````````!!D97-C```!1``` M`'EB6%E:```!P````!1B5%)#```!U```"`QD;61D```)X````(AG6%E:```* M:````!1G5%)#```!U```"`QL=6UI```*?````!1M96%S```*D````"1B:W!T M```*M````!1R6%E:```*R````!1R5%)#```!U```"`QT96-H```*W`````QV M=65D```*Z````(=W='!T```+<````!1C<')T```+A````#=C:&%D```+O``` M`"QD97-C`````````!]S4D="($E%0S8Q.38V+3(M,2!B;&%C:R!S8V%L960` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````````6%E:(``````` M`"2@```/A```ML]C=7)V````````!``````%``H`#P`4`!D`'@`C`"@`+0`R M`#<`.P!``$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\` MI`"I`*X`L@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9 M`1\!)0$K`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$! MN0'!`$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z M`H0"C@*8`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8# M<@-^`XH#E@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2, M!)H$J`2V!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4% MY07V!@8&%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&09!ZP'OP?2!^4'^`@+"!$,@A&"%H(;@B"")8(J@B^"-((YPC["1`) M)0DZ"4$9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+ M"R(+.0M1"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28- M0`U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6 M#[,/SP_L$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$)%ZX7TA?W&!L8 M0!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;8QN* M&[(;VAP"'"H<4AQ['*,0!YJ'I0>OA[I'Q,? M/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B--@U$S5- M-8Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y& M(D9G1JM&\$25^!8+UA]6,M9&EEI M6;A:!UI66J9:]5M%6Y5;Y5PU7(9O5\/7V%?LV`%8%=@ MJF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I M:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAO MT7`K<(9PX'$Z<95Q\')+%V/G:;=OAW5G>S M>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6` M1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C. MB3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2 M$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M" MFZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E M.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:QK_UP'#`[,%GP>/"7\+;PUC#U,11 MQ,[%2\7(QD;&P\=!Q[_(/%$XIZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9 M\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW_ M_V1E%```8VEA96B````````````!0````````;65A M'0`````0V]P>7)I9VAT($EN=&5R;F%T:6]N M86P@0V]L;W(@0V]N4``#]C___^Z'___VB```#VP``P'7_VP!#``4#!`0$`P4$!`0%!04& M!PP(!P<'!P\+"PD,$0\2$A$/$1$3%AP7$Q0:%1$1&"$8&AT='Q\?$Q M)!P>'Q[_VP!#`04%!0<&!PX("`X>%!$4'AX>'AX>'AX>'AX>'AX>'AX>'AX> M'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'A[_P``1"`!P`+0#`2(``A$! M`Q$!_\0`'0```00#`0$```````````````4&!P@#!`D"`?_$`$80``$"!0$$ M!@0+!`H#``````$"`P`$!081!Q(A,5$($R)!87$4,H&1%18C0E)BF.O4:Q@S.S:"4.U)8VF6SWAM/[0_6/9^U'A\C6"[DW1T4]9)T<(N?0=Y M4W730Y#P&!&C"+ZQQR;DNSH]EJ> M,7G)Y]%,E8Z1^H4XL^A(I%-1W!N5+BA[5D_E"&YKGJDM>U\:"GP3)L@? M^D1O!%!FD/%;+,*HF"PB;Y7_`'=2E):_:GRZ@5UJ4FDCYK\BV?O2`8=-&Z45 MPR:@:[;$A4&1ZRY)Y3#@'/"MI)]XB!(!QB6U$C3JJ:C!**9I;T8!YC+]*[.G MVN^GEX.MRK54-*J"]PE*D`RI1Y)7DH5Y`Y\(E$$5!@,OE('85O`B3-)- M6M.8X%7X@A MJ::7_;>H%#^%+?G0YLD)F)9SLO2ZC\U:>[P(R#W&'7%X-UDN:6FQU1!!!`H1 M!!!`A$$$$"$0000(1!!`3@0(1'Q9`&\XB.M4M:M/-.@IFOUQ#E1`R*=)CKID M^:1N1YJ($56U=Z6EQW32YRB6M16J#3YE!;(&,(1D;CZQQWQ!*D M6)S3]Z1FL;]=F9FT[7FBBD-*+)YFWNG$]<]';SA];GV&S_`#C5OBW1O\(?]Q7ZP;T'(J?I\=/Y6CR]DEIO)&>U3S[' M?^HS-WC*$]N2?3Y*28W3;-&/]F6/)U487+4I2O5])1Y.9_,0;U.>!1T..M_( MT^7LM>WK.ER"69UY)QN"T` M_EB$1VA3*<]6XTOP.1%T?1$6:5C8@<29)OU#!<\NSN3\L6[*W9MPL5ZWIXRT MTUN.#EMY'>A:>"DGE[1@[XOQHSJ/2-2+4159'$O.,D-S\F595+N8^])XI5WC MQ!$@[ONAYZ0ZJW'IO=K-=II1-HV2U-2KJBE,PT>*5$<"# M@@X."/,0PP%NA6-4RME'6:0Y=18(@?2_I2:<7(M2*]P000(1!!!`A$$$$"%JU:H MR-)ILQ4JE-,RDG+-J=??>6$H;0!DJ)/`"*0](#I3UJX7YB@Z=/OT>C#+;E2Q MLS4T.:.]I![OGGZO"-OIY:I351N4::TN9+=-IP0]5-A7].^0%);5S2A)!Q]) M7U1#[Z)?1\D*'2Y&^KUD$3505S3R`-I2TM$YX;]I9&?&&JQ0*+*/K7*2ZWF M]LEIGI05M=&T>JB&E;+M06W(I(._"SE?X$JBD_?"-7( M00T+M-EZ"-\;JB1H.=A<7TU0-P````[H^YC7FIN5E1F9F6FOMK`/NA,F+HI+ M.0AQQX_4;./><0HUCG:!=3-6TT'\D@'B/TEJ"&J]>3>?D9!9^VX!^0C5'HR?X?ZF/'QJJW][+_P"T M(]?2R*@[4T(_Z\OE/V"&&FZZJ#O5+'^'_P!QF1=]0'K2\LOV$?S@^ED4MVGH M#J2/#V*>XA!F$[+[B>2C&@U>2OVU/'[CGZB,3E?DGWU+4AUH*.=XSCW1ZBA> MTYA*8EBM'51MZ-^8/(A*&8UYF3EI@?+,I4?I<#[X&9Z4>P&YALGD3@_?&>+L MPLKJ/'-*UC:/5R_9&K*M&9E9FI4U*'54Q]?5N/M*R-IM9[)(4,%*L<1OC:L3 M5/571>L*H?63DNRPKY:AU=I1:`[]E)PI&?I(('G#UZ*==50];:,@K*6:D')! MT<]M.4?C2F+IWW8MI7W2_@^ZZ%*5-D#Y-3J,.-'FA8PI!\B(8C-PL2LB$4EA MH5%6D72AL&\RS3ZVY\5ZPO"0U.N`R[BOJ/;A[%[)\XGAM:'$)6A04E0RD@Y! M',12W5KH?5.3#U1TYJ?PBQO/P74%A#P')#OJK\E!)\3$5V1JIJSHK6#0GU3C M+$NKY6B5EI1;`YHSVD#D4'9\X]W2JZ401!&D72?L&]2Q3ZP[\5ZPO">HGG!U M#BN3;VY/L5LGSB=4+2M(4E0((R"#N(B4+U!!!`AF9UM"&I5J0DD M$&>=`P%N@'+BSNX]D<<#>8\WLA37TOM;[/N"4D+;M2>-94?!M&/O,.J" M%W5+SIDMV#9NACS<"X]I_P`"16;8I#?K-.NGZ[A_EB-INBTEOU:?+^U.?SA0 M@BHR/.I6E'AU)']L;1X!:Z)&10,)DY9/DTG](]B5E?\`#,?[:?TC+!'FYYI@ M0QC1H\A[+`J3DU<927/\)/Z1A:%D0B5*W)9J84AA]U(P"-K"H>,)%4_KBOLC\HOAD??586,8= M2B'>$8!N-!;GR31?HDVC^C4VZ.0.#]\:Z7JA(*"=IUKP4-Q_E#K@4E*DE*DA M23W$9$-B0\5RCJ!HSC)!6.P;P31KPHM6G4J0B2J#$PIQH9(2AQ)5N\@>$=-K M-NNW+OHR*Q;-8E*I(KX.R[FULGZ*AQ2KP4`8YA-VXU4ZA+RDF0P_,O(91NRG M:6H)&1QXGNA?JE/U.T`U`1E]^C5'&VT^PYUDM/-`\N#B.:5#(SW&+6$<$A5- ME:0)#?DNG,-F_P"PK1ORD_!EUT.5J3(SU:G$X<9/-"QA2#Y&$+H]ZDM:IZBB3G6W52L^PDY0A]`!.P3OV2%)4,\,X[HD.+$JJ2:N]$&M4WKJCIW4/AB M4WJ--G5I1,I')#FY#GDK9/G$96!J]JKHY5C0G7)L2\LK#U$K+2]E`^H%86WY MI.SX&.E!WPU]0M/[/OZE_!]U4*4J*$@AIQ:=EYD\T.#M)]A\XBR$U=&-7T:D M66FX9:TJW*E+ZI9U"$H=;ZQ(23L+VD[2>UC)`W@CN@AZ6):E(LJTJ?;%!94S M3Y!O8:"U96K))4I1W94222>9@B4*C?3NS5ART9-QQ=+M]8EFV6\_+3:@ M.L5CO(R&QY'G"1J3T<=1;%M^1N-EGX68]'0]._!X47J>[C*DE(WJ2G^\3R.0 M.,(][.MV[TJ*E-UU.6)*[_2IG;&XM>DAS:\M@@QTN:6AUH.-K2M"AE*DG((/ M`@QYM="H9:5[5W4/0*MTVX:D[5*E:M1E9QB8?5M.JE'0ID@JXJV5]YR<*&3# M*B]M;TFLNG/2$X]+#JT/I4G3&Q96UZ2XY,!"E/3,RX,*F'E8VED#<.``'<`!OXP\X((M22(((($(@ M@@@0J>=.[22;>F1JC0I93R`TEFMM-IR4A(PB8QW@#"5<@$GAF-?HG](Z3I=/ MD[#U!G>HEF`&:95G3V$(X)9>/_T=1W)^PK=R(X1"%;AIUM]A#K+ MB'&W$A2%).0H'@01Q$5H=8:5L(Y[`.%-^:3@\C%GM/>DEI[J>VW9]TTQ^B MSM5'HIEYDAV5?4H8"4NC&R2>&T!OQ@YBN5@D;NE/X;7.H:@2MTXCF%6""'WK M+IQ4M/;B,NX')BDS*B9"<(W+3]!7)Q/>._B/!B1DN:6FQ7U*">.HC$D9N"B" M""/*M1!!!`A$$$$"$<-\-]Q6VXI7,DPMSB^KE7%=^,#VPA0S`-2N>QR2[F,\ M40HVU1:E<=?DJ%2)>20,DGN`,:3#+LP\VPPTMUUQ00VVA) M4I:B<``#>23W1:O2&D6)H12DU_4NX*;3KIJ,OM(E'%]8]*L'YB6T@J*E$=I0 M&-VR#N.6F-WBN:J)Q"V_'@IYTSM&1L>RJ;;O#IE6?(E;5KVY5JRL9`=F%)E&CXC.TLC]T1$5T=+K5*J%2:0Q1:$WW M%F6+[@'VG"1^&&<@L`DDW*O[D><(=QWC:EN(4NO7+2*6$C)$W.-MGW$Y,_Y0[9]T%U"N-J1Q/"*[6IT+Z_,%#ETWG(22>*FJ?+J?5Y;: M]D?<8L1HCHK:^DQG7:#.56;F9]M")EVT*\XMO!`A0YII1KSK%DO6!K-;S4\N7:"6:LR^EYF=;3N2 MHJ&%MOIW=H@;7'CF(-U@T5KUDNO5&FH>J]!!*A,(1EV7')U([A],;N>(NKC? M'Q:0H$$<1B*I86R#-:>&XM/A[NIFTZ@Z?![5S5W$`@Y!@BZ.HN@MF72MV:FCV?:G9,05=?1]U!HREKI\M+5R73O"Y-T)H=94A%,L^JKV_5< M?:ZAL>)4YLC$2UKG9`*N:IA@;O2.`'>$P:P[O2R#PWF,MJ6W7+JK+=(M^FOU M"=<_9M)W)'TE*.Y*?$D"+&6!T59EYU$[?==2A).TJ2IQRH^"G5#=^Z/;%C[- MM&W;/I0IEMTF6ITMQ4&D]IP_26H]I1\23&C'`0+% MHJY6;GW-MZ:JTPF7QR`;&5I2!N"=G EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`&SU:ATP$``/(2```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F-%NVC`4AN\G[1TBWT[$ MV-LZ-A&X8-UEA[3N`3S[0"([`*G` MW2Y5K,XY_.`\Z1I:E4H?P.&=A8^MRO@V+GE0>J66P.5P>,.U=QE<'N1N!IN, M?\)"K6TN;K?X\9XD@DVLF.T7=ED54R'81JN,I'SCS*N4P5-"B3O[-:EN0OJ$ M&(P?3>CN_#_@:=]O/)K8&"CF*N8[U2(&WUK^X./JG_>K\O20(Y1^L6@T&*_7 M+9Y`F4($95(-D%M;]M>R58U[YCZ1WR].O+^(*X-TWZ\??"&'),+QF0C'%R(< M7XEPW!#A^$:$8T2$XSL1#C&D`D+%J(**4@45IPHJ4A54K"JH:%50\:J@(E9! MQ:R2BEDE%;-**F:55,PJJ9A54C&KI&)6^5YFS?A$#[Q_??L/MQ]SYI$RY9V% M=.6_@?NAYY)K%<'\R1&[CZL#O)Q]AD,KJV;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+ M\>QRI9$P4P>J/OH\^;*W-$UO>"_F M?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;',@H@0!**```0`````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``"\6,MN@S`0O%?J/R#?&[.;=Q620ZM*N;;I!UC@``H89+N/_'VM-(5$BK87 MM!%B)R7IE,58W1 MB3AJ)S;K^[O5JZZ4#R^YHFQ=%+(8EXC"^_912I<6NE9NU+3:A)U]8VOEP]+F MLE7I0>5:8AS/I+W,(=97.:-ME@B[S<+YNV,;3OX_=[/?EZE^;M*/6AM_XPCY MU=B#*[3V(:FRN?:)Z$).GG86HX!8R-M@8,R,!L8D'&YR@&0'9\SLX(QBA[M6 M9*D0N+D!BILY,YHY!0:0&0T@"8>;'"#9P2DS.SBEV.&N%5TJ;L4!4G$PW)ZL MEQ7&9*F60\)Q_EB%R[^[.'_7U/GGD(T"[-20W.!DR$;I'%7?*UWH M;+)P0O4-M^"1>@?<:("$@]RN!FE;,Z@#]>&S0?==EZZT'F:8$E-TWA0K4E5E3X5JC0]G"Y$H>!6&%)@N`M$U@>XJ0&2&V0W M>*3#0VXSCJ09'P\J-:Y05F=OWH:_+9?.ZC+\-U3RZH?+^@<``/__`P!02P,$ M%``&``@````A`*SM)WL#`P``&`D```\```!X;"]W;W)K8F]O:RYX;6R45DUS MVC`4O'>F_\'C>V-;$)ID`IE\MES23*')4:/8`C21)5>20_CW?3+@/*.$H2=; M%EKMV[M7R(`4'88+YRKSI+$Y@M>,GND*ZY@9J9-R1P,S3RQE>&L ML`O.72D3DJ:#I&1"Q6N$,W,(AI[-1,YO=%Z77+DUB.&2.:!O%Z*R\>A\)B1_ M7%<4L:JZ9R7P?I-Q))EUMX5PO!C&QS#42][Y8.KJJA829D][:2].1FV1#R8J M^(S5TDVAO"TZZ$7ZA`S\+[T4CX(O[?LB/XS>GH0J]-+_%*1=M:,>$%@V4T^B M<`N83].T_?:3B_G";3\"?(+P&P5AG^89J::\K2(4.D5OE1-N1<=JK;[0T$*O M^A@JR^+(G`EX,>,B\\0QRK56!5>6%Q3>K):B8"`6O6*2J9PC%()0R/^A`(&6 M3`_!-'H?0&;B@%.)R?012O]`,AL43`;$;Y4Y_ASF3B@00S!)-QC*6502@;RT M,(TS<$T_-.3*BYMS`\9OA2"G:-7WWE5B":SE_P*NR!+'#D$S.PF[/T$GS]JPKVQ+W//G!B60KG3PK; M!`.$=]``..`$'&/O\OLPMKIE@1,G];/E?VN`H;>O'@PO'>"E@?WVMP[;K_<= M`P4&#)I'IPPZV:&"K9<%WFNE]$?$1LH/0+`3L\"*OHN?*DJ1+GULQ2SP8B<( M](8[)J2E][[;3KPBG*S#)W#F?GW!D6W$^MCA]$VY.&U7Y]C^]B/GWZ41^M[7C=%=5K;;.'85G[* MJFUQVJ_M?_[^_!#85M.FIVUZK$[YVOZ9-_:GIU]_>7RKZF_-(<];"Q1.S=H^ MM.UYM5PVV2$OTV91G?,3?+.KZC)MX6.]7S;G.D^WW4OE<U,ILC5Z;UM]?S0U:59Y!X*8Y% M^[,3M:TR6WW9GZHZ?3F"[Q_,3;.+=O=A)%\665TUU:Y=@-Q2=W3L.5R&2U!Z M>MP6X$`-NU7GN[7]S%8)%_;RZ;$;H'^+_*TQ_K>:0_7V6UULOQ:G'$8;XJ0B M\%)5WQ3Z9:L>P^'MN_JK??\V)_:"'<'CA2QE;;GW'> M9#"B(+/@GE+*JB-T`'Y;9:%2`T8D_=']?2NV[6%M"W_A24BDMPGL1>*,787S!`X]Y_GV5I>Y19S!.V_3IL:[>+,@::+,Y MIRH'V0J4E3,!XZ/[EX_`Y#FO5(=`/Q M,;*Y(&H`E6Q\>3#(,OQ*PZOVEW4@_`.VK'8[; MW8P)7V(D'B-$)!D3A@BR([`=%27WW?R[V%(O030-%WZ`^QAIQ#40$K;-72*^ M2R13!+()'9D?-06O;1C#:Y#\D-C32-`E)'-E0,WI[^'W5<(56"*^(Y%,2B!S M$*_YYA2,8R<=W+-((V;GJ;V[1'R72*8(9,__B#T%X]A),K,CC?@Z=CP4C.3N MQ@1\&?I$(#:_YVX8!F2Y23#`?7\88>0,EK7Y@5,P<4:F?:21WAD+/3:TVRU[ M&P1X@G/2\]@$7-A#!&DB,0'!',_(?&1-%2C&ZC^]3"J86".S)=*(MN9Z4G@T M)4V`R3!PJ343\*7CT;`G)N#Y(1=#7B!KX4>L*9A8<\ETTT@?-4H&0`X'<,=BCYT>NHXD_$IFH9WJ#4@;,V(QT7B(D MY)Y'B1@1KN/[H(-'*4$(#P(G,)($>U2;^^SL9+H4,/<#29(KZAGM\8%)7XA@ M&.#>I-;IF=LN$>)"DH8AF0D);FK:IZH#YOO450/LJ==-2Y+2(V*:F=H;[B/Q M?2291'`P51$PWZ0N&5`P22)%;%Q6T-U[,X.)>Z9/?%>$`1G.9%H%VU3UP'R; MNGI`-FD-PS33YZ/+A`/U/IY3FYXQXTV'(L8Z0OC"HUMFI MJPC39T`VO4B=IV`-GO8YKD;&/I&.X+#!2K(0)WU;[XP7-JJJA/E&=4V!C)*Z M)&*:>:?Q?A&ZS\0S=))I!AM5-<-\H[K"0$9)5D;,K$(>O"`4H4LBL<',[=46 MR4@NX<`[FJ&(F5YM50$QWZ?,?)W.4ZYH M$D?B(>J9L#L_/CB+TL`%H MP_H^55\WEGF]SS?Y\=A86?6J[DH%A.;Z]'J/^\S5-1QY'K$57`Z.G\=P[]L] M7UY?@&O7<[K/_TCK?7%JK&.^@Z:_F@+A>O5_9/_P,``/__`P!02P,$%``&``@````A`+:P"XXJ M"0``J#8``!D```!X;"]W;W)K&ULE)M=;]LX%H;O M!]C_8.A^;(G49Q!GT&[1G0%F@<5B/ZX=6TF,VI9A*4W[[X?D.3+)0]'6Z46: MI$_X\AR^?$6IT>-O/XZ'Q??VTN^[TSK)EFFR:$_;;K<_O:Z3__[GZZ]ULNB' MS6FW.72G=IW\;/ODMZ>__?+XT5V^]6]M.RS4"*=^G;P-P_EAM>JW;^UQTR^[ M5WUYTN[V9D?.AY6(DW+U7&S/R4PPL-ESAC=R\M^VW[I MMN_']C3`()?VL!G4_/NW_;D?1SMNYPQWW%R^O9]_W7;'LQKB>7_8#S_-H,GB MN'WXX_7473;/!U7WCRS?;,>QS1?!\,?]]M+UWU6!;OOBTKZLDT_9P^#\._NX_?V_WKVZ#6NU`EZ M=C^_M/U6M50-LQ1F&MONH":@/BZ.>^T-U9+-#_/WQWXWO*T362Z+*I69PA?/ M;3]\W>LAD\7VO1^ZX_\!RO2DKH,('$3]C8,(N:!-F#VKDL3*8Q[766*EJ>GJ03WJ4=5(E"U5%KQ;H^Y.HZ\?5 M=]73+3*?@5$?KTQV)59J-MAJ3:U-T)W_)VQ`LO05)@Z'"&WXU&+9ZP@,S25IR9' MR)>W>>YE2J8H1MLU3>6IS\V0ZP26O(C'F;X$,Z2G`HUFN!ERG;B5QZS.BK5L M*M<"JP,TP^JL6,NF%PT'MCM6%3JK9EQ-#4V%J=83MKF\,&/)3V4:M;H;TLTVF=HY>J@M6 MNAF:5D]3':'[5F>%FPC#3:;V,`AG"(3LS@HX,15P--41@KK%C%F:"I/O8Z0*R]3"WE> MEZQX,S25IUY'"->\U*M^/5+[VJQXDY!<[FVH=-84.P^06WILV14S/V.DIFGA MMBP4!P@*EWF>%O:$Y1?.RCDFPW03C;4Q]AP@7][>POG5L_)-3N6;+0SE`8(EKYN\*&S\^MJL?),07;[7 M[3T(:@/DEA[Q>LZ*.$/?\SI"XR8OZY@T*]YR35-I:G6$QERO8LJL9,LU396I MUQ%R.R[3R![/6>%F:"I/O8Z0)Y_9$/+\EBMJ?KP9FLI3KR,$2YZ791.KG*2; M?JRJKXBWGP'E8% M0\R-\9Y71G[\8'WJ>X"5=_E4WMF1L0<`N0L0WP&LR,O#R`O3'B%//K-S]*HO M6*%G:+H*=`<@A#N@R57_IT\V!4F]>5O`_)0_!YG9ZPFL`$)N"R);H&`%H*%] M\;#_"+GB,K,QY?>?%8#%Q.DNLX5A[;-/=X6:XOSX,S2MW2XMBNLAQP=SHJD* M"_AUD_B['7M%&'NBH;L?(7CX';,[*_"*J<"S(V/%`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`^_JAWT<*JI=Y MDS;.'0;I/BOELA2.:[=-/U*0[]FRL'0+[;=NWX7*%._ MIW_][O5%I4_"O&ET_0?UFM!Y\]K^-((OANYL M7M9Y[@;U@I#Y]$V]$=:J5U[4BQ?)XJ7KAO$+_2K3]1VSI[\```#__P,`4$L# M!!0`!@`(````(0`+ZA[5+0,``.T)```9````>&PO=V]R:W-H965T:_V#YO6Q9(%%(U:3J3*6I-!K-\NR`"58!(]MI MVG\_USAQ6-J(YB$)<'SX?*[-977[6A;HA0K)>!5CW_$PHE7"4U;M8_SG]\-- MA)%4I$I)P2L:XSWZZY?5D8MGF5.J$#A4,L:Y4O72=662TY)(A]>T@BL9 M%R51<"CVKJP%)6DSJ"S

WAPS@MWX8+3>I4RF(&.'0F:Q?C.7VY]#[OK51/07T:/LO4? MR9P?OPF6_F`5A;2A3KH".\Z?M?0QU:=@L#L8_=!4X*=`*!(MCC&8VPR",+*^!LYHHB;%,)A/>SENV]=] M?QJ%"VO0`9M^!DR+^V`77P-F-`;L$H;)JWUM,O/@\SX4;)KQ:6EQ#RJZ^!HH MHX';VT1G]LX&[9JB$]B\RZ:WP@0>.-?7EA[49^RMZXW1M!F#J+_@AIK+/#J4 ML,G:"8ZCU(/ZE)-N3ANCZ5).NYKM4/,!I>Z?KM=W^+FCZM;T`S;8F>_I$ MQ)Y5$A4T@Z&>$\*N%:9=FP/%ZZ99[;B"-MO\S>&UBL+CW'-`G'&NS@?ZA<"^ MJ*W_`P``__\#`%!+`P04``8`"````"$`9/)SMV`"``!A!@``&0```'AL+W=O MAIC9"RM&*@K!^%*QG>2U M#1#-*VHA?U.*QEQHDG7!2:JWN^:)*=D`8BTJ84\>BI%DT]=-K31=5U#W,>E3 M=F'[P1U>"J:5486-`$="HOR57X`WC7)>T%UE?ZC# M5RXVI875'D!!KJYI?EIRPZ"A@(G2@2,Q54$"\(ND<#L#&D*/_GD0N2TSW.M% MZ7B0#(:@1VMN[$HX)D9L9ZR2?X(J.;,")3U3X'FF)&EG"@DI^0J7U-+Y3*L# M@ET#GJ:A;@\F4R`_+@EJ<=H7)_93(%D#R["?IZ/>C.RA=^RL63S07!4$3*_. MX-;=V8FA;1BUG/M7KL]N$33]EF9P5?SG#)CNSDZ<86"WG/]Q@W/0C$-'TE&: M//:%U+K[.K'S]5V.DUO+$![Z\"0>C]/'EK"]NELZ<$6&*D/X7QFX6^CZ<9C_!0``__\#`%!+ M`P04``8`"````"$`8V,O);8"```$"```&0```'AL+W=O/7[_G@>'K_VC;!"Y.*BRY'.(Q1P+I"E+Q;Y>CWKZ>[ M#`5*TZZDC>A8CMZ80O>SSY^F6R'7JF9,!Z#0J1S56O>3*%)%S5JJ0M&S#MY4 M0K94PU*N(M5+1DN[J6TB$L=IU%+>(:M-?U>(M@>))6^X?K.B*&B+R?.J$Y(N&XC[%0]I\:YM%R?R M+2^D4*+2([GVP!?LB@9!7=-/JGV'YE?%5K MJ'8"`9FX)N7;(U,%)!1D0I(8I4(T8`">0!CYT=-YMC MW%_T;+,=`N>;S0UR-^9ZNF+?J5SQ3@4-JZ!-XM`,7>G&N%MHT=NQMA0:IJ_] M6L-MRV#FQ2'`E1#Z?6$NBOW]/?L'``#__P,`4$L#!!0`!@`(````(0!06>%W MM@,``)(-```8````>&PO=V]R:W-H965T&ULE)?;CJ,X$(;O M5]IW0+Z?@,EI$H6,&EJ].]*NM-KCM0-.8C5@UG8ZW6\_94R(;9(9*-",EXG"$\B%-`ZYP6K#PGZY^^73Y]1(!6I"U+RFB;H@TKT M9?OS3YLS%Z_R2*D*P*&6"3HJU:S#4.9'6A$YX0VMXBXHHN!2'4#:"DJ)] MJ2K#.(H68458C8S#6HSQX/L]R^DSST\5K94Q$;0D"OCED37RXE;E8^PJ(EY/ MS:><5PU8[%C)U$=KBH(J7W\]U%R070GC?L&H(-(:]>1(MA15CCG?6NALPH9I9B[BJR[RD<,C`93Z;%"8)1 M]S.Q<..F1F&3+5U%-E1G]Y\1T\L-ENUO85@KP[33O-]/N-C:^[QZ4UZ M/)_9TFV^V"]7;#1V[-BOUQN:>WQZJQ[/9S9VA\\KR10/-__8JY[LAN8>'XS3 MYM.]SA36Y`].=?V6NPYCKSQ3;#1V'J\,;2%EG631;C]X-IM'2WQ=SFZ=/'1> MZ&[-Y_."IYW&YHO],KZAN=JX?`^=&M#R#OBN`S>[3*=Q^`9U_..#PW2\IH&K MJ#C0C):E#')^TATLAM3W=_N6O.N5^P?0W#;D0'\GXL!J&91T#Z]&DR5D69CV MV%PHWK3MX8XK:&O;GT?X[T.AW8HF(-YSKBX7NIGK_TUMOP$``/__`P!02P,$ M%``&``@````A`#>1FR5<"```FR\``!D```!X;"]W;W)K&ULG)K;CMLV$(;O"_0=#-W7ED2=O%AOD#1(6Z`%BJ*':ZTMKX78EB%I ML\G;E^2,1'$HRF1RD61W?\_/F2$_4EH^OOMZ.:^^5&U7-]==$*W#8%5=]\VA MOK[L@G_^_O13$:RZOKP>RG-SK7;!MZH+WCW]^,/C6]-^[DY5U:]XA&NW"TY] M?WO8;+K]J;J4W;JY55?^DV/37LJ>?]F^;+I;6Y4'^:'+>1.'8;:YE/4U@`@/ MK4N,YGBL]]7'9O]ZJ:X]!&FK<]GS\7>G^M8-T2Y[EW"7LOW\>OMIWUQN/,1S M?:[[;S)HL+KL'WY[N39M^7SF>7^-DG(_Q)9?&.$O];YMNN;8KWFX#0S4S'F[ MV6YXI*?'0\TS$&5?M=5Q%[R/'CYLPV#S]"@+]&]=O763_Z^Z4_/V2UL??J^O M%:\V[Y/HP'/3?!;2WP[B6_S#&^/3GV0'_FQ7A^I8OI[[OYJW7ZOZY=3S=J<\ M(Y'8P^';QZK;\XKR,.LX%9'VS9D/@/^]NM1B:O"*E%_EOV_UH3_M`I:MTSQD M$9>OGJNN_U2+D,%J_]KUS>4_$$48"H+$&(3_BT&B;!T7:91F]Z-L8$0RP8]E M7SX]MLW;BL\:[MG=2C$'HP<>><@,QC'F:DN5YRB"O!=1=D$>K'@6'>_/ER?& MDL?-%U[3/6H^@(;_/6JB4;'AHQF'Q(-Z& M^=@(\2[@LK>\Y2K7N;Y4:10[TC01CG@DNU;FY6'$58M%KGJB6Q/*.7;= MI-U,UT$TK8"MZUZLBP%C^I'9Z#J(\!AG66R$Z;O(MWAI=-_G&$LMA*O8B MG%3?[3H0#KN>A)DJB]YU+\K%)N58HB+C&@>10[?%$<)]MDLUS5M5%,Q1A*>I MPGZD801RRRV7:NI-6XZB:>+6AQ7FA3>IIO8*(9BZ"+D+\#271PNY$\BY+74V M8X)(SZJ2:5H#./!0M`IX1S-WINXFW>$L)*T..A(VM^RHC<',L MNPDYEJ@S"_8>1-.I9R$L\T*=5-\M.Z!ND;#,"W%236V-LFN(8V&F!!KBF!?B MI%JW9HF*C.5V1ESBA3BIULW-!T84P3KG+X!L#\J)%^&DFEK3U8VBZ32S$B[Q M(IQ44WM*.!1!YE&ZM;_]^B[`)7.`4\L(6H^B:0F41)MWB1?@I)H6@`(.1?"\ MFJQY[:=_5+GT<7@1+W$A'HKP=!$G3&W#NO5W$2^9(YY*#OO@3+S$BWA2?;E)-*ZXF%)BC")>^@)Y2:(FG7M23:NJMNHG>\-`ZO/L.U<]U9R_@I4)-G2EO M432%C96W*6'>\L%&JJD]G6PH&I8Y?T\T__B4>I%.JJDU7=XH&C8Y<9BU>'O1 M+37IQA+U!@;[#:)IU2V(3PG?[M3B3?PEKR]J)8"L*8+W'QD M1=$T;_ML\T);.HLVUJ2YVPS>TE"1]&PT#.FGB]T:X(XM\IG)NK8I+>8/(BF MD\^RZ#(OT$DUS=^H/)S\QG-5,CU6;=5$U8OA1;U,J.DXC#Z`:-C=T\F#AV[M M!;UL!GH3E&/]G:&7>4%/JFG>:F&C.9`1EWYF/==G7M"3:FJMFHG60$:P3I,L MM,TZ`CS'J6^"CZ5TE\]`Y#+U"?F6]YO,))[Y4AQ%]Z"3$]RYI2\_I7>`I8HM MT`$4.:2?>Y%/JG5S,WT4^:W\G&!PN0U2K8^#I73EH\BE"%[XRX%L?,#C!0KS MS($B6`/B-^]J?6K8R06>G%_92;6>=SQA*39?A-P%\.Y(OK*T>1/D.4[`.?2I M%8YC<$9?[H4^J:8%H%L/BA;?6>8$>XZYFV<^EE+\R=!.OY#+"0#O3'H3?#.+ M#T2++PYS+^1)M5[RZ5,+]MOYD%<0ZBWG+-6ZN7G(1M%TH5L/V07AG5O?Y:?T M89A[#HJFPU#+0EOTA1?LI%HW-U^8HPB/.1%_R)E_QBD(ZASS-Y%G;CHRM-.\ M+[R@)]5W\P?HCX<(\%+GTWXMY!9SD]/V&'GA0-#6WKP'"OCM+ MT&3>S/0#T7#*#FW7^@I"/,?I9Y+/Q*X,[3;]O/A7S!WYC/*;_&.V"PG\RK/' MEB_5]V8_BH;R;S/UHA'``W>DX0KQI6I?JI^K\[E;[9M76QN^.=[/? MQ_)V]?@#?C7Z5KY4?Y3M2WWM5N?JR#\:KG.^-EJX7`U?],U-7E!^;GI^*5K^ M]\0OP5?\FF^XYN)CT_3#%^+Z]GBM_NE_````__\#`%!+`P04``8`"````"$` MEE;A^+("```0!P``&0```'AL+W=OT6A!A6PI-2:4DM#'5%3*V1JM?^D1?%%M!S"AC*Y`FR5 M>G+0Q\)-P6)RL?K!%^";1@4OZ:ZQW]7^,Q=5;:':*1AROA;%ZSTW#`(%FFB4 M.B:F&A``5R2%.QD0"'WQ_WM1V#K'XRQ*I_$X`3C:1I-1NET=@4+"8J\P7MJZ6JIU1[!H8$]34?=$4P6P'QT%G3T M7O]E%3PZDCO'DN,I1N#"0'F>5^-TNB3/D"D[8-8!`]<>DV5#R.82DO0(`H)[ MU9#%J>JWZW`4Y\!.G*N+4[L.$Z=*1OTV'K%Y#S$0`I%=+\2!H?0G"23)?+CS M.F`F)YATB-B\AQAH`Y+KM3EPCL%W7YUQ.AONO`Z8F:]O-IED<7:&V+R'&&B# M8W^]-@<^UW:>6\!D7MLD&<=I=E[3@`"%O<._R0ZT9?^CS8'/M&7Q66X!\_;. MX;P%1$@VB>'7,P1EH3.%%U=R7?$-;QJ#F-JYKI.`ZWZV;XAW(]_3^@?0D#I: M\:]45Z(UJ.$E+(VC*>2B0TL+`ZLZWQ:VRD(K\K&ULE%3+CMHP%-U7ZC]8WD^%+Y(U2>-X0B05#0X,,WT/ARI+P?A*L;WD MC0TDFM?4@G]3B=9":654:2.@(\'H;>8G\D2`:3$O!"1P;4>:ESE^26;+#)/%W/?G ME^"=&;PC4ZGNDQ;%%]%P:#8_;,3A:UR/)I$ MV6,\2@".-MS8M7"4&+&]L4K^#J#$F>I)TC,)/,\D21JETRS))O]F(<&1#[BB MEB[F6G4(A@8T34O=""8S8';)1M"?]Y.!&U?SXHI\*:`-G,9A,9HD`:C^OP-7!$XQ&CBX\GN7RX`9#S#9^PZ`9NC@[]D=.,>I3YW& MR;BG#*)A>^JWI^,TN[;E36AP=;^D`P\DKRF"9-B>!$?C;-H[>J,(@W:_H@,[ MQ6%[1SUOD`V887O'5TB0#AIVI)OZW:_=O_^Z^$N<9U^*-IM M<>1MM7;?JM[]MOGYI]69=T_]H:H&!RRT_=H]#,-IZ7E]>:B:HE_P4]7"+SO> M-<4`E]W>ZT]=56S'FYJC1WT_\IJB;EVTL.RNL<%WN[JL[GGYW%3M@$:ZZE@, MH+\_U*?^W5I37F.N*;JGY]-=R9L3F'BLC_7P-AIUG:9<_MBWO"L>C^#W*V%% M^6Y[O)B9;^JRXSW?#0LPYZ'0N<^IEWI@:;/:UN"!"+O35;NU^YTLG/_#S+UV]_:UN*X@VK)-8@4?.GP3Z8RO^!3=[L[L?QA7XHW.V MU:YX/@Y_\O.O5;T_#+#<(7@D'%MNW^ZKOH2(@ID%RBCY$03`I]/4(C4@(L7K M^/=<;X?#V@VB11C[`0'<>:SZX:$6)EVG?.X'WOR+$!&B)B-4&@E`O?R=+F@2 MDC#ZVHJ'BD8'[XNAV*PZ?G8@:^"9_:D0.4B68%EX%D!\/O8,U(A[OHN;QEN! M[F$Y7C8T77DO$,%2(MD'B$GD9-&\%S7>%F;@,$'UYFT!60R.\K/ M$&$:$II$?HDPI,%SKIEX`M7B@$;*-T.7&&]:[[A'[61 MMMJ9,HR9)AFHOZFOJ`4;D?PB8LK[?P,!F[G>VIAJYE(F,AC$*`TB9N5E3G0B M)(F?*,(4*?JSEGE73BWLZH9(57%2)#(HDD(SB:U4R(E!4$I3E0JFR)MF`YD/ M!Z8ZE12'C(P@8Y$?S=0AHN?"9S5"1,/6@GBY?$?:K!*F')?Z]!%`TA1JV.P\ MN;0BPTNBY-/@W30FQ%[,*F%FE4`F&7QT'"9^.*MA`TG#F,;*0W-I;QH69#XM M[-3/)(/J@B@FVI@:@YL;!`MH0E3NFN)N&A=D/B^8W935.#8,N'K)YZF[WQR"2CY[QZMI2'9CY&3'G6Z!"M)?IZ0SR? M(6S6II'1-6BE*75>9`RAU)HC0F@,=7"YC,>[S#(.[48M&5QNPH+9CLH$H(J5 M!5.B-4N^D#:?(=J&:(Q/1O4)06`*BUEL]1B3H3YE4$T38PH4O5QK@=?-$8H3 M`#ZGG`RM1I=)!F-XEP8AM2O&),(T3E72FB)%2]=$?A%%'`"&.+5)DE%$1HHC M21C%++'2-:P<\EI^*??5[ MT>WKMG>.U0XRS%^(LN[PK0->#/PT'K\?^0!O"\:O!W@[5,'9W%\`O.-\>+\0 M[S6F]TV;_P```/__`P!02P,$%``&``@````A`/T_X@S@`@``1`D``!@```!X M;"]W;W)K)+1B M@2HINUD0B+PB#18^ZT@+=TK&&RSADF\#T7&""SVHJ8-1&*9!@VF+3,*,7Y+! MRI+FY)[ENX:TTH1P4F,)_J*BG3BF-?DE<0WF3[ON)F=-!Q$;6E/YJD.1U^2S MQVW+.-[44/=+-,;Y,5M?G,4W-.=,L%+Z$!<8T?.:LR`+(&DY+RA4H-KN<5(N MT%TT6T?E.2-;\,5!TB#(AHT-(#/:' M^R-_-$VB)/U_2F",=('W6.+EG+.]![L&YA0=5GLPFD&RJBR&_KQ=&92DQMRI M07HHT`*6XWF9I//@&3J8'Y#5.3*RB?4Y$8<]$H!>[PB5GSH.NRD8:D!>[S:> M]K%:?V60\0F2V,1ZB+#48)[+U12\0)#=JR43>^*503+=T^C336S?7K][VY*" MRBZ74K`CY?;+(*F1"O6?XS5$6&JPW2]74["CEMD3KPP"T_&POYY^\'F'&W*UVM./N5EJR/<%@+DID26),L106 MV6H%8!YBCR*GV1^_V^M555<5:34WLX<@$EB1R+7X5O?^;26 MOO[GS[?3Y%,V+R;Y[)MGO9WNLR2;C?+Q9';]S;,?+MYN'SY+BD4Z&Z?3?)9] M\^PA*Y[]\ZO_^!^^+HI%PMQ9\Y:,\N5L\?5U,7GV]>/4F'RUOL]DB`8SD9+:8+!Z2TYE;'["_WEV\^GI70]WP MH^1=/EO<%`P=9^/XV_/L;B<9=#M)O]L;QE^^SS_M)-W]]B]+,(Z?!,;S>'$/ M^E(LYBGG>9_>9O&HYS]^^/[TXO3#^X__*?G^XDW\M5_D->B8IU/0,,X^ M)[_/'N)QS[OZS]%@T#QD>8Z+A[OF]KWN]A_BQ].*5/5)^ MRJ;3[9]G^?TL.<_2`GX=)Z=%LYMS\$4^^KF3G-^D\ZQ(/BP7)KP`&!^DI*E'O"?M6V2M`?'S/PP> MFVYT:Y_<)FBO\CHM;N+/SN;973H9)]EG%%;1I-.'Q0WX'WG^3(L" MD.(U+O(%3!NXX;AUS-D3NXD(IUDEBWBY4YAO=GUY'*:)6Z_ MUE%NT_;-OC\]_O94"N2D@8/CD6G;(KE+'U+;`GC2T6B^!//327HYF4X6DR8> MWJ6S]#HK%?!X,L]&BWQ>/$^N,GC,KQ8?Y0VJXE.ZF'S*RK4;K/O\[W_[^]^: M$Z\R5,(XN38=.<$:-;7D*MZ_7P_\=[:(*&UGCC=SZVR8?W[QX?7O?_?A^SG+P]?7UZ\3(Y^<,/IQ=_C)>#I3SP)H?)\7)QD\\G?\G&7R6]#@I9 M_R2%$\[\*L$L^O&%D]MTD6QU=[K='FB=)Y_2Z3)S*@Q*0:V\DN>ODO>3:5A* MWU6_=A)D_PXB@?QI`^EU1;$*H`,O`A'L2Z_\"OAZP\Z@>]@YVB]/+#![O<[^ MP5'G8._``[\9VN/Q&*;,9TB9A'5[,DM&Z=T$J8MQ#WLO;Y=3TR.Y$UT4YCR[ M0;B-"_.B(;[U.6^RJ\EHTA!)QR%&SIM\.L8DB`W<6-@`<5XT4-S@*B/>EZWQ M1`UYAI['V"U9!T_V=`=-K#X&Y(<5((\1W2:0\:H?LT_9;-GP M\4[66-COLAE8F!H&TO'M9&:.L=16O#`V]"HK%*0P7&8G'G".YS#'>#DU>84H M8T)7EFR=]C$K<#A'-S9M#/33W*QSO+R3:$\TO+UU)WJ?+0)I&24ZQBLYK^*T MU:J9L2K0WJ,,'#2$Q]@"78P2"J9U#D>EQ5+_-VNH+@/&-.$Z<$'KIXFPFA!- M)<[4)HOT#O%X[L(RJ>-,EPB@\Y33K9Q/8O)R-C@S62Z1.IBPOT$_#=R4H\)EW&(6GSL MIRRS1J^O:@>YJ\G;:7[_)#50L>6Q;'ZK$R?,3%O8\;A"?;+(Q7KY;$3D(^_4 M)NA3_3P22$MY[)A@.;20#A9/RQV_BA'V)D.EC2:>Q.B/]%:QTE_L@WBP&8_D M,M4&(Y0A1KMU'-0MW1&CUGTZEXM7)$YY"UP<]04GJ+FTQMY%-O^$6FBPV'$- M+*GF0JY86([#IN-/%I3HJS5+O,]GVQ5.O!QM.P_V"^5Y>X-`O[XA.D#'K5+` M@@[#1>W$#6J8:(B&/PC%I[.:FEK/-:>S3UEA=%X_YFR)_H1N9M;N6F.=F-BK ML'":I^SS=C*##.*Y#;#,\U&6C8OD:I[?&@D#Y>`IXQMSO6-X2KTK%S/^D@`\ M?;#H!P:8Y8OU(4]Y+%.K8]#\K=((CX-]0PV;FLP^@U-HG:`=)7DQ M4-@/,FI%)E9HBVU-@:#4R#7-9L(9:Y]9\B9>R8]42F?MF//EW=W43`S6]PV) M&C0)-L/(7"V4&:G]6MDRX[8BLFO&GR^HB"\3I!Q M&V>7#0-9Z6)/)8Y7*>(8SO=&>_3+4P@$1_(F);R^S+*9(DDB1ECN\B$AAV4QDS*(DUMYD,D+#&CRRU__ M%>S#?24A&UIN-L)R;Z:S(W*4(VJ?+-MOU5GB]F,$0RKHF# M0P#G\6@Q6UF=JT:XDEPL+8+/QZ:H1!+[?4F6&_+?@<;1!-DKDFOG*[,XXW5: M6UR(^V%F)#;&-521AIT3#M:.AE'W7`@^ MP#:.L#[AY_@5<-L0NY-<,!LB-]G&?`"M'7B!7#6K-#G'Z$O2J&"\%V/U=Y*- M@W30"DUMR##X2TY;%MJQA8W$?TU^@S%UA+7,E6(20(3RB-`O3:[M0/"`#I0X M[4R M_@/^H].='P2!H\-LYPF#'@Z*G5S?-+TU[%4A'Q M1!K79\\DX8OYY'(IA&CM\2Y,Z[D(/F&_V_0!VP+-H(PL"V0N"--,&THGNQB` MV3M)E2)&8J$W%(,GQF,$0H1'R\QPRX*4@\D7Z4N#0(A1!CZ;CR:.J@M%67R' MLV`@YE-6R/6SG&\T$WJ?^9BD.8P M38^]GDZP=.(%(5;SBQ&$,W2ZCX6(L4Z'!Y""@#N7SA#;+I98OP?B%@0"GF*5 M>5(@0>PA#BN/:#*0+HRX^/!7)%@EV74:BS=7?!,_&>ZOJ?8QT2(:T^MSEN44 ME1<`O)B86R,QK%6Y!)-5;@=-V!VO6S8)4'*Z8:)G?LSZGY=(;&#]#D("/RVG M.$N(6PXRC+E'YE#7COQU5%@^7][>RG\!<>?D,B:(E*JXQY7^/,/S0LP:(:8I M],%.\NM7(&K3OB=$8U35FSN(.D[5ESJTE3XH4_#)H=%M#\Y,_W#^=*O@E8&4 M0UD4@N5OTY^S!"?"P>:8B?SOK:E;:0"HGKH@1XR,KTHF`*R3$<#R&"NNV(*R M%F5+52Z64.#8`3O&DJVA;^*\F$0E14W0CJVXD!NR#IR@]`V`4"%,QDOS:ZM) M)G7F6ZY:(2K=2J9<4X^0?YNIDF-&8SV2YIGLI''B."3A$2.*7Q8:V5FM(N0( MC%SG]W(:4;\7G#`8"J50L(`@=?U6J!TSD*#PB@0.FA(534D/?IY:.91,JBRF M$/2)M&J^A$0<&@/!<$I_CJ*(T64VG:!G3$6;K5#9W007#.F@.9LJAK1O`!_AEP,%3PF[?UJ.KRTSZ*VKK4C.YT%?6H'L,?;1#!37 M'%7H^*<`.3I:25;'GRA(J2ZYLW+T<'"LMN)R"2NJTV$<5&C)X/1I-8`S:`!#(+5%1HDKG=JE-^N6O_Z-&0G;,#3_9YX4XGX&` M*_\T+.@W$-T*R+*X5U2H]5;90)^L`MX)'D()0>_<]V2M]QY,CSNIN;;& M(?H]$$2HEXC<4]*;/FS3,8+@R9^;C"=61J"#`OY*45-9&4XG9^B3[Q?C#FF5 MZ?4$)R<$VLGYL0LW?T='S1S51(@U*C1^1Q-VDF-\M*)F,B;*AR#:=[*/EZ[I MP?&DI<4AD'EE56R*F%$>,?W@-'B%Y`9!+".C$]H/JE`B)C!-PRJ)'`$CPO\$ MB04*8+W!0L.3SBG'F-.OM'1"Z")4<1VJ$`MB^G6>P8>NYPHB$:VRBO%H@D4P M':Q$C$6X&`N8R8)WN5D>,C!D4]8$8XT8T&F1`/L-\>=6OS/L'>'2'YA<;1T> M'G8.NL/5XC(G<5L+.PT88FYM5`02)?BL<'"&))\KE1C/647I[1V%!/F^/I4. M<[B"J@"1+U4/^X_/7R?]?1K33M*Y4G;P3]@E1!ZE];U#5J%H:>HO44]*GOL* M!OI+%8R$R-.M5&W\XN3L'(?8J0:T>6DAO:DI7;D=7Q%AO+Q6,:NM27YIC-=M M_F9YL/13.IE6_EJ5:O4E\^3%#/ZA9)#/7RI#)5F\#_44@*I0@2T1,T.\UU3.4IWF]%LFC^YVO8#^=+-MN2;P[!VJ1W%,7K`D%N*I!!DB]2A/&8E]F&L<89R43'5 M`]S`*ZX$U#!/`UF\\_E[$BI*FNN(]7C,[9E[3P[Q#@67G>2MU\C$3Y4"6*>7 M.\G><-#I'^Q5E`@K&?+ZG<'>@7U?$@@-5%)M96R`YEY&D%2Y4I`U\&OX0\JG M(S6%**]`3,OI)@1XCC/`F<+WSQU8ZB4=0UVH*75X..AN]]&()*X;D+\C6I6Y M^N6O_UV,V'(L;T7)=3L#O"9:*!6+DYXKOY8'WEH*X+)0KF90)^OG+3OZC'9&BT<7*2^\ M&--8TO05C97=<-714-"*CHO$!3W+25><$:96G@H8\7Z6J1SG'4N#K?9;-7R3 MCZ0JHI!YGL\(`DGRMKDH56+)F"-X*<`FG:[$A\+`*@`G=U%;#?RH"6W>V7D M3?)KYQ3:/H^#MD%F#5\AA5GSYTU,9<^=ORNF_( MH1"S*YKUS+=>,6HA?Q`#(YM2WG0[X9*P@@EY/7%R3G0X3N?C(OGASN+V]_F. M=>AO]Y#_-U5CCNISE$5/T-OJ54U>7%"P&B5'O;V77R4GWDN6LE8UK6>H&/6_N*WZM*,!1]0)YK&FX?>%&1P_B*Z"-,\#K1 MN`')`&D*36@\=[$M/`RQ%P_TW;DHC\-`?[0=X00AS\B0:"I`A[+?7>U.2_U( MLO_;24YTY&3(S[.P]9+B&WK2M5[`&N#3-!O6&>RBS?3U5'Y<<'X5[!ZY:HHI MNM[!FM)*/5J(D4JN+C2)QE^YZKU++,3?O28='7]6;QN)O^/DS2ZXK7C4F<-C M_/%*$!1_^8:P"\P(VY63\KA$2NHU1\4H'SK7T211&ZP&56BQG!PGK><*Y],@7I5ZS%>>07NIJT-MJ`Q?.ZLW'Y"F#R9 MF\'R]1QX:VNP9\W4.\E[JH>-$>89UHY0"QB>CK:&]:H)4C@\*DAXY7+4];;8 M%B\\1)J?2>DIRK&JH_P#G-XK/"VT6*-50A$@C)"/5I)V5$O4UR, M-<2]464('#)(W0`8QOG/>$MD!I88GSH,6F,B7;%6F`:7QW+MG&*S&

G$%F(+G!>'M.>/T!RB-$YURW>XSJ MCS[Y>X:-?4@NY+%Y]S4>^5Y:?V\G>?J,%12JZL?*I+ZLU0`$3CG(6*4C-H9T M=ADK=PVTQ1T)@HX2-A@"8G[&V;3P-6U!F%/Y"5=7+@%FSHVL"?5W\CVJ/+FF MNVH%!.,RNTFGN%\KM1NJ(T21=KQ#BV[SR^GDVBF7995,]@=HR";:0\'\N9KW M6G&VKV:<=6/FNF?X89:\S2[)$Q/<]_TEP(Y;B^_UOS/^5?Q%O,E=R>ZSW5=? MC_(ICO'\^O*;9V_YCR[=Z>/Y6^!TXRY(@16DCNZ3CSF>H[Z]2F^587;+Z(-= M6WGQ*MR&>60[I.66NYB]?\=.+%&Z:-Y+[G7V&A=41CY%8BV1"CY2>$17GDP% MES=:D))4+H)+)VWUN<$BF^02.41?%!:EJ\1?;%QD(0OFLX)PHR+Y"H`0[5.J MNT4.Z2%5BMRG)2S/Y&#QGBC`U)0>P``!BK0&@60@+.HV,V%&9S%XT#G:V^OL M8>&JT.[;:3KZ>?M\1`(+ZGUP?0.DND?2U[?Y.)O6!CL%JV]0_J'J]15]8EX1 M)TK(=`35_J'/!QFR[",`+?,M_M/^X.B?DD\YDJDK67A?O9V][C\EA'0_8RN0 M$L6;H%5%L*J]5*U/1^17PCD[85U#&+(AFA=<.35PS#+HDS`\!$O"K.5&E0^G MTNPR/TZ\:T@[[,,N!R&3:,LZ^X;*HP_B$_"]6;*5>D,`%_+3_5>VF_MHP^^= M4+7.+`#TJ1DA3G`(/BH94W[U^676BV5T#]@(!C66.=RF%"'*4U4Y="7NI.H$ M('%.V4,?>DW4MF6Q9)R5/>RA;S^P/A9*-][D3)6U(W<=#NXD'V']%"$-2I@B MZK"F=XF\OH/[0S;<\_U6;WC0Z1WN:ZPP[W"]U=_K'.FVF'4SES4E$U8M%9*D MJHBZ/*:$E()#=BV7P5^Y(#F%&[1H@4_XJ@#!L5CB^9N(;AV:B^=5++JH=KFZ M54<:[E&N=RIG!&VR;\GX=BC%%H]T:3L'P`OHGFD:">NJFNG5A3S6^H#ZSNYV M@$B+)5<=W``GB`=JCO#M8I[I7K%;" MLN80$F-!?OI'!U+LZV9Z-*`>_F6)CZIP6\&`^4>P*DT\UHL)2_FM357[6=IC M9IT^85#(*\1V6QJP+,.A1[D:FB5G*%DG]N^(J'%ZQLM;G(-12E(KH8_,]RY= M%@3K"!.%RMD8A]JEXE,*;:&E1>,3DMW%@%=GT*4_*^6SFRW^OT]];2:^.N7\BOP_W.P?#0 M,CR!SAVGT=E%R8Q6^(:DO0>]_<`/X&2%%=L`7$$@37>'@T[W:&B*M$_2?_!% MIY5)05%;!P@:T?HT/TVGJ@18Y/8#3:[1(W#0KC2[3`1 M+/EFGXKDT4'7!1Y.W6(9W$TOS)6+(U51PTK:)08X[`JQ<39'G`>3ZOJP.-ZX MW6ZOU[$AP[0%>L&G?0=V7&:V-%N7Z>SG9(0.H>6W@953L.K%_0EL``\+FM+0 M`HA,BGD"1ISUSIO%JVAR*]TYLRBOQL6LH'1K4"'1X:O4+(-BGL,-6@G#$),[M2RR17KH M9G1D&>Q)+&81>DP>^SM#-&?=D:\[^%K#%1.-%1XA/7I2=NVW]=F-\MMURA-* MH.LL`/)DQH\?MCCM_!('F<]K'*>E]!&_6_:S4B^5D,,.EY)EO/PW9420EL^K=><6I$V.LW M9)L3^#_P#3C_3;BF9GI:A+5R&S;ZDU^@+$W^ZH(6TYP*>/>H_X_0]5K3\53:E-F[MDBJQ7$I_,;W,J`R"5^2V'(%3U?L_[+TEC/0X[:$E<(&?U]\+,G9PB<_..QT M]XBMR%/QJEJ[T6HJOE'`*ID!MO88$X5//!;V,'!9;X%WJ!SY5FA&GY#_C\H&M*6-E'^>>6:WXNMEU[B!7@8TSL=X;$SMU]'.8(3E4H#YEV\B\6VJ1!#,ELLE?C`GK;I/G?B&U]CJ- M)^X3=GI#P!_+VWOKR8P_/?GL[FO%G[_VQ1EJEO%7)Y_O)LY;BK_Y40R63*[B MST^M=R?^]$/5$QI_=6;UAT:5_?O)59:\^".%[^)E/"4"ZQ27,'5#IUN(AB7#$3U>)O#JA_9]3;5\=8QDCT[M M%CI3$_*JBCWK"4B[YP>^\+[?<;NBYW,XP9G*?;^JGJ^0`B&!J`SFY+.K(Y`. M5U,[90/7U6X)B;H74K;"6DL/9[#]G$XDM4Y.G5/5&ZOF@T9YWA,7CR:M\9U_U>H=39^FI.UZN[K&Q33T[91][@T!XOO5=4WQEX^8 M52)8%<0W*`M$J%]&^>N/R$UH;X\OJ@,YAI>`>4FJR^/^@5,`3B#7R=SBGD80 MDSM:#F84`%%11FYC;?^9"0S*J1:9>WBHN0D>S]N/#J>\+^=0&P20O:!>JG2:IY3(]*=DU8_R^7O2%B!]G725]OYQ#I:$B?\+5M M6)#T':S&BA2R'T^(8CJ]]/T*UGP*9\H..,XTK_$Q:R"M0\Y'LEQ:$-1XJ?/_ MOXWX/VPC')_NM]J(-5PJ^UO9B(A+L1'-C$:L0&NMC4]O*:25PS'HJH[B\DII M`Z7!N,/IGC^3A:VGV4-?..IPU"QU/AHKA%W_O:&"84\^1HR4[MYN?V^WM[?= MZ]D/!_&`XT);FA_UXP&`;'1=_R`EZ^[N]@VW.Q`_]QEE-T0D3\4ST9MN" M@N%PMW>T[7YH+CA@WOY.8SD_[W"[R^S#%D#<&XEE&R=/)]0Z7T>T983'](@' M<&E"RQ^J?<:[=;*#V'F7^:L8Q(4DG^U&/PJ2LF*_2S&U3V8!M\URK7IB6$ZB MW1^H;;FIO->(;W&@>(K`N>%:63$DFI9F^77O*%"P_J))/^'FYS@8>GB?__L. M9Z31S(W)<>D/'TB0HI`<>N^.?E:<48Y*<[PO/N/[6T>RZ^9E:+3+M9`PLR&$ M'PCF]83>AGM=V^9WK1U-N+<'*=3AP+L@PJFNB(!^9J$#0/^@?\05UT'RXI?_ M]C^I\0Y)\_2[+S7R)IO>66^$K8M32=1`\E6ID/23;NNOQF"*AP0`<4BJKZR% M$5(2(/&>!6T7L5NB-)"O4VN>XE$>;?)W?]7-9\^M:%GV%E.8U@J.LG4BT41" M0S!&TX!9S33M\,@0:1B#23Y_"6_9%;9*#'AO3,:`@^O-,UAS<'38.80QA9D! M317#[CY77'U/KZ]+7;9'?`1EK@B]DC'2VK4/^H,8(]9TQ^U=<3\8"?>\'*'X MLPN=?7+I`N=@,.#GH9')E>+]/5L0P4PB04Y#!TVMU[4\5ZVL5E["L3==F!E% M"9X^`LL>X'4=Y:04QDOU^JZ49O6"#!?LC9L-^AJ:"7(J[`JW:;(O#-DUJWG^ MD$Y%=GHNU'T=]@)@(6&5GQW&`@=[(OA'V(7>Y@Q+NM882"/2:QH#Z0$N;RF7 M?1-A*:&\E?XAN&R%WX/.EI#A7FVKMIOUP(ESQ-!R]P+?-[36\>K3PGH@49W0 MQZ&/,38)Z!?OTKI$Q9?I%_6Y3\'"YC9M<@#F%KA@Q7=P;V[1-I?V"SJT+XPF M0?>5U]&%O*`JH:T)Y3YW>5TOC/G8*T"IK=S,B'6.U]H&U!!)$*>\D]1'S?I@ M%TF8J+7&+8>RL:86I5`4:!89KQ9RM>4S+QTI7>9S+P$JZ.ROE?@;2QY,3<<\ M@-_RX1+35_:&BG]%S+%RB5V6TN9Z-L@.U>N'WE374K]1F;#G626,YB67@(2U*H\04Z$&M1=]_(Z&BZAIVZ#%4>M6RL@6EI\X]-Q9J`*KM4X")4Q@R?6W&/1GR'ZRJXJ M?/.,LZ@))7OVBH-"5(O18F'D+R7$'XU;D?AM/IOI!3Q,.;?:'M:+MQIN_K'_ MC0%&H?S+$K^,/Z>@Y$U_U40^XJ]$Y^HDWT%.>G=5S4#/2"M`0[7:YN0]S0&A MKH22KJ>^=3)26PU)C)DO!GLK\(I8N[6+95#.H'EHMK[1M*#:YY=S-@I(+ M]!YG>"PBL"R2%[^;(>53`T0V=6MX-.P<\+*?>01'%G&]I(4;)7PWYZ]FA&SQ M9J25\EOY$D&]\V:.%$?ML"DVPU6]UA][&!V;E)7$,3HVJ+G4LSY//GP$9QT; MEFIN14;,3UFK`/R.2S_Y)S#ZN[RXTQ_=T%W<&>6GG]?+0F7JRKQB<']_]`_3 MZ9>>:(,)=K]$>LQMUY4@=>ZB>SL!*->=ZG!R-:QJMQ0M6I52O*\Z7 MKO!2IW=%9>CE3;L[KZAJ5V1*1GYA5^7MCY``^#37*UOVR+ZYA8'83MVN_>//[CTH@]/D=<_BR80NN6JGH;@2O4E:/.H7W?1O@GW/C!#.( M]DI.]'AA`]#W:H,\TCMZCPR$"3^,%KD]"!RRV^[":&@7\GK^Z7^348JT1X^]_L\"D[$_V0$/_1AM"\D*7_68BYSZ:66HP!7R+ MJ7%Z))2A*U;+M75:5*T42P+2:6.//?-GOJ#K8X7$X7"&"WDE#D4M-YD4O]W7 M[BTY:$KNA&TOW)%V5D/#[[0 M:UHXLF-IP=XCT%-"LU*>W.D&QBO>(9&UK4I`CTR[KI][FNS*ME4*2Y[ M&2">Z^MO53+:+^+\Z'!;.IYEO/UP>VX"M1' M#Y2S3MV+)S9Y?:M$;6:5\;.G4@1BK7LD1A8&8'VV;BWQZ[,$V4J.+VD_W`=B M/>>*6A!0!@Z]P+QJ[>()S:U2R#36N+47@))CFNO*L1+UY\%T8LFS7<]@LI:=^SUP"6] MM>`U)P4&:51.=)&,9QP^AF=3XA,TEPK(>0(/D[;8Q,-US)'PP"5O_H77T]77 M.6+PWO'6B[+<3T=?>=*:E9C2Y16O_-P_%Q-_O@(TRC-^O,,RG*32HI<[XF6> MDXRW^#;^XIW/VZ\[T?/P=$T\\3D^?NN*I7#6C4*@(CSDOR]QV$G:_W(JKA]U MMAX%K5XY-@;"M?QM^M.Q)[[]+[&.NWB^E+NJDVJXVM1[]]SW],3S3\I.P=:_ M,0R.5"0<;/<:%;O02-X;7?^_G#3^G[V_W6ZEM?Y=;R*$/@++U<"/PU-C9O5'QU_3^;I\B M_.;IJJAO]QM5?4VGEP#FW#R=W5FA[>SJ+'AT=YN^;O1$N&LC!A/4.;(`EEBH$S<<23YD=%,=Z%O?BOW9`;#2_<'_? M_!.+AC\"K.#%8+WJW##T"4KGD=F/*)AJMN]^6:^B-PS](C`;&VGVD\%$*\@0 M/0G,6.&NIQ&^27]%DW[9B=IF/^U$8G%4A0ZU5E%YQ+<-?3J8ZV8_'4S4V4:5 M5`,S'OIE8+;-?@3,S6KJ\8#Y3=L=)U*N"Z7I8[:QA]C!)T7*\-=PRY=\XK$A MZ4*$HAIK_'4]/Z$$R&I^HN9GMWO5]>G-](:/V^(]R5OX^F3US6Y1+%[]+P$` M``#__P,`4$L#!!0`!@`(````(0`CU"Z.3@L``,5C```-````>&PO[5][3/3A2[83#1 M>Y==77."1;AT@Z>)_M='ZV*D:W%B!TO;"P-GHK\YL?[=[:]_=1,G;Y[SZ=EQ M$@U$!/%$?TZ2]76G$R^>'=^.+\.U$\`GJS#R[00NHZ=.O(X<>QEC(=_K&-WN M5<>WW4!/)5S["Q$AOAV];-87B]!?VXD[=STW>6.R=,U?7']X"L+(GGL`];5G MVHM<-KO8$>^[BRB,PU5R">(ZX6KE+IQ=E./.N`.2;F^"C6_Y2:PMPDV03'2C MN*6EGWQ83O0K74M-GH5+`/&[GS=A\NUOTC_O_O#N7?=?WWS[CQ^YF6W5BQ\G$KN9!;SHMXN:;IVXV*'PV-T%;XB>J*G^42W+,@AO6X7::4..Y&R\:P+^LZF M[&IP-LOZ5M\:2K6,B\5=OZ'"OB63R@:%UOOAW=GHE*^LRKHL#9^K!F"%D\NB M"U6WIGX/+7R=(T[.W*"=QF-,*I?T6=4K<^.CZSNQ]N!\T7X(?3M`8FFCQK[- MMT2/L#[#/!'=N;Z!SFCA1 M8,&%EKU_?%M#CRF`?C32WDF_U_#MI\A^ZQFLWR!6(`X]=XDHGF:LGY99.[NZ MMV;W3"]!)HJB0JAES88G$'H_'<_D(YV-Q[*%&A:\)`M]/\"79*$6_#>3QFF6 M*4U9(`MY6N+BN*I[.1R/QZ/>U6@T&IO]GFDRDN=91+O!TGEU<*@EC:9=!`-` M,.Z/QE<&`.F:(Z;JK`CZ`&`X&(P&O;%APO\L-9\>@6Q.![IJKQ($BKQ*$"CR M*NO:=R1D_JRFP"R'XKI*$"CR*D&@R*M#R1EXJ-RK!($BKQ($BKS*)J0DUE68 M/51<5PD"15XE"!1Y55KG,\O`8^5>)0@4>94@.+=7\V'5[/[>8M,3NSTS:?WC M3!=VXMOK8J-&&*?.PV@)RSSYVD6O#V/$]-[MC>>L$AB11N[3,_Y-PC7\.P^3 M!!9%;F^6KOT4!K8';SMYB?QO34E8-H(5HHF>/+N+%U#&S4JDW*0J3J6AR'HF MCB;,H=D=F@/C*AVP25+M.TMWX^]:5^C>&Y=`(W+;;#CA,"B49.%0SHQUT`N9 M^P1+,%;3LB)ZJD72(#OB9C]($B973X;B^QAM+%,6ULAO^S4C:F!+]8[ MWF-I0XE=.QL*[+&RH82HC7S]R#9XIO[^F$P0%%:,,>SE02S M_(0+!>E2@7"ZVV]NHWAB-4@XLKG:XJN=,5G[",WMPO&\3]@`_GU5M+DPC75[ M\[HB"_NPVP)7OG'?`+Z%N>+L;=J^IA=@4U4A6+>O**39Z[7W]K#QYTYDL2T8 M3`6[:X&>\FK*.@;E]7O/?0I\ATW$Z:F8[Z,P<18)VR+")M*K\/0K\/0R02)X MCM%O5N@'GH3Y.$8_3/3L]0?PHE0_!)>P?IGQ@)MALJ`&%]"@KL,C$P$,YW,$ MX`05"'#S3L8!A*<*!#!,RA%`@)8(`$Y-5!Q3#WHDFT$,E"I!_ZE40H[)K>14 MGM#*JO0+^FNLM+CT>Q3-)-]"H)U&&>D@4!0 ME2%)-!BJ4B3%H"I'EJXP5*5(`D%5AJ2>4)4B*095.9*X0E6*)!"`$249DGI" M58JD&%3ER-(5?54IDD!0E2&))_HG3I$=.FV:3J*2^=,![JZMFGH$!^7#_VU? MO:X:)U)[58,FD)473T=/Z<@1?,'&4F0HC8]+V?GX"WKG2V2O'YU7&(JFZSROJZ,,;,!4ZH<9/$_%9D\)/;C1'2"`(G=U1C0*XS#-)#0%(5P9JKFB9H))5CH*Y"/-F< M,]SF^A!'9[.?-G'BKMY:YH_6B&I6O8Y/`$=DGQYT1KYV;H]-C^<*M:SAA%#H MU+6,.(P_F4ORQKLQ71-2<$#]=0#"V=&ZC##-)F4;6[-]R;P-9=2'_>U1R06M);8X4RSP(&0J;_9AIG#VX.# MW%W3/'`,;4]FJ`RE$V"1Z89#X`FZ`;+,\9V0QEI",C"-`2G**='_;Q*)0:IK%]4#Q7'CNEFP'7'M*A2'3FBU* M<55N5>:VQKI'`J$;X-05&&ROJFHIS!?+9\3:&!$ED%!S>X'@MQ?[?4C'ZNX24@$%Y55^I&/U;Y@K%)9I1_Y M6$63V^(J_0A2*??P05M9I1_Y/&$*Y@EJ8^E'GON!(/?;&96/>$,PXE,II>_@ M'>$(.VHB'*522J_Q4=X7C/)42NDO/KY-P?A.I92>`GG$(A,^$+>H\%&?9]<4 M9'=J+_.LRP<,MC,B,.`P[L7&@T/20SQBG6V"PZES8A!N>1:2].PL7K09/--< M".+K`S:C(H+N7]>>'=A)&+UIN/&M$,<[?2`H[H]A6'#$2S#@4@30G^!`>CCK M7@->4H;X&,9-3VW$%'6!IP>?@FDC!DJG:/CXPUY<&S%0.A7#)U7L/XF(^1"L M-X6'^%R*3;>(B(]N\.(L^31'81?WR5,@2)><`GX0L9?(I( M3XC-']O/^I\/\.![3B)N"B1U!\=U(L#_LDD(C5B*"#$$\]*CF\`!(7DEYD0@ M+!$_1PF3,1$+]]_Q#.-H!;#0C6D MFX\QG),#?[5-Y$[T?]]/A^.[>\NX&'6GHPNS[PPNQH/IW<7`G$WO[JQQU^C. M_@.4X>];7,,/)!SQ^Q'L=RY@&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQ MFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5 M]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[ M=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+ MRSPA,S*A/D%#3=+;RHCW M&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\ MRM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=VJ^>?__J^5/TZOF3 MXX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,G MO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q M)2"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@) MYQMAY`#W.&<=+DH-<$/S*EAX.(N#UO5D"53,+2L?V MW9`X8NXS'"LY1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV M:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD" M.S1P1%H$B)Z9B1)?7B?-AOZ'&(KA\1JCX_M M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8 MG,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z M+_NH9IR4Q>Q,O91&\\!)0 M.YF.+"XF)XO14=MK-=8:'O)QTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63Y MPINM3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-#3.5A@"+-2[\JIB4OR!5BF'\/U-%[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7 MT#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43? M*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:- M`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2B MS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9 M_>"A-]0A/X#:BN#[A28&80-1?F#R`Y+<&ULE)7;CILP$(;O*_4=+-\OIP1"4,AJ$Y)VI5:JJAZN'3#!6L#(=C:[ M;]\Q#B2$MIN]">#\_CSSSS`L[E^J$CU3(1FO8^Q:#D:T3GG&ZGV,?_[8WH48 M247JC)2\IC%^I1+?+S]^6!RY>)(%I0H!H98Q+I1J(MN6:4$K(BW>T!K^R;FH MB()'L;=E(RC)VDU5:7N.$]@5834VA$CVT!:+C(&&6C;D:!YC!_<:#O%]G+1^O.+T:.\N$>RX,=/ M@F5?6$W!;"B3+L".\R$ M=%Y1]II0F8*A@+$\7Y-27D(`\(LJICL##"$O[?7(,E7$>!)8_LR9N"!'.RK5 MEFDD1NE!*E[]-B+WA#(0[P2!'2>(ZUE>Z+M^\`Y*<*+`M:,$UM3S9^$-L=@F MK]:FA"BR7`A^1-!Z$+ELB&YD-P)RYX_)IG?L7X:!4QKRH"DQGF$$7D@H\O/2 M"]R%_0R524^:U5@3!$/)NI/H.FANTBVA.+UY]B0=I\[ MU.4R][_W1)>B%NL4NX-69F%P4'],&_UZK`AF0TDREIQC;2&;L>(:LAU+SI!! MPI/W)*S%T.X#(R?#\%=&,[W0^$/%^DU%\J9B\Z9B^S_%P`$(]?:2:W&,P=V^ ME<*SL6UU5D82MBU_YX?SR7PZO7)@()E[OG]=OV2@F'DSF`M7?;(92+PP=$+_ MRFF8HCK:4RAN&`2NXYXUQ@4S)\T`J*C8TS4M2XE2?M`S<`)I]*O]>'[P=,]? MK:_<"-[6\7KB1O!*PKK=;X!QVI`]_4K$GM42E32'HQQK!M-0F(%L'A1OVG&T MXPH&:7M;P'>3PAQP+!#GG*ON01_0?XF7?P```/__`P!02P,$%``&``@````A M`'ALW<0P`P``$`H``!D```!X;"]W;W)K&ULG)9= MCZ(P%(;O-]G_0+@?/@64B)-1!G>3W62SV8_K"D6:`4K:.L[\^SVER@@ZXNR- M2'WZ]ISWG+;.[U^J4GO&C!-:1[IM6+J&ZY1FI-Y&^N]?R=U4U[A`=89*6N-( M?\5&5;DS<, MHZR=5)6F8UF^62%2ZTHA9+=HT#PG*8YINJMP+90(PR42$#\O2,./:E5ZBUR% MV-.NN4MIU8#$AI1$O+:BNE:EX==M31G:E)#WBSU!Z5&[?3F3KTC***>Y,$#. M5(&>YSPS9R8H+>89@0RD[1K#>:0_V.':T\W%O/7G#\%[?O)=XP7=KQG)OI$: M@]E0)EF`#:5/$OV:R2&8;)[-3MH"_&!:AG.T*\5/NO^"R;804&T/$I)YA=EK MC'D*AH*,X;1AI+2$`.!3JXCL##`$O;3//FN;WB!Y=J`:QO,14*DI*ZE M.RYH]5=!M@RJ$W$.(BY$?_C=,9RI9WO^!U0F!Q5X'E0'X[$5`:W]8J10(LYHWL-]@!8R!LD=Y0=@O"Q4,K6KG3O50[< MEB(/4B7283X4A4.W/2\1XED ME%A?(TPPKG,/6FSHG@N;Y7*;'\V2DZ19LE>E>\OAP&HX$*N!7MJ^-TC\$N/W MF>0&9GV)>5NKES[LK-/TKZHY!&?CJ4/R!!K?0W+2T*EIOU66BH$PWNN$ MU2@1CQ*/BE!>.JX7G)F9]`C;=F:S@=UP$\ML+D>JO%(WK3JY*\RV>(7+DFLI MW4U>Z>A&T:>^1#15P%;=?"_CGA>%HLPR`&PO=V]R:W-H965T MO M/;8CY!'P=K/1:'6###__Z_?GI[/?=F^' MQ_W+E_/@HG=^MGNYW=\]OGS[;E[N;I_W+[LOY'[O#^;^N M_OF/SS_V;[\>'G:[XQDHO!R^G#\9PL7_=O<`W]_NWYYLC M_/7MV^7A]6UW<]7SS>/+N568O?V,QO[^_O%VM]C??G_>O1RM MR-ONZ>8(_3\\/+X>2.WY]F?DGF_>?OW^^NEV__P*$K\\/CT>_VA$S\^>;V?) MMY?]V\TO3W#=OP?AS2UI-W]1\L^/MV_[P_[^>`%RE[:C^IJGE]-+4+KZ?/<( M5V"&_>QM=__E_&LPVX;]\\NKS\T`_>=Q]^/@_/GL\+#_L7I[O,L>7W8PVA`G M$X%?]OM?C6ER9Q`X7RKOJ(E`^79VM[N_^?YTK/<_XMWCMXZ?H`/P_[/G1S,U8$1N?F\^?SS>'1^^G`]&%\-Q;Q"` M^=DON\,Q>C22YV>WWP_'_?-_K5&`4E8$+!L1^$21R<5D.`Q'D_'/B\",;$3@ M$T7Z/]V!*?K")_J.3[Z(8$!#`7]`E>'IEV$&WXXHCT807O0GPV`X.F%,@S'I MP!].'I"`1M/\`;U_/B:7=I(T'&$0?72L7LO M13]FQKH)%PWSM26#D1/`8-(76=8:D=M"D:4BD2(K16)%$D76BJ2*9(KDBFP4 M*10I%:D4J179NL2+#@SK"=$QUGYT+('HT,#/%5DHLE0D4F2E2*Q(HLA:D521 M3)%K6R-J?XM"S:AYP8?A]X)OSP(7 MYL1W?'B\_?5Z#]V#/6G'ZCF`/;\]"1@1?TY8$L)!V+FZJ=_-.;KQU2TLZ7M3 M:=KSW9:M$5U=A$+.G%#2<>OE]&@J#B-):T32:R6=*NFL]7*EQ2]%WAJ1]$9) M%TC@PQDUD4DE&O&H59:(41-N=6M$[6]12,\)&'YO3G3$'H[`%'QC[0??DC!H MSH1A;Q2(:3U'@Z:@8@]]*#)MEX>E)0,K`N4H^,^?!Y&UZ+/*2NG&2C=I;+/L_3!:%!>Q%+1`.K MTW45$7G9NE>SXA-B[9@0:R>$K+8.-7W/PBDA%LX(L7!.R`K+<-.W+%L@"DW2 M-`&7=9*2G+CABA`W7"/"T1KJG-B24].X'W-36'"K/A]G=6#K$'!^H0EWC8CS M>B"F[9PLV&E!.CQQEX@^F+D1FKBYK;5CK9VP57=Z:^&47>A*,RVJ,N0U55YZ;4L4),;>5#2_F%K5Y/@[$=)^; M$RZL_UZ>(^*9NT2K#_,=SMFJ,^9*MD"' M-L^'H=@%E"Q)#5>$^(IJ1!_EN=NXG^>FL'%"S&T=!%JD#EV;$CI$M,WS\4#^ M?I,%.RT0.3-WB8A^PCNF;H0F7IYCZZP=:^T$$=R3,:&!.V-B6JZUFFS+("5&W M51,OZA91I@>]4.RWYH&U\#(=$<_=)5KAW!V$86\H]OT1";F9KK1CLF+MA)#- M]/Z%V'.LZ7L63@GQ#VM&B(5S0E98Q&]#W[)L@8@S7<:J)"=NN"+$#=>(<+0F MTW`HMP9;\FI:]U/=5%=."+HMQGA!MXA2O2OH:,%S=V'NC9D=O_N3;E$[=T<3 MD8\1.CF)LT)D[ZLVQX!82R=L93-]+)376CEE'\YTU>F'7EO MJCDGS`$L_O"DO#:WI)KD,H`(WIL5X-/@(AB.80T>#T:3L!_TAN'R MDYAJ)4EP=RJ-:D+SIV6B!R M%J8E(EK&I^.AF)016GC+N)*.M72""#=L8E376C9E!\JC3,OF;-7LUF0Y9Z.% M"W+!51QV*.+WOB0+'JP*D3-8-2(EF1-"CM4?[M`U]*0) M*.Y8@G`J5J\Y6GBK.%:$>/(NT8H6(K-)]]>AB'0XCU:$>'K'A%@Z(=0NXK[P MFKYGX900"V>$6#@G],ZJC1?)L@4ZM*OV<*)6;73BABMJA1NN$>%@!;V)&JTM M>>DT[Y]6=&O,_:(;HC;-1ST9<[+@B;(@'6>WAHCV'\-1;R2$(C1Q\UQKQUH[ M82N3D/T+D5MK+9RR2YOI6CAGJR;3_;FTT;(%.;1YWI=!)PL>K0H11)'Z4B/" MT0IZ9H\N2CE;M.G(]/YI9;?&7$3=EG?:_=IH(*YCCDYNIA/BR;M$A)-W%`ZF M8A6.R(DS9T6(\R(FQ-()H?$6#@G9(7%C]J&OF79`A%E^B`< M":>2G+CABA`W7".B3!^&PU#%',MN'9ENBC,_O[K#K&G.4SP-KQ%QIH]D"88L MV&E!.CQWEXC:N:O6JP@MX(,F_`J1LU>($3EID;#5.XF.%2H63MF%VLJT<,Y6 M1E@L3!O\%CY(HR`'.I:-Y6I6D@4[58B<*ZH1X6#U.[;D:`$?T+AW%(>=]$DA MMV4D]UC6*,`.S4[U,!A-175CCA9>FF,YBF?N$JW:F3OHP3;.7RTC4N+$61'B MM(@)L7A"B!+=GOI@5MG_Q(*R)G-N)R7$[62$N)VEMRZTA\4\4Z(?%MTD^CNB`G?BQJ26C<5,H[5K6(=#B=5H18.B8=EDX(31IIL5*O28-E M4T(LFY$&R^:$.F4WI,&R!3G@[=5!KR=VG24Y<<,5.7'#-2$[5&.SN/D+YY9T M.E+?U(K^]WE@*T[>/+`HG#:#'`;30*QL\SY:\.19(()M*4V-):)ASP8KG/:F M?3%,$;FQTDJ+QV3%X@F)VZ( MW$V MI*4WP0-9^/I+AZ%&1:2Q+2;]R?/DY,@7N4!DEA@>'?5$.5O114:DQ2.](L3R M,3NZ\J)2F+`5R:])B^530BR?L:,K+S:D.5N1_(:T6+X@Y&>,.+259,6=J%C> M[81PK-F*.K$E+?V`^>"T:EEC+B:$+0%1G:0W&8M1F:.3L[]?D(Y3)T$$4]K4 M'$;FAHXX\T5HXA9*M':LM1.VXH'KRZ/I6LNG[$ACF6GYG*VZRB5:MF`'MS]B M42O9BAJO$+FU4D0X;OUQ\^2V."RC3<$$Z;LY;:G/X$(6LE6U'BE&Z\1X;#!2X'D$_=;M+#7Y:>^+*K]R8+?ULZH M0]<#B]J?^[&\I3E'"R_UK9.7^A;A'#9/V(O1B$B'DVA%B',S)L3ID1#R4U^< M2-=DQ?(I(9;/"+%\3LB3#\1ORH:L6+X@Y#N*W7+)5C3F%2'N1(V(E@"S6Q+C MMR6OCB7`U,!.^`&P)3/W5H@I$\!O0KL$3$9J"4`+=PE`'7<)L`CG\JAYMMA? M2R)LRDG2%;7.VC$B9V._/@+Q4)&A7_3("H723T]$`+=Y$@)S[P M+@G9VX`C/+#F>W^^_F=99P M;^'JPK*,$:([Z!^Z4SJFG M\(&W?7[M;!_>`MH4,X7]-0AUV@^@Z8Z6OX:@W[R"3PJ%T*,.A^OA;-NLE=)^ M--LV*Z_D_3'TJ*L%N'$R,[=%]'#`/8^9N:.AOX';%3-S,T)_`_<09N8.@?X& M"N_03M>@0,T#N/ MYM5X5G?QQ60&[YO1]O%D!B^+T3R;S.!-+YI7DUG=\,LV5/#^UM>;;[O\YNW; MX\OA[&EW#PG1:]Z\\V;?`&O_&ULK%;;CJ,X%'Q?:?\! M\3Y<0RXHR2@D86:D&6FTVLLS#4Z"&G"$G4[WWV\9@X.A%_5(^Q*'HD[YE(]M MSOKS:UD8+Z1F.:TVIFLYID&JE&9Y==Z8?_T9?UJ:!N-)E24%K:WDI2<2E2DR+AR)]=\BOKU,KT(W)E4C_? MKI]26EXA\907.7]K1$VC3,-OYXK6R5,!WZ_N+$D[[>9A)%_F:4T9/7$+4."4^VZYK>#9P& M+":[)N)LN2'4NI+)I%41_ZN&*)X0V0F5C;DP#92'8=^];&%_;;]@LZ0M)QIS M7)VQ[QAB9PC9PQ`X#H&X!]API&RA^O^#+:$B;'4)11W0\SGPT#&ZD,,0.`Z! MN`=H'K`1AQY\G,GW3U-7"1&$NKDCB?@X?`]7D+NPP0HXC).XC6LJ8[.,I"[*>LD2\N3H8^Q%R M&"''$1+W$2T_W"0?ST^0]?Q:9"5O(L>=#593O5>KJ9!'$=S`T\..DN2[C>P2 M-_S@`HLEP?/$NFA^1(/3NV6GMX@@ZWXDXOF=G^%I5>^5'X5,^9$D?R9E9\'@ MGHA;D>93K=E9_8H=0=;MM`B&QX[W!I/O%4EYDDB`<]@+&QS_HR)U86AXQ/S] MHL@&1GX&2U*?R9X4!3-2>A/-B=@U"I5]TV$50AB*`QS]U*XI]@"/T&"V2@A]US4YDQ]) M?.'*2I@F2%.V*;@4V M8!AV>59M)1%J6X:D-.W?CY1LQY)S<5\,FSDZ)(]$BEG'43!DK3(J69*-@R?&1%:AKGLPR'6 M:YZP!Y'LC,%HMC$!_.=NKUGN@MF+_5?+T.R\8J`W[A#OP+,0+0I]2-,'BJ+/Z MT>S`3QFD;$UWF?XE]M\8WVPU;/<$,L+$YNG[`U,)*`HT@WB"3(G((`!X!CG' MHP&*T+=E&(-CGNKM,AQ=#R;3X8@`/'AF2C]RI`R#9*>TR/]9$#%!62X3V@/5 M=+608A_`?@-:E11/#YD#<1V396BB/!4D1(VMHNXF/NQE]Q`V"0>]V M\&36\%K/%C-N828-PDD0(/T31#!L#J1UT"WV75M0#]=P4/J[1K!QW8A;61P= M1L/C65Z[KO!DC<9`<'X_<97KL[)`N1T$&)'C/N$$]D\/P:ZKRF++N'TDL06W MJN1\"@AV>2N+*]N)8SES79F"))/!1>%PG>NULKC"C8X+1P#5/T.#=IW5IJYV M!`N_MW@&[5%7G<.5;WPB$:][H'XS2.[\EF%Y>>K5)E>^$Q5-L/;[YXAH+\?* M=$2^#W4+TK2+IF9KDRO?]0GYL,);B?2L6KS&_(PJDZO?](1;KUE1E5)C&PO=V]R:W-H M965T&ULE%7+;MLP$+P7Z#\0O,>TY%^]**3T!AMJEM/2^21ASHI2: MNY%I9`U?/QG&FN:AH8$GL.A\ES)>2-$3LM:Q]( MK*RXA_I=J1IW8-/B'#K-[?VNN1!&-T"Q597R3RTI)5HD=T5M+-]6X/LQFG)Q MX&Y?3NBU$M8XD_L1T+%0Z*GG)5LR8%JO,@4.L.W$RCREFRBY7E*V7K7]^:WD MWAT]$U>:_6>KLJ^JEM!L6"9<@*TQ]PB]RS`$R>PD^[9=@.^69#+GN\K_,/LO M4A6EA]6>@2'TE61/-]():"C0C.(9,@E300%P)5KASH"&\,?VOE>9+U,:P\[8 M2N=O%5)1(G;.&_TG?(PZBI`<=\EP[Y(G\]%L,9Y$H/4."0N%M+YNN.?KE35[ M`GL%)%W#<>=%"1"_;@0<(':#X)0N*(%:'33_81W%DQ5[@(Z)#G,=,'!]QO0( M!J*],JB=KXQ@5,:68BG7(7`L$[\N,_D?&02G%*[/Q4?+GCUVXB6^Q//UCAU,'&ITD:&=>=_DP>KAQ#[[8"!X M*-5%3NTLA[QA@DQ&BW?M8.)0HXL,[2Q>V`FS+)QY+6TA/\FJM%QN&8WCQIH'*8489 M#\.M?2SA'R;A((]'8#PWQA]>0)CU?\7U7P```/__`P!02P,$%``&``@````A M`'*3:["$`@``408``!@```!X;"]W;W)K%OP1K>0TV>P M]&;Y\<-BK\W6U@".($-K!%?TDU M+(WC:Z:X;&E@R,PY'+HLI8!;+78*6A=(##3<8?ZVEIU]85/B'#K%S7;770BM M.J38R$:ZYYZ4$B6R^ZK5AF\:K/LIN>+BA;L_G-`K*8RVNG01TK&0Z&G-C[\TO"WHZ>B:WU_K.1Q5?9`C8;Q^0'L-%Z MZZ'WA0_A979R^ZX?P#=#"BCYKG'?]?X+R*IV..T)%N3KRHKG6[`"&XHT43KQ M3$(WF`#^$B6],[`A_"FG*0K+PM4YO;R.)M/X,D$XV8!U=])34B)VUFGU.X"2 M/JG`U:=VRQU?+HS>$QPWHFW'O7F2#(G?SP63\-B5!^=T2@G*6.S?XS))9@OV MB$6+`V8=,/C[BAD0#$4'950[7]F#O;+OBD]E'0)CF?1]F4XR\>:QPB MQ^6\M4Y8X;`G"DP%GZ!I+!%ZY]'+L4J].=_&K[)5;UHVO,"-[G@% M#]Q4LK6D@1(IXVB*?3;AFQ`.3G>8.>ZU=KC+_6.-GVY`\\<1@DNMW`=M<6YT>#8QF=Z0= M:;7:RS--G`1-"!'0TS-_OV7*`;O(M5_233@N3EV/<9X^_*AWSG?9=E6S7[IL MX;N.W)?-JMIOENX_?W]^2%RGZXO]JM@U>[ET?\K._?#\ZR]/;TW[K=M*V3M@ M8=\MW6W?'QX]KRNWLBZZ17.0>[BS;MJZZ.&RW7C=H97%:EA4[SSN^Y%7%]7> M10N/[2TVFO6Z*N6GIGRMY;Y'(ZW<%3WP[[;5H3M:J\M;S-5%^^WU\%`V]0%, MO%2[JO\Y&'6=NGS\LMDW;?&R`[]_L*`HC[:'BYGYNBK;IFO6_0+,>4AT[G/J MI1Y8>GY:5>"!"KO3RO72_<@>PG1 MACRI#+PTS3<%_;)27\%B;[;Z\Y"!/UMG)=?%ZZ[_JWG[75:;;0_I#L$CY=CC MZN,!@<_%7WQ_-0V;PY4 M#3RS.Q2J!MDC6#YZACQ&7\^Y"CXJ(Q^5E:4;NPYXT4%^OC\GZ9/W'4)::D@V MAS`;D1\1*A/`;J0(CIL43P?]R$2!%1.5!$4MPR_`]DB-D^?.$5$\0BPF$*#; MF2@P)-IX<.J/9I$;0@(#$MJ(_!+"H@9&;J>FP$L7_!YCDI)D9`A)AEP^Q#R& M*IN",K#/+0A/$C\))_H6.2ARDYPJ,@%->#F3:A&)'\E)F:`I/X"3MQ&4*B(7YIFOJ!?3\W[S,?[D\`BQ?TE!FZR[P4F/":S&+) M(01Y"<92GV;5!'`1I5$T,K>(*6TC@^-Z3M4B0I!D+$,($@Q\$20DLKD)@-LL MGJK"(IB^AZ!:1`A._F,$$6(674`I(@1]"'GH3WUO,630`_?'<%A%.)(D9AJ# M#!Y8(-*$0'(-.>.'S5--9B/7EXN0X1RWIDLRUA#&4&-T&8I(A!$90+F&W,1/ M37"#WVWSA>' M%I).RK4A39"+.$C%5,4VP[NTA*$0F.W!?-*DF0:=+GZ=9+1S&F+S(Y)RI3_F M6L+\J8)T!$VQ>.!I',WTCB$DT#L==BZ]1$ZND)OK"/,GRYJ<*1-GR"'D&CE. MA.0RN0%M[ZP8W9]D&G0Z;9C9BQ`KLYP(R&T#>EAE#QGF3^,+@ZA!6/]!DHJ0 M3^6O>:(@(80EL)4U.LWF283D2AQ1',P)'9/VS#AB]+-/Z;"%B'QXG9L&J4WN M+OG@<_E@/IENF0;IX2$$S#=;J'.-,,O`V.W8_`!TNX)PA:;))7N43(/./%UG M%PUI'YC@TXRRZ;U+1=2;]8SF+,FFC$!Q!2(D2I-K.\B2!W$H##&W>=ZE(_R4 MCI`&R#1(AXC'T4R)"2+B4R9LEA%M,204`RB!IEM/)'`+KX(L7D2+;D\ MH\7\982Q:)>."-01^!S/6!@C*I%ID/ETXD1^$6+S`S-W1%"A:02GZ:43C""3GY$_ M'4'$X(E7',_G,YX.X^%I+=N-S.5NUSEE\ZI.?CGL'\=OQU/ICUP=1)+O,SBM M'HYVO?$&'!8?BHW\6K2;:M\Y.[D&D_XB!F%I\;@9+_KF,!S9OC0]'!,/_V[A M9P$)!YW^`L#KINF/%^H8=?RAX?E_````__\#`%!+`P04``8`"````"$`N:MZ MH6X"``#&!0``&0```'AL+W=O+SY^ MF!^TV=D:P!%D:&U.:^>ZC#$K:E#<1KJ#%O^4VBCN<&DJ9CL#O.@/J8:-XGC* M%)[?7C[F&=LQI!I,2\D M1N#33@R4.5TFV2JE;#'O\_-+PL&>?1-;Z\-G(XNOL@5,-I;)%V"K]'+R"KVF&U4PS(QY45+VNP`A.*--&HMR%T@P;P M293TG8$)X<_]^R`+5^=TG$1W:3J9WMTBS1:LVTC/28G86Z?5[X!*O*N!971D MP?>)91JEM_$X0=%_D+#@J`]PS1U?S(T^$&P:E+0=]RV89$A\.2(TX;%+#\[I M+27HU6(5GA9).INS)TR=.&)6`8//5\R`8"@Z**/:][)5]/KR55=@XEQE= MEAG_CXP'8W'.S2=O`PR8R1DFO:R,D.L#]&"L`8;UFK=I/!"'H`/H"FGLAW-I MWZ_32?37CCW5UQ_K30QI/N[@Q)S92@9;H:!A;D);*3`5?(*FL43HO9^)$3;* ML#N,ZW+D:_EV?Y(M^_EAPP\&PO=V]R:W-H965T&ULK)O;D)#-OOPT2S0;P8Q0K ME9LH_M#]$V@T231(?OC]S]W+X%MS.&[WK_?#X&H\'#2OF_W#]O7I?OB?/^+? M;H>#XVG]^K!^V;\V]\._FN/P]X___,>'[_O#E^-STYP&I/!ZO!\^GTYOB]'H MN'EN=NOCU?ZM>:66Q_UAMS[1GX>GT?'MT*P?6J?=RV@R'E^/=NOMZ[!36!S> MH[%_?-QNFG"_^;IK7D^=R*%Y69^H_\?G[=N1U7:;]\CMUH?NR/?W5B@X'N\TB>WK=']:?7VC/IBN1&74=Q MS'>CNQ$I??SPL*41J+`/#LWC_?!3L*BG-\/1QP]M@/Z[;;X?C?\/CL_[[\EA M^U!N7QN*-LV3FH'/^_T799H]*$3.(_".VQGXUV'PT#RNO[Z<_KW_GC;;I^<3 M3?><1J0&MGCX*VR.&XHHR5Q-YDIILW^A#M"_@]U6I09%9/UG^_M]^W!ZOA]. M*#4^-\=3O%52P\'FZ_&TW_VO:PRT1.<\T<[TJYVGUV<=IMJ!?OEHLZOYS7@: M4.?.'6FF'>E7.\ZN;N?SV?7MS7E':FW'1[]\Q/-CH@&T#A0%=GA?%^^T(_UJ MQ^#F76,+:-*[.9`X3MYWS(`#JO[#W3T_OH!#J?[#+F>/-NI2ILW`<'U:?_QP MV'\?T&E-!SJ^K=5%(E@H-:"W`6%"TH75"ZH M#6`%DTZ07Q%,)7,_I'\E68,[.WI+;4.7G-YH;INL>I,^PD`B(#&0!$@*)`.2 M`RF`E$`J(+5)KQ>!7!%O)T,6%IK0/9#";V:%<=D;3<]'N3?IH`XF`Q$`2 M("F0#$@.I`!2`JF`U":QHDU#MZ+MO_?SY599MT'E8"P[HF[=1IC=C.V-V"T$ M$@&)@21`4B`9D!Q(`:0$4@&I36+%D`9_00R5M1W#CDRN^ZOL"D@()`(2`TF` MI$`R(#F0`D@)I`)2F\0*&-VO+PB8LK8#ILE,`@8D[(@1U`A(K+VZM:VZ\2>: MR%2DVDMN@1F0''0*T"FU%RT-C1/EVKX>5;T1GRBU*6W%4!5AY@+J_(FKK.T8 M:B(C70$).S*1L4=`8NUEQ!!T4O#*@.2@4X!.J;UNVX7>9!PX*[VJ;^_#9ZI: MX:.5]@7A4]9V^#0QP@W`JT+`O!YT M!=65*G%/S]O-E^6>`D5&GNO$E,XG74YUY02MFOB0RT`CZ?X*4:C1A!)#YF/N ME`:16+%\S%H2L(21'#$5QS/RF5BQ?,Y:(E\P$OE2',_(5V+%\C5KM5L;]GRH M6L*<#T_<:=^B#WQ7>EB!U\BXRZG5K+H."0HUFK8[/>TD1HAB=NRV8-H['2/1 M2M$Q0Y2SHV@5C$2K1,<*4,I6(IXQZL35+E?@+!=R-A'M M`K5+MA+MBI'N^'@\&;O;)C7;M.)V;JMJPIR;'^1V5WQ8D]"AR;2?EY7:!*)Y M,5"(*&(DF18SDE,\823R*:*,D6CEC$2K8"1:):**D6C5C%HM.WZJDC#C]W.Y MW=4C5E@UNC/""BA46[PJTI(/$:.SB:S=)-D2[4;G$I\E*2N)>,;H7"*#=H': M)0N)=L7H;"*;XO9$J`K%G(@?)')7T%@1-VN<]O*["@"%B")$,:($48HH0Y0C M*A"5B"I$M87L^*GJY(+XZ6)&,F@9:"3GS0I1J)%9S"&*V5%.WH21W.M3=I2B M)D.4LZ-H%8Q$JV1':Q4Z=S:9*K'BLZ1F+<^U054L%X14F3L+:(VDGZL`4*B1 M69P@BME1PI`P$OD4'3-$.3N*5L%(M$IV[&L\B&8W%EKY2S3U\#S15(7*!='4 M=8V9H!I)%U=JZ:!B+BC4R(IF9V6@F!TE`@DCT4I9BP8E2^F96^Z)%8LA5&F.\DE46[-[9QE)/U<(0HU^D'1)U;<]9BU)#() M(SEB*HY&9*#H$RN6SUE+Y`M&(E^*HRGO%GUBQ?(U:WD"_TN*/EJ^NM<01M+] M%:)0HQ\4?6+%(XI92P*6,)(CIN)H!LRI*3.Q8OFD:_$BN5K MUL*B97)9T=>:.R<"5'@KMI);9*B16?0ABME1"K6$D6BEZ)@ARME1M`I&HE6B M8X6H9D=/_-RB[_QZC&H%2-QW57?L*.O6$%&DT52O+2?!W=VU6]UI&QH2IT>" M2BFBS!:?SF\F4-VA=H%"):+*UKZ]GMS,G?JVMK2M-=WDLN*N-7=R&"JYE;:B MHW*80D01(\FHF)&3X MJ>).O=+BK.L82=*N$(4:324A(T9JFX_>C_#GL5DCM75,@N(I*XEXQJ@3]^H7;*0:%>,.FU_'IO:]CRXM9T[#W_LWRAOO1NB=&#>F*.:`R:B0_3,DY-Y MI:T,%"**$,6($D0IH@Q1CJA`5"*J$-46LN-Z6W/5WNR)FR5$MBNEP8 MP5HA"A%%B&)$":(4488H1U0@*A%5B&H+V?%3I=8%\=/UFQF_#CDIZ6RWKM1" MUXYRB"A"%"-*$*6(,D0YH@)1B:A"5%O("BDM+2\):6MNKP(TH@L)GZPK1"&B M"%&,*$&4(LH0Y8@*1"6B"E%M(3M^;F5V_I2F-:9[E61$.2?;`'-G&V`E5ASE M4)#IZ)1-D;:B'[4HF$QH_6D_?HRU1;>TM0=W69E#:Q$87(=H/=@>?1RX5W_M M8RX8!9T=5Z<\G;7*=^/;6V?D,>O@TFUZ6?G1FCM)WYESN)81]9!$7"CH[ MKDY9SY=W7)V%;[XN6])3[&"^^B6]'A?D86\@>=BCL^/JK,[-E];QS)=:_+W_ MNJ]>\W/6U(SN.`^=?;"5&,BXM(Q]8CI9%FG'<_/UMTM7=1NZ9%RX1&T5[/4` MHA!1A"A&E"!*$66(BM)#D"1 MEJ?NLE6,*$&4(LH0Y8@*1"6B"I'ZV$1%HNMJ%]+NXY'NU?U=6.VII+XINRW1,'\&T3_R@ MY9I:VJA""_6`QH(]H"]J/K7+/M>#OK1IMZ-7264SJ`AW^:+3YY#[R< M+>@=7.S0%]FD7$6U:XE%HBW6A-E"Q MA79'%VKO$UMH\Y'4?$&AK412\[70QB"I^5KHR!QZ#K+(O"WT"&-1 M>5OH"0'US9<2,W70F\1D9IO?NB=(%+S MM=`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`MW=]_ M^OQ"X5[3&:D3N_[PSV[_?$[M74H!&Y_7O\^>W^ MP\OGMZ=+FAJ_[Y]?XGLE=7IR]^?SR^'A?_7!P$AHYZ5QII_LO'K5@8Z.K=%/ M=@C.+M?K<'-Y09U^I:G0>-)/]GR]*9(;FZ*?[+`\"\+%AH;AM88VQN]"_%YO MB(9K;(A^FH;"GSNE*^-(/XUC0+^^,@8!S0X=K)\>\(!'7/W"K81GZXO%*OC! M0`0\Y.H7'L+7AT)-/-U!&?75^N=&(^"!5[_\9',4(]VOMVIQ#:Z5'.>L#OV4 MQ=]+8LI>I?)>R;P]I5.G/'VFE>>O=\'%\LWY7[1:W!F;FQD;UV++%FII4+([ M'T0^B'V0^"#U0>:#W`>%#TH?5#ZH?=#XH/5!YX/>!X,%SBE>4]`HY?X=05,R M*F@\W#<,)(I>#+=LP2X['T0^B'V0^"#U0>:#W`>%#TH?5#ZH?=#XH/5!YX/> M!X,%G`A1$OX[(J1DWI[2_R6M@BLW:6Z,#:URD]':-=E.)E/8@$1`8B`)D!1( M!B0'4@`I@51`:B`-D!9(!Z0',MC$"2-=;?X=850RM,#29)E"%%RLW"#=:*/5 M:W&<3*8X`HF`Q$`2("F0#$@.I`!2`JF`U$`:("V0#D@/9+")$T<:5">.\W>D M?#%3UF.X>)AO-%FYU[?0#>#6&-%%W(JRI*+3(;JO.*)#RMKMD";+S;1V;X'L M@$1`8B`)D!1(!B0'4@`I@51`:B`-D!9(!Z0',MC$"04%]8A0*&LW%)JL2-\* M^\:;&Y,13ZD=D`A(#"0!D@+)@.1`"B`ED`I(#:0!T@+I@/1`!ILXT:%L.B(Z MRMJ-CB84'1[X+9`=D`A(#"0!D@+)@.1`"B`ED`I(#:0!T@+I@/1`!ILXH:#= MP1&A4-9N*#3Q$N7"2Y3)B..U`Q(!B8$D0%(@&9`<2`&D!%(!J8$T0%H@'9`> MR&`3)SIJ0WY$>$9S-SX&V;F":(`!%:!4C2A"EB#)$.:("48FH0E0C:A"U MB#I$/:+!06YXU-;VB/#HG;`3'K,Y=G9)EPO_"C592<0`1:JR[\8U1I0@2A%E MB')$!:(2486H1M0@:A%UB'I$@X/CK7H:X@[\#E&$ M*$:4($H198AR1`6B$E&%J$;4(&H1=8AZ1(.#W/"H_:X='O78Y=?N!O7.V8G< MM)FV*A*7@9]KDY7D&J`H`!0C2A"EB#)$.:("48FH0E0C:A"UB#I$/:+!06XP MU8[9#N8/[@;U!MN)F+WG'I]\;=6S0#_7`$5H%2-*$*6(,D0YH@)1B:A"5"-J M$+6(.D0]HL%!;GC4EOF(\.@=MA.>:=-M)Y3_:$P]/?4C!BA"JQA1@BA%E"'* M$16(2D05HAI1@ZA%U"'J$0T.K<@823RJ3C:\O((9UR:,[%B^9RU1+Y@ M)/*E.-KRWJ."2JQ8OF8MD6\8T?79&@FOFMJRE72B$WG;T:L5]6+%G1A8:^R$ M.R'\1,O4;U\OG^[H^;`_61IL',1%G1RR+Z%9(E5DD,"FD]L$[2WX:S MHYSDSJ"E,\&NO.U&)%9\DC%KR4@GC$0^%4>K7U?>'58F5BR?LY;(%XQ$OA1' M6]Z[WE1BQ?(U:XE\P\C-&"_56K:23G0B;W?"<^S%BCLQL-;,/#FN+J/>9*(+ MJGTE-B@,QE>,Z`6ZP)OQ6[:08LZ.=:ZF=20R:*5UZ#51^L^]/XZ-"9T-GUF" MVBEJ9V*E7H-:G'G+1X["A;AP6R4*5V*EA#W9&F4;=E`Y]M>[+7=Q4"67G[_]6NH*C1-TC<*0@[[TELRM<:(? MW.<=H]6$(H-66F?N-&+VTF^GZLN$;MW23ME*M#-&6GLFZ$9%A`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`39&BL+[1!%C.3L8D8R2@DCD4\198Q$ M*VZ/[WX+EO29SW/UX8V/:@7X;746K"]H#;Y8 M;2[#9;!8A]%OWE1K64*ZTR'J&4EW!D8SX?1+=3,E.;HKYIK<"FMR!DW+>+CR M%LDM6\C"M&,=:QDWB+JJQF-Y=;'V)F5L+.QE'*53E,[$:I1VYWJ.LH4X\!0M M4;82*R5+K^ZYPC4*-^QB5G&Z0_&N]RU;R&!U!MFKN$%FL-97>+MF+.96\>.J M;BNLNADTK>+AE;=Z;8V%LXIK'2O'(V/%"Y&Z27>',&8=R:.$D4SOE)'D1<9H M6L1=X9R/BW#!2(1+1B)<,?K.JFU.4F0;XS"MVNM+6+6-DS3<<2O2<&^0&:Q@ M<0FC-;#73)JKNM#/WZU1(_YFW*`IS3<+B+EVLFZI=JQCI[FV,C,W7&\6&T\H M-EY.GH-VBMH9]U$78)9G7F[E*%R(BV2Z.7GI="568Z:[Z6N4=7GQT[)NJZEF/?HX\*5%33LST,-BOO/+;& MPLET4Q.2R1L9*^JJ&L!-N+KRKFTQZTCF)(PD+U)&(ITQ^FZFF]Z(<"$N$G3H M,]%!= MJ,7-73@'UL'45^_#_/_GP:CBS@.#PJMQD,/@*O!6MBU;R.39&43OBW'"10:M M%SI8X=7B:ND-4\QNHI2@>,I6(IZQN"X;5I[0UWSU9Z(*G2O0S][>1@;/3BZJP7 MM+*[\^3U8L]H[DT(7;NCNQ6.[=9866B'*$(4(TH0I8@R1#FB`E&)J$)4(VH0 MM8@Z1#VBP4%N>(ZKQ='L\==M@]1-@DRB*^\>8FNLUE1VL*SDCL_ME"I.V->8 M'\P97H1S0XR`V/VF;;X?GE3V+1C3"LSQIYN>;?6QM' M*[X[1!&B&%&"*$64(H1#0YR@ZEJ#78P?W#QTJ4) M)]3%2^%.T01HAA1@BA%E"'*$16(2D05HAI1@ZA%U"'J M$0T.^UEMS>W4TR+YX(=HABA#%B!)$*:(, M48ZH0%0BJA#5B!I$+:(.48]H<)`;'G^W_NNYAAOYM49>KGE/`;=B);DV.3** MT"I&E"!*$66(D2#@]Q@'E?E4*43KV1ND)-K4/C8 MH56$*$:4($H198AR1`6B$E&%J$;4(&H1=8AZ1(.#W/`<5^588Y7#("^AO/+J M5JPX>W:((D0QH@11BBA#E",J$)6(*D0UH@91BZA#U",:'.1&3%4??O[6?JV+ M%<[%"^H76V-EY=@.480H1I0@2A%EB')$!:(2486H1M0@:A%UB'I$@X/<\/A5 MCM?OX]=8RC#(2RCO.=Q6K"2AIAH(HPBM8D0)HA11ABA'5"`J$56(:D0-HA91 MAZA'-#C(C=AQI8PUEC(,HL]W\T018AB1`FB%%&&*$=4("H158AJ1`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`&8S%W.7^N+K8!NMB!DVI?^%_PF)K+)S4USI. MZIOZFDX@]0<_O-&(64>2*&$DN9DRDO3(&%$8K,N]MR/-V4KD"T8B7S(2^8J1 M(Q]XUY2:K42^8>0Z>GN(5JQD$L#P]<:*EP`:/7_\!A::60*.*[]ML/QFT+0$ M7&Z\E6S+%G(=V[&.O028:IR^[&_&/W7@KF2Q\7+6`.UE+2\I:F?2`VL:!-[M M68[RA3AR!$J4K\3*EO=F68WRS;PCW/S#.7;8B=X@7D+IH_OX46RG"^Z-@%_4 M^Z4BP09K?09-B\3,]-!.SB*A$;U.Q<,>L8[^5,(&)WEL+)P]`4BGK"/2&2-[ M$SZS)31:DL4%MV@O$M#S:E8^\.Z-:]82^8:1NTC`W@#.L>,6Y1Q[1M;G7[Q% M=N#F9A8)52.T[Q-^;7(H%>_V02-ZC41O&/%3'1MC8:\=&MF?ZC!6]`:#T@DV MP>7,#81Q$Z4$Q5-6HCOFZ8(1^!]^R-A*KU6K,_^3#[DQL%:J`ALKVG M["Z`-3O(.33B8'7XREM[6F-E+9,=.[YZICU;Z9&E/\L4K-;>^C08F[E[#+_T M^(--I2XHVL_>-AI9#]JVB':((D0QH@11BBA#E",J$)6(*D0UH@91BZA#U",: M'.0L^A?'5?Q&!#7*?O07>S?56K'@YWR&*$,6($D0IH@Q1CJA`5"*J$-6( M&D0MH@Y1CVAPD([8N?7]Z`_[IT_[[?[+E^>3N\.?C[1.T>/5=V\F?/*T__CV M]&:]OE;/76G(XE] M>/W^.Q.=1FNN`8KC;!@IBK-!I!C.AI`B.)=&],#U6CU.Q:&@9Z77ZDDH'J'' MG-?J(28>H6>/U^K)(AZA!W;4SEP/Z%D;M3-WA!Z343MS1^C9%;4S=X2^1.%: M?44"]H"^_^!:?;L!'J&O+KA67TR`1^C[!*[5MP7@$?HC_-3.7.CI[^=3.W-' MZ$_?4SMS1^COT5,[XY'S:7X_OWOS]?;3OKI]^G3_^'SR9?^1ENG%^+T#3_>? MU/VS_L?+X2M=44]/?C^\O!P>QE\_[V\_[.EK(.A/=9^>?#P<7O@?="+GWPY/ M?XR7@G?_)P````#__P,`4$L#!!0`!@`(````(0!M/2P3V`H``(PR```9```` M>&PO=V]R:W-H965TV9#L7 M3Y(SM>[7V=DYN_OL.DKBJ6UE++=IO_V"(B&0!->INWVIFQ^!OT4`H@A&N?_S M^WXW^M8!A[5]/QJ#ELVJ?MX>5A_*^_XC]NQZ/NM#X\K7?MH7D8_VBZ M\9^/?__;_7M[_-*]-LUI!`J'[F'\>CJ]+2>3;O/:[-?=5?O6'&#DN3WNUR?X M\?@RZ=Z.S?JI=]KO)OYT>CW9K[>'L518'G]&HWU^WFZ:L-U\W3>'DQ0Y-KOU M":Z_>]V^=:BVW_R,W'Y]_/+U[8]-NW\#B<_;W?;THQ<=C_:;9?9R:(_KSSN8 M]W=OOMZ@=O\#D]]O-\>V:Y]/5R`WD1?*YWPWN9N`TN/]TQ9F(,(^.C;/#^-/ MWK*>^>/)XWT?H']OF_=.^_^H>VW?D^/VJ=P>&H@VY$EDX'/;?A&FV9-`X#QA MWG&?@7\<1T_-\_KK[O3/]CUMMB^O)TCW`F8D)K9\^A$VW08B"C)7_D(H;=H= M7`#\.]IO16E`1-;?^\_W[=/I]6$\N[Y:W$QG'IB//C?=*=X*R?%H\[4[M?O_ M2"-/24D17XG`IQ+Q9E=S?W%S>XG*7*G`)ZIJ'P2,@_CF_$(W]Y-O4&D;9;/B-IYI$:"% M*"LA&]H@LD%L@\0&J0TR&^0V*&Q0VJ"R0:V!"81VB"^4\.^(KY`1\<7(K!!H M`;>"B1;H$MH@LD%L@\0&J0TR&^0V*&Q0VJ"R0:T!(YA0^;\CF$(&UB6C6._, MZ*V4#=SV0T4O3)-@,!DBS$C$2,Q(PDC*2,9(SDC!2,E(Q4BM$R/8L!C\CF`+ M&5A<(*5#(/W%U`SE2AK-SD5[,!FBS4C$2,Q(PDC*2,9(SDC!2,E(Q4BM$R/: M,'4CVN[G+2ZWPKH/*@9CI66,Y$RG8#JE\KJ5S]RI-[/"-XP/X=-5C?#!T_N"$A369O@4 MT<+'2"B)'CY&8N6EA8_II,K++)T;<^[98(1SSYETP:3+P4NO2FLO4PU&*%WK MTD9816>D[[#.W]G"V@RK(EI8&0DE\>%#NY.L1UHT&.$UQTI(B[0B]&7IX*5) MV^MW-ABA=,ZD"R9=#EZZM+4GK`8CE*YU:2/2L+TV(BWWLE=BMW]ZW6Z^K%J( M#FS4'!F8P?TC=[)"Q$R`(A23@)%0$A\^*`$+WZS':##"J<1*2$N`(O1EZ>!U M1CH;C%`Z9](%DRX'KS/2U6"$TK42ZGLV(P$>M)M&!AR1AC800]V;F[%&I#W' M.`H5FO6M;)^VB*,8'65OV3_+$)%\RATSCG)T)*T"$6F5W+'BJ$9'1_Q$%Z&O M%;]4P9[L16#+A1E;(8+,:?5I/2L"LD+'4"%?C[24][W^D>/-O/EB82TU,;K1 M)21`K$MAM5&0R%'$2*JM!B1MG(@(OF4HPP1:>6(2*M` M1%HE1Q4BTJH1]5IF_$2CH(E;LNP$%'(4*&84L'<\7 MLK*A[TNX>,K%,T3G"IEI%UR[1"&]D,T+=Q>R+FXF0O0@>B(^*&39LA@1ETAK M)`)Q="0*F9Y;(4<11S%'"4U@$5+4P>D@5HNL,/(9"A?3V@Z,8'2D,"2*23[ECQE&. MCJ15("*M$AV'+HY%4\X%-O@4334]1S1%*W)!-%7GHD=3(;K$P&,H5,B(IK32 M4(R.%($$$M9NT#ZHJL4+Y&+4>411MR M0915UZ)'62&ZSL!C*%3H@]Z.K/#28]2BR"2(Z!M3#J9R40WSYJY7,#JY@*.0HP@1 M552,B&[E!!$U9"E'&2+2RA&15H&(M$J.*D2D52/JMHA)=589(BKOKF&D77+M$ M(=*N$$EM=QWKVF8>[-[.?C;^U;[!VNL\`M4.YGS>\RFD=2,!1R%'$4HX*CDJ.*H-I`9?-'IZ(O+!P](U1C1 M/;6"JA5AG\&'%G9K4Q60%<8OY"CB*.8HX2CE*.,HYZC@J.2HXJ@VD!E2T:== M$%+5_.DA59T>[2T#Z/I$E.%;*7X,1=PJYBCA*.4HXRCGJ."HY*CBJ#:0&;_+ MFC_1O,G;'B.S0@0-QE"2WL)J>`.R0L>0D.YHU7*DK-0VSO=AIV4N,K&R@&B2]."2"1UG_)MC4LU^=$=V3*!7:@H2$SLY+.L[FO?+=]/;6 MFGF,.GR3`IW#)?/JSS^[)L,T9`OZ]?X M`1G0O)0,%-JY>4DKN'@1,6>^I(6>+_G2K7S]VZT:;]*EZHG8O3 MOP&KMWW]Q?*3W-9:([!)6(IG)EPW&[F&D7X19B,W,-*?`5LC\%;QI_[^M?@* MWC;N.U:;^R#D^NX9O)WLX)_FH-]W$K;0?`GO1#DFX<&`/""W/7P8<6K!T+,5Q`1^!LX"E:/[Y"!R6 MPK6Y0@]'GW!MKA$XM81K`F)=/$0TNC*2`I)=/$24NCB M(230E8L4TN?B)23/Q4-(G2L+*23.Q4M(6\\G0QG"WP*\K5^::GU\V1ZZT:YY MAJ5MVK^#.)Q>02/SW+8G_`%NI\GP M=R2/_P4``/__`P!02P,$%``&``@````A`&A&F&:#`P``M0L``!D```!X;"]W M;W)K&ULE%;;;N(P$'U?:?\ARGM)'`*4B%#1K;I; M:5=:K?;R;!(#5I,XLDUI_WYG;!)R*9"^(#(Y/C-G9C*>Q=UKGCDO3"HNBM@E M(]]U6)&(E!?;V/WS^_'FUG64ID5*,U&PV'UCRKU;?OZT.`CYK':,:0<8"A6[ M.ZW+R/-4LF,Y52-1L@+>;(3,J89'N?54*1E-S:$\\P+?GWHYY85K&2(YA$-L M-CQA#R+9YZS0ED2RC&J(7^UXJ2JV/!E"EU/YO"]O$I&70+'F&==OAM1U\B1Z MVA9"TG4&NE])2).*VSSTZ'.>2*'$1H^`SK.!]C7/O;D'3,M%RD$!IMV1;!.[ M*Q+=DYGK+1V!:KI< M2'%PH-Z`5B7%[B$1$%*8"@2R#OE;^QW7%O0`-?0,$W71GQX MMA>K9.,I$T.=[:,%\M:(ZDQ=IVV?EQ.-X)[<4R5MIBUH@%SHS*Y<0B:CJX+Q M7%OPT=(6/*[+T*HO#N[&MW59,()[@L.:V`JVH`&"YVW76-_YU>;&0VVU1TM; M[9EN)H`:+M>@.WJ#<-;1>T0-$$QPO#22/;"CS;&VYLK4%GV*K%5B_!Z;;B_7 MV*`[HLGXMBO:CK`AHM^9860VQ^OCRAPC=DA!0/6G7)G:NN=U<&W=$-T'=".Z MJSOL#B]B44-TX]CI%)OXP6AV73>>[-3[:&KI#L_,,/*A(6;0'6_'P697A>:U M!ZM'7U0(;7VEI_HSRC"!V[:BT_"TE;1[BET&:&("BO7KB7_P$``/__`P!02P,$%``&``@````A`*84J0U:`P``?0L` M`!D```!X;"]W;W)K&ULG%;?;]HP$'Z?M/\A\GL) MA@(%$2JZJMND39JF_7@VB4.L)G%DF]+^][NSDT`2*&$O0([S]]UW=[[<\OXU M2[T7KK20>4#H8$@\GH%3>AS`J`V(A4 MF#<+2KPL7'S=YE*Q30JZ7^DM"RML^]"!ST2HI):Q&0"<[P+M:I[[%0>AN_R M\'@ZF,R&8PI<%T!\%XC5]<@,6RV5W'O0+$"I"X:M1Q<`?%H(*$#?-3H'9$8\ MB%5#]E]6=#I:^B^0L;#T>7`^\'GPJ3U\(*V9@:T_,SHC,Z840WEPAF.:0R`- MFO$U-.@<$/@\!$_G=?B.V?G<'OE,:H\&,[CT%XC.4`.0=:">CFM@1^V<>E!# M/QQ38YN.Z7QPME.K`N,Y&T6=Y]("-^4HKMLZKH;@:9/U_5Y"YR95:7$W\+A3 MH.'::B9T,+NH!L\U*4I+4\V9\N',[GTST+E)55JZ:N9-7*Q-+S5XKDE16IIJ MIJ=K0\&KOQSKW22K3%U!%*_\4:;L4*23R]UF#[98RO'1U#0[H^FJ$8)WJY7` MRG1"4VMLV!L$^7Z_IZF;#0!;WY_*U!1T=T;052.#UC/CP%::3@C"B_Q?1>K. M!'SC82:;F@YSLC$4Z%53P7JW6N+L7*`G!L-LAF_>2W7J3@:+U=8T&YZITU6S M@7:'0V4Z4:<3XX'VNDS=^0";4+=.,]K2Y)8=MQ1D7&WY)YZFV@OE#A>9$;SF M:VN]9*UMA[?MMXNU6[[\^A]8?@JVY=^9VHI<>RF/`7-H9[=RZY-[,+*`Y,,6 M(PVL/_9G`FLNAU?]$`=)+*6I'J#;_7IQ7OT#``#__P,`4$L#!!0`!@`(```` M(0"J/_Y'EP,``-0+```9````>&PO=V]R:W-H965T49*JH>HV:9.F:2^?'3#!*F!D.TW[[W>'@6(GB]*I M7T(XWSWW^#G[N-7MLVJ_=7S\?;A:N(Q6I4E+P MBJ[=%RK=V\W'#ZLC%X\RIU0Y@%#)M9LK54>>)Y.$TK6,FX*(F"5['W M9"TH29N@LO""\7CFE815KD:(Q#48/,M80N]YU@"Q8P53+PVHZY1)]&5?<4%V!>S[V9^0I,-N7D[@2Y8(+GFF M1@#G::*G>UYZ2P^0-JN4P0Y0=D?0;.W>^5'LAZZW634"_6;T*`?_'9GSXR?! MTJ^LHJ`VU`DKL./\$5V_I&B"8.\D^J&IP'?AI#0CAT+]X,?/E.US!>6>PHYP M8U'Z1Y9JO*U&\#1V%&I'AA"N4YR MD(J7?_2BWT+HX*`-AF<;[/NCZ7P<^I#K4F#8!L*S#0QGEP(]S;H1X9XHLED) M?G3@9`$_61,\IWX$8-WN->=>CW_)`3H@R!VBK-VYZ\".)=3P:1-,QBOO"71/ M6I_MJ8]O>L2=!Y8+Z/4<09UWX(@HR!%+B*2WG6%`VB+4>=B$0*AW((0H:Q=^ M>]%\?VDRV+8^61MII:F@]"WHGX[3-WL('G4T^VA+.^G,6 M#RU&)N`\W#G>O7"!7::]^5=?/P0R66@+L!A6[77#S06(>R>[)/AM&S2%RR5! M9S.YM@PE&%H,"99F)I0@F([>K@#BF"2TQ5(@[$NN%>B=;`5\^(Y<+T'C;:9O M34,1#).A@F]UX@_FKE\D)F]_5AP#[@U6`UF0H MH+VTR%D)>Q&'&L%9I^[\Q$0<`X)4ISU MAP3-"&7C3Z([/5M9"]M)%$_.)9A%<=/9;/]Y!-WDS-864;PX9U]&\1+M7@\$ M,U5-]O0;$7M62:>@&4@\'LVA%P@]E>D7Q6N0'B8LKF"J:O[F,#U3^**/L7%D MG*ON!1/T\_CF+P```/__`P!02P,$%``&``@````A`)?V"RF=!@``BAP``!D` M``!X;"]W;W)K&ULK%G;CIM($'U?:?\!\1YC&N.; M;$=C0^]&RDJKU5Z>&8QM-,98P,PD?[_5%Z"KBSAVE)?Q^'15N4YU71IZ]?%+ M<7;>LJK.R\O:]4=CU\DN:;G/+\>U^\_?_,/<=>HFN>R35B_U*8 M*Y+JY?7Z(2V+*YAXSL]Y\U4:=9TB77XZ7LHJ>3X#[R_^)$E;V_(+,5_D:576 MY:$9@3E/.4HY+[R%!Y8VJWT.#$38G2H[K-TG?\D#W_4V*QF@?_/LO3;^=^I3 M^?Y;E>\_YY<,H@W[)';@N2Q?A.BGO8!`V2/:7.[`GY6SSP[)Z[GYJWS_/U&TQ' MX6P<^"#N/&=UPW-ATG72U[HIB_^4D&34&6':"'QJ(_ZB-W)#,="*\#GPZS<4 M)UH1/EO%T3P,)]/Y#-R^H0BKDB]\MJZ"US<4IEH!/EN%Q8C-0S^I$.F($ MB0G"301Q@Q+Y"=R$%4A<"&#G-V-C[/E6"06WR'4B'3F"Q`3A)H+(P4^9Y(:[ M7ELZ0EAR:'][JY#`K"9_-L&L=DHHA``;U/N"0OY`7=_OCQ#&_B@DF'9EL"-( M1)"8(-Q$D'_`U/1/]B`V&P'%!]N0,(1]5PCX;H:)6;'LA-HMB`@2$X2;"*(C M3C%&2[V]_4(8NZP0,]P$B0@2$X2;"/)O\8A_0AC[IQ"Z'UI#+]92\!@HCNOS"0O[TX/<-JXEF*PB3$O,EOMIJ4F$:"F( M!2TM4HB=0$^K@V[24E+!1%F>A'.HSEP*Z7 MZJGI<0G%;RA:#U"Q5@PG75?C&AK8(O;04)72>*AJR"P0"D44BBG$$81BSJRA M>KN.I;3EIAZJLL# M"L44X@C"GEM3\L>/*%"9A)6>H-`2C4CW9SK5Z[6BV>LI%%.((PBS$C/Q[F[# MU`0UNXV&4"HK*0.*J%1,(8X@[*8U9[^3RG28BCI#U8=XQ`D44 MBBG$$83=?&CF,3KS-&0EK7T"U%)6TO:3$?D4/#2ZI#2>"1HRMG-'H8A",84X M@K";#XTN.&?9#55#5FY:4W_72[6)&%$HII!XP=_7J?)Z#88?\DNGE==&`FZ!K&UL(*($`2B@``$````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````G)%!3\,@&(;O)OZ'AGM+6;=E(2U+U.SD$A-G--X0OFW$0@F@[?Z] MK.OJC)X\DO?EX?D^RF6GZ^03G%>-J1#)AI\TJ7:#$!VXDKQL# M%3J`1TMV?54*2T7CX,$U%EQ0X)-(,IX*6Z%]")9B[,4>-/=9;)@8;ANG>8A' MM\.6BW>^`SS)\SG6$+CD@>,C,+4C$0U(*4:D_7!U#Y`"0PT:3/"89`1_=P,X M[?^\T"<73:W"P<:9!MU+MA2G<&QW7HW%MFVSMN@UHC_!+^O[QW[45)GCK@0@ M=MQ/S7U8QU5N%7)UXOR_Q[ZR4HK>CP@$/()/X'CW9G9/GXO9NLT)L MDI-I2DB:SS=D08LIG2WQN#??9"-2#P+^)9P#KO7_^.?L"``#__P,`4$L# M!!0`!@`(````(0"21XK=H0(``.P'```0``@!9&]C4')O<',O87!P+GAM;""B M!`$HH``!```````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````````)Q574_;,!1] MG[3_$.4=4CHTILH-Z@H,I`W04N#1,LY-:^'8F>U&=+]^UTT;$IIFZ][\<3_. M.??:EYR_YC(HP5BAU3@\.1Z$`2BN4Z'FX_!A=G7T)0RL8RIE4BL8ARNPX7G\ M\0.Y-[H`XP38`$,H.PX7SA6C*+)\`3FSQWBM\";3)F<.MV8>Z2P3'"XT7^:@ M7#0<##Y'\.I`I9`>%77`L(HX*MW_!DTU]_CLXVQ5(."83(I""LX$"BYI8DG$F88N`X8]("B=X.R#4P+]H]$\;& MI'2C$KC3)K#B-\HV#(-G9L'#&8%ZV;1MKL5I/#Q;6^"J;>DC5$CPHHUQ)IP$>Y?=,^.Z()\U,:]15(@K0-LJ M4NP->JD*H9FWH=:FR]+N< M'.*3.,R6'Y1FX_*W-%="(0'!)-TXJ';I:C;?-':()\_!J$[LR3+/F5E1G=%$ MS)7`]X*=0B>Z2[4A%9PQUZTY0,_0-OF'89^\EVTN4=G)H]0.]`,>$ MM/362^M$V>G2WR##3I]=VIM4AUG3?Q6U2:0S12UMHWFV]`]VV`.K+P>][$D3[(=($O M&]*MS>Z%GVN/U?".3TZ/!Y\&.+(:9R1Z&]/Q'P```/__`P!02P,$%``&``@` M```A`$/")^B?````O@```!````!X;"]C86QC0VAA:6XN>&UL/([-"L(P$(3O M@N\0]F[36O&/ICT(7KWH`X1T;0+)IF2#Z-L;$3W.?/#-=,,S>/'`Q"Z2@J:J M02"9.#J:%-RNY]4>!&=-H_:14,$+&89^N>B,]N9DM2-1#,0*;,[S44HV%H/F M*LY(A=QC"CJ7F";)&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$` MK.TG>P,#```8"0``#P`````````````````N"@``>&PO=V]R:V)O;VLN>&UL M4$L!`BT`%``&``@````A`!KBD*O&UL4$L!`BT`%``&``@````A``OJ'M4M`P``[0D``!D````````````` M````T1P``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`%!9X7>V`P``D@T``!@`````````````````N24``'AL+W=O M&UL M4$L!`BT`%``&``@````A`)96X?BR`@``$`<``!D`````````````````.#(` M`'AL+W=O&PO=V]R:W-H965T&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`//[&UL4$L!`BT`%``&``@` M```A`"/4+HY."P``Q6,```T`````````````````]V@``'AL+W-T>6QE&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0`_+_IDZ@(` M`,X'```9`````````````````#5[``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`'ALW<0P`P``$`H``!D````````````````` M5GX``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`&R(W%VD`P``%0T``!@`````````````````RY@``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+\!FJ$#!@`` MK1@``!@`````````````````2:(``'AL+W=O&UL4$L!`BT`%``&``@````A`#$1 M_*W5"P``Q#D``!@`````````````````)ZL``'AL+W=OAD``+V(```9```````````` M`````#*W``!X;"]W;W)K&UL4$L!`BT`%``&``@` M```A`&T]+!/8"@``C#(``!D`````````````````X]```'AL+W=O&UL4$L!`BT`%``&``@````A`*H__D>7`P`` MU`L``!D`````````````````/>,``'AL+W=O&PO=V]R:W-H965TG,@$``$`"```1`````````````````-_M``!D;V-0&UL4$L!`BT`%``&``@````A`$/")^B?````O@`` M`!``````````````````'_0``'AL+V-A;&-#:&%I;BYX;6Q02P4&`````"4` ,)0#L"0``[/0````` ` end XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Warrants And Options (Details 1) (USD $)
9 Months Ended

Sep. 30, 2014

Number Outstanding 1,618,300

Exercise Price $ 3.89

Contractual Life (Years) 3 years

Value if Exercised $ 5,531,355

Issued on 08/18/14 [Member]

Number Outstanding 670,000

Value if Exercised 1,842,500

Issued on 08/18/14 [Member]

Number Outstanding 60,000

Value if Exercised 240,000

Minimum [Member] | Issued on 08/18/14 [Member]

Exercise Price $ 2.50

Contractual Life (Years) 4 years 6 months

Expiration Date Feb. 18, 2019

Minimum [Member] | Issued on 08/18/14 [Member]

Exercise Price $ 3.00

Contractual Life (Years) 3 years 6 months

Expiration Date Feb. 18, 2018

Maximum [Member] | Issued on 08/18/14 [Member]

Exercise Price $ 3.00

Contractual Life (Years) 5 years 6 months

Expiration Date Feb. 18, 2020

Maximum [Member] | Issued on 08/18/14 [Member]

Exercise Price $ 5.00

Contractual Life (Years) 6 years

Expiration Date Aug. 18, 2020

Issued On 11/25/11 [Member]

Number Outstanding 680,000

Contractual Life (Years) 3 years

Value if Exercised 2,710,000

Issued On 11/25/11 [Member] | Minimum [Member]

Exercise Price $ 3.00

Expiration Date May 25, 2015

Issued On 11/25/11 [Member] | Maximum [Member]

Exercise Price $ 5.00

Expiration Date Nov. 25, 2017

Issued On 09/01/12 [Member]

Number Outstanding 30,000

Contractual Life (Years) 3 years

Value if Exercised 159,300

Issued On 09/01/12 [Member] | Minimum [Member]

Exercise Price $ 4.31

Expiration Date Mar. 01, 2016

Issued On 09/01/12 [Member] | Maximum [Member]

Exercise Price $ 6.31

Expiration Date Sep. 01, 2018

Issued On 12/13/12 [Member]

Number Outstanding 100,000

Exercise Price $ 3.01

Contractual Life (Years) 3 years

Expiration Date Dec. 13, 2015

Value if Exercised 301,000

Issued On 03/20/13 [Member]

Number Outstanding 37,000

Contractual Life (Years) 3 years

Value if Exercised 123,950

Issued On 03/20/13 [Member] | Minimum [Member]

Exercise Price $ 2.35

Expiration Date Sep. 20, 2016

Issued On 03/20/13 [Member] | Maximum [Member]

Exercise Price $ 4.35

Expiration Date Mar. 20, 2019

Issued on 09/02/13 [Member]

Number Outstanding 16,300

Value if Exercised 54,605

Issued on 09/02/13 [Member] | Minimum [Member]

Exercise Price $ 2.35

Issued on 09/02/13 [Member] | Maximum [Member]

Exercise Price $ 4.35

Issued on 05/16/14 [Member]

Number Outstanding 25,000

Value if Exercised $ 100,000

Issued on 05/16/14 [Member] | Minimum [Member]

Exercise Price $ 3.00

Issued on 05/16/14 [Member] | Maximum [Member]

Exercise Price $ 5.00

Issued on 09/02/13 [Member]

Contractual Life (Years) 3 years

Issued on 09/02/13 [Member] | Minimum [Member]

Expiration Date Mar. 02, 2014

Issued on 09/02/13 [Member] | Maximum [Member]

Expiration Date Sep. 02, 2016

Issued on 05/16/14 [Member] | Minimum [Member]

Contractual Life (Years) 3 years

Expiration Date Nov. 16, 2017

Issued on 05/16/14 [Member] | Maximum [Member]

Contractual Life (Years) 5 years 6 months

Expiration Date May 16, 2020

Warrants And Options (Details 1) (USD $)	9 Months Ended
Sep. 30, 2014
Number Outstanding	1,618,300
Exercise Price	$ 3.89
Contractual Life (Years)	3 years
Value if Exercised	$ 5,531,355
Issued on 08/18/14 [Member]
Number Outstanding	670,000
Value if Exercised	1,842,500
Issued on 08/18/14 [Member]
Number Outstanding	60,000
Value if Exercised	240,000
Minimum [Member] \| Issued on 08/18/14 [Member]
Exercise Price	$ 2.50
Contractual Life (Years)	4 years 6 months
Expiration Date	Feb. 18, 2019
Minimum [Member] \| Issued on 08/18/14 [Member]
Exercise Price	$ 3.00
Contractual Life (Years)	3 years 6 months
Expiration Date	Feb. 18, 2018
Maximum [Member] \| Issued on 08/18/14 [Member]
Exercise Price	$ 3.00
Contractual Life (Years)	5 years 6 months
Expiration Date	Feb. 18, 2020
Maximum [Member] \| Issued on 08/18/14 [Member]
Exercise Price	$ 5.00
Contractual Life (Years)	6 years
Expiration Date	Aug. 18, 2020
Issued On 11/25/11 [Member]
Number Outstanding	680,000
Contractual Life (Years)	3 years
Value if Exercised	2,710,000
Issued On 11/25/11 [Member] \| Minimum [Member]
Exercise Price	$ 3.00
Expiration Date	May 25, 2015
Issued On 11/25/11 [Member] \| Maximum [Member]
Exercise Price	$ 5.00
Expiration Date	Nov. 25, 2017
Issued On 09/01/12 [Member]
Number Outstanding	30,000
Contractual Life (Years)	3 years
Value if Exercised	159,300
Issued On 09/01/12 [Member] \| Minimum [Member]
Exercise Price	$ 4.31
Expiration Date	Mar. 01, 2016
Issued On 09/01/12 [Member] \| Maximum [Member]
Exercise Price	$ 6.31
Expiration Date	Sep. 01, 2018
Issued On 12/13/12 [Member]
Number Outstanding	100,000
Exercise Price	$ 3.01
Contractual Life (Years)	3 years
Expiration Date	Dec. 13, 2015
Value if Exercised	301,000
Issued On 03/20/13 [Member]
Number Outstanding	37,000
Contractual Life (Years)	3 years
Value if Exercised	123,950
Issued On 03/20/13 [Member] \| Minimum [Member]
Exercise Price	$ 2.35
Expiration Date	Sep. 20, 2016
Issued On 03/20/13 [Member] \| Maximum [Member]
Exercise Price	$ 4.35
Expiration Date	Mar. 20, 2019
Issued on 09/02/13 [Member]
Number Outstanding	16,300
Value if Exercised	54,605
Issued on 09/02/13 [Member] \| Minimum [Member]
Exercise Price	$ 2.35
Issued on 09/02/13 [Member] \| Maximum [Member]
Exercise Price	$ 4.35
Issued on 05/16/14 [Member]
Number Outstanding	25,000
Value if Exercised	$ 100,000
Issued on 05/16/14 [Member] \| Minimum [Member]
Exercise Price	$ 3.00
Issued on 05/16/14 [Member] \| Maximum [Member]
Exercise Price	$ 5.00
Issued on 09/02/13 [Member]
Contractual Life (Years)	3 years
Issued on 09/02/13 [Member] \| Minimum [Member]
Expiration Date	Mar. 02, 2014
Issued on 09/02/13 [Member] \| Maximum [Member]
Expiration Date	Sep. 02, 2016
Issued on 05/16/14 [Member] \| Minimum [Member]
Contractual Life (Years)	3 years
Expiration Date	Nov. 16, 2017
Issued on 05/16/14 [Member] \| Maximum [Member]
Contractual Life (Years)	5 years 6 months
Expiration Date	May 16, 2020

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Contractual life years.

+ References

No definition available.

+ Details

Name: VNRX_ContractualLifeYears

Namespace Prefix: VNRX_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Expiration date.

+ References

No definition available.

+ Details

Name: VNRX_ExpirationDate

Namespace Prefix: VNRX_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

XML 16 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets
9 Months Ended

Sep. 30, 2014

Notes to Financial Statements

Note 4. Intangible Assets
The Company’s intangible assets consist of intellectual property, principally patents, acquired in the acquisition of ValiBio SA. The patents are being amortized over their remaining lives, which are 9 years and 17 years.

December 31,

2013

Accumulated Net Carrying

Cost Amortization Value

$ $ $

Patents 1,314,559 312,516 1,002,043

1,314,559 312,516 1,002,043

September 30,

2014

Accumulated Net Carrying

Cost Amortization Value

$ $ $

Patents 1,219,969 357,216 862,753

1,219,969 357,216 862,753

During the nine month period ended September 30, 2014, and the year ended December 31, 2013, the Company recognized $72,646 and $114,879 in amortization expense respectively. During the year ended December 31, 2013 the Company also recognized impairment losses of $350,000. No impairment losses were recognized during the nine month period ended September 30, 2014.

The Company amortizes the long-lived assets on a straight line basis with terms ranging from 13 to 20 years. The annual estimated amortization schedule over the next five years is as follows:

2014 - remaining $ 22,721

2015 $ 90,882

2016 $ 90,882

2017 $ 90,882

2018 $ 90,882

The Company periodically reviews its long lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 as of December 31, 2013. The result of this review confirmed that the fair value of the patents exceeded their carrying value as of December 31, 2013.

X

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: VNRX_NotesToFinancialStatementsAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\T864S,&(W85\R9#EB7S0V,#9?8CED,U]D8F$W M,C4U,#1F,S(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O5]O9E]3:6=N:69I M8V%N=%]!8V-O=6YT/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I% M>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E=A M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-U;6UA#I7;W)K#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K#I%>&-E M;%=O#I%>&-E;%=O M#I.86UE/DEN=&%N9VEB;&5?07-S971S7T1E=&%I M;'-?,3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN M=&%N9VEB;&5?07-S971S7T1E=&%I;'-?3F%R#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E=A#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C M=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)S$P+5$\2!796QL+6MN;W=N(%-E87-O;F5D($ES'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO2!&:6QE2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)U$S/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPOF5D.B`Q+#`P,"PP,#`@3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SQS<&%N/CPOF5D/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,"PP,#`\'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPOF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XQ,#`L,#`P+#`P,#QS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO M'0^)R9N M8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'!E M;G-E'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO&5S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB'0^)R9N8G-P.R9N M8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO M'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E6%B;&4@86YD(&%C8W)U960@;&EA8FEL:71I97,\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N M/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA M2!&:6YA;F-I;F<@06-T:79I=&EE&-H86YG92!O;B!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M/B@R-RPV,C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6EN9R!U;F%U9&ET960@9FEN86YC:6%L('-T871E;65N M=',@:&%V92!B965N('!R97!A2!N;W)M86P@'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E2=S($1E8V5M8F5R#0HS,2P@,C`Q,R!A M=61I=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+B!4:&4@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\T864S,&(W85\R9#EB7S0V,#9?8CED,U]D8F$W,C4U,#1F,S(- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&%E,S!B-V%?,F0Y8E\T M-C`V7V(Y9#-?9&)A-S(U-3`T9C,R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPOF%T:6]N(&]F(&%S2!H87,@:6YC=7)R960@;&]S'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2<^/&9O;G0@'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!O9B!T:&4@0V]M<&%N>2!T;R!C;VYT:6YU92!A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!O9B!3:6=N:69I8V%N="!! M8V-O=6YT:6YG(%!O;&EC:65S/&)R/CPO2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG M(%!O;&EC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@ M'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'!E;G-E2!E=F%L=6%T97,@97-T:6UA=&5S(&%N9"!A M2!D M:69F97(@;6%T97)I86QL>2!A;F0@861V97)S96QY(&9R;VT@=&AE($-O;7!A M;GDF(S$T-CMS(&5S=&EM871E'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6EN9R!C;VYD96YS960@8V]N0T*86YD(&ET'0M:6YD96YT.B`P+C5I;CL@=&5X="UA M;&EG;CH@:G5S=&EF>2<^/&9O;G0@'0M86QI9VXZ M(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2!C;VYS:61E2!L:7%U:60@:6YS=')U;65N=',@=VET:"!A(&UA='5R:71Y M(&]F('1H2!I;B!C M87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S+CPO9F]N=#X\+W`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`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA28C,30V M.W,-"FEN=&%N9VEB;&4@87-S971S(&-O;G-I2!P871E;G1S+"!A8W%U:7)E9"!I;B!T M:&4@86-Q=6ES:71I;VX@;V8@5F%L:4)I;R!302X@5&AE('!A=&5N=',-"F%R M92!B96EN9R!A;6]R=&EZ960@;W9E'0M:6YD96YT.B`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`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@8FQA M8VL@,7!T('-O;&ED)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@ M6QE/3-$)W=I M9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`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`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M:6YD96YT.B`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`@(#QT9"!N;W=R M87`],T1N;W=R87`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`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)W=I9'1H.B`Q)2<^/&9O M;G0@6QE/3-$ M)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`X)3L@=&5X M="UA;&EG;CH@6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`Q M)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`X M)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I M9'1H.B`Q)2<^/&9O;G0@6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V)O6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V)O M'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)V)O'0M:6YD96YT.B`P+C5I;CL@=&5X="UA;&EG;CH@ M:G5S=&EF>2<^/&9O;G0@65AF%T:6]N(&5X<&5NF5D(&EM<&%I6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&IU6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!A;6]R=&EZ97,@=&AE(&QO;F65A'0M:6YD96YT.B`P+C5I;B<^/&9O;G0@6QE/3-$)W9E6QE/3-$)W=I9'1H M.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@'0M86QI9VXZ(')I M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE'0M86QI9VXZ(&IU6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!4'0^)SQS<&%N/CPO'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2<^/&9O;G0@2!T;R!R96YT(&]F9FEC92!S<&%C92P@8F4@ M<')O=FED960@=VET:"!O9F9I8V4@2X@4V5E($YO=&4@."!F;W(@;V)L:6=A=&EO;B!U;F1E'1087)T7S1A93,P8C=A7S)D.6)?-#8P-E]B.60S7V1B M83'0O:F%V87-C3X-"B`@("`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`V7V(Y9#-?9&)A-S(U-3`T9C,R M+U=O'0O M:'1M;#L@8VAA6QE/3-$)W=I9'1H.B`T.'!X.R!F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2<^/&9O;G0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@&5R8VES92!P6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE65A'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2`R-BP@,C`Q-"P@=&AE($-O;7!A M;GD@:7-S=65D(#,P+#DW-2!W87)R86YT65A2P@,2XU)2!R:7-K(&9R964@65A'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@2!I6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^/&9O;G0@2!I65A2P@ M,2XP."4@'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@2`R-BP@,C`Q M-"P@:&%V92!B965N('1R96%T960@87,@82!D97)I=F%T:79E(&QI86)I;&ET M>2P@:6X@86-C;W)D86YC92!W:71H($%30R`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`S."4G M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q M,"4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q,"4[('1E M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q,"4[('1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)W9E M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`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`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W9E M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$ M)W9E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)W9E6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V)O M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V)O6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2<^ M/&9O;G0@2!);F-E;G1I=F4@4&QA;B!F;W(@=&AE M(&1I65E2!C;VYS M=6QT86YT2X@4'5RF5D('1O(&ES28C,30V.W,@8V]M;6]N('-T;V-K+CPO9F]N=#X\+W`^#0H-"CQP M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@ M2!I;G-T86QL;65N=',@;W9E65A M65A&5R8VES92!P2P@,"XX,"4@'0M86QI9VXZ(&IU6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2<^/&9O;G0@2!G2`Q."P@,C`Q-2X@5&AE('-E8V]N9"!T65A&5R8VES92!P6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@2!G"!E M<75A;"!M;VYT:&QY(&EN65A&5R8VES92!P2P@,"XX.24-"G)I6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@'0M86QI9VXZ(&IU'0M:6YD96YT.B`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`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W=I9'1H.B`Q M)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H M.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)W9E6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)W9E M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2<^/&9O;G0@F5D(&]V97(@82!P97)I;V0@;V8@=&AR964@>65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS M<&%N/CPO'0^)SQP('-T>6QE/3-$)VUA6QE/3-$)W=I9'1H.B`Q,#`E)SX-"CQT'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!H860@2`D,SDX+#@R-"`H M)B,Q,C@[,S$T+#0P-BD@;V8@=&AI2!H87,@2!R96-E:79E2!A(#8@<&5R8V5N="!R M;WEA;'1Y(&]N('-U8V@@2!O;B!R979E;G5E+"!I6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M3L@=&5X M="UI;F1E;G0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W=I9'1H.B`T.'!X.R!F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^/&9O M;G0@2`D-BPR-S`@<&5R(&UO;G1H(&9O<@T*;V9F:6-E('-P86-E M(&%N9"!S=&%F9B!S97)V:6-E&EM871E;'D@ M)#$V+C`P,"!P97(@;6]N=&@@:6X@9F5E&5C M=71I=F5S+B!4:&4@0V]M<&%N>2!I6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`Q,#`E)SX-"CQT'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`X.24G/CQF M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$ M)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W=I9'1H.B`Q)2<^/&9O M;G0@6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M:6YD96YT.B`P+C5I;B<^/&9O;G0@6QE/3-$)W9E#L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@0T*,3$L(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A M;B!A9W)E96UE;G0@=VET:"!";VYN(%5N:79E2`S,2P@,C`Q-"X@5&AE('1O=&%L('!A>6UE M;G1S(&UA9&4@8GD@=&AE($-O;7!A;GD@:6X@86-C;W)D86YC92!W:71H('1H M90T*86=R965M96YT('=E2`S,2P@,C`Q-BX@5&AE('1O=&%L('!A>6UE;G1S('1O(&)E(&UA9&4@8GD@ M=&AE($-O;7!A;GD@:6X@86-C;W)D86YC92!W:71H('1H90T*97AT96YS:6]N M(&]F('1H92!A9W)E96UE;G0@87)E("0T.30L-S$U("@F(S$R.#LS.3`L,#`P M*2X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M:6YD M96YT.B`P+C5I;B<^/&9O;G0@6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P+C5I;B<^/&9O;G0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^/&9O;G0@6QE M/3-$)VUA3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\T864S,&(W85\R9#EB7S0V,#9?8CED,U]D8F$W M,C4U,#1F,S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&%E,S!B M-V%?,F0Y8E\T-C`V7V(Y9#-?9&)A-S(U-3`T9C,R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R6QE/3-$)W=I M9'1H.B`T.'!X.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI M9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W=I9'1H.B`T M.'!X.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2<^/&9O;G0@2`R-BP@,C`Q-2!A;F0@:&%V92!B965N('1R M96%T960-"F%S(&$@9&5R:79A=&EV92!L:6%B:6QI='DN($%S(&$@'0O:F%V87-C3X-"B`@("`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`P+C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@ M'0O:F%V87-C3X-"B`@("`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`V-R4G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)3L@ M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SX\9F]N="!S='EL93TS M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)W=I9'1H.B`Q)2<^/&9O M;G0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT.B`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`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`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`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQP('-T>6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^0F5L;W<@:7,@82!T86)L92!S M=6UM87)I>FEN9R!T:&4@=V%R6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0MF4Z(#$P<'0G/CQB/D5X97)C:7-E/"]B/CPO M9F]N=#X\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]LF4Z(#$P<'0G/CQB/D-O;G1R86-T=6%L/"]B/CPO9F]N=#X\+W1D M/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@F4Z(#$P<'0G/CQB/D5X<&ER871I;VX\+V(^/"]F;VYT/CPO M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0G/CQB/DES6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE M/3-$)V9O;G0M6QE/3-$)W=I M9'1H.B`S."4G/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG M;CH@6QE/3-$)W=I9'1H M.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C4\+V9O M;G0^/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)W=I M9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M M6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)V9O;G0MF4Z(#$P<'0G/C`S M+S(T+S$Q/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0M6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0G/C4\+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C,O,C0O,C`Q M-CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$ M)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C$P,"PP,#`\+V9O;G0^ M/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O M;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C4P+#`P,#PO9F]N=#X\+W1D/@T* M("`@(#QT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R M('-T>6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0G/C`N-3`\+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C4P+#`P,#PO9F]N=#X\ M+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X\+W1R M/@T*/'1R('-T>6QE/3-$)W9EF4Z(#$P<'0G/C`W+S$S+S$Q/"]F;VYT/CPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T* M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O M;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C4\+V9O;G0^/"]T9#X-"B`@ M("`\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M+7-I>F4Z(#$P<'0G/C`W+S$S+S$V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H="<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE M/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C0\+V9O;G0^/"]T M9#X-"B`@("`\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT+7-I>F4Z(#$P<'0G/C`U+S$P+S$V/"]F;VYT/CPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T* M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M+7-I>F4Z(#$P<'0G/C(V+#8X-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!N;W=R M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C$N-S4\+V9O;G0^/"]T9#X- M"B`@("`\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0MF4Z(#$P<'0G/C`S+S(P+S$S M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G M/C,\+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C`S+S(P+S$V/"]F;VYT M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`^)B,Q M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0G/C(Y+#6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C(N,#`\+V9O;G0^/"]T9#X-"B`@("`\ M=&0@;F]W6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M="<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C$R+S$P+S$X/"]F;VYT/CPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M+7-I>F4Z(#$P<'0G/C0U+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!N;W=R M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C(N-#`\+V9O;G0^/"]T9#X- M"B`@("`\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0M6QE/3-$)W9EF4Z(#$P M<'0G/C$Q+S(U+S$S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O M;G0@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M+7-I>F4Z(#$P<'0G/C4\+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C$Q M+S(U+S$X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0M M6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C8T+#,Y,CPO M9F]N=#X\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0G/C(N-#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0M6QE/3-$)W9EF4Z(#$P<'0G/C`Q+S(X+S$T/"]F;VYT/CPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0M6QE M/3-$)V9O;G0M6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G M/C(T+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`^ M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)V9O;G0M M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C4\ M+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C`R+S(V+S$Y/"]F;VYT/CPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT+7-I>F4Z(#$P<'0G/C,\+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G M/C`Y+S`U+S$W/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@ M6QE/3-$)V9O;G0M M6QE/3-$)V)O6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@6QE/3-$)V)O6QE/3-$ M)V9O;G0M6QE M/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0G/C6QE/3-$)W9EF4Z(#$P M<'0G/CQB/C`Y+S,P+S$T/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT+7-I>F4Z(#$P<'0G/CQB/C,L-#DP+#DR-#PO8CX\+V9O;G0^/"]T M9#X-"B`@("`\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@ M6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`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`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG M;CH@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W9E6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V)O6QE M/3-$)V)O6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2<^/&9O;G0@6UE;G1S(&]N('1H97-E(&QE87-E'0M:6YD96YT.B`P+C5I;B<^/&9O;G0@6QE/3-$)W=I9'1H.B`X)3L@ M=&5X="UA;&EG;CH@6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T864S M,&(W85\R9#EB7S0V,#9?8CED,U]D8F$W,C4U,#1F,S(-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-&%E,S!B-V%?,F0Y8E\T-C`V7V(Y9#-?9&)A M-S(U-3`T9C,R+U=O'0O:'1M;#L@8VAA2!O9B!3:6=N:69I M8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A:6QS($YA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!D:6QU=&EV M92!W87)R86YT'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAAF%T M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-3'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\T864S,&(W85\R9#EB7S0V,#9?8CED,U]D8F$W,C4U,#1F,S(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&%E,S!B-V%?,F0Y8E\T-C`V M7V(Y9#-?9&)A-S(U-3`T9C,R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T864S,&(W85\R9#EB7S0V,#9? M8CED,U]D8F$W,C4U,#1F,S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO-&%E,S!B-V%?,F0Y8E\T-C`V7V(Y9#-?9&)A-S(U-3`T9C,R+U=O'0O:'1M;#L@ M8VAAF%T:6]N(&5X<&5N'0^)SQS<&%N/CPO'0^)SD@>65A65A'0^)SQS<&%N/CPO65A65A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T864S,&(W85\R M9#EB7S0V,#9?8CED,U]D8F$W,C4U,#1F,S(-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO-&%E,S!B-V%?,F0Y8E\T-C`V7V(Y9#-?9&)A-S(U-3`T M9C,R+U=O'0O:'1M;#L@8VAA'!I&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA M'!I&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA'!I&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA'!I&5R8VES960\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N M/CPO&5R8VES92!0'0^)S0@>65A'0^)S(P M,38M,#4M,3`\'0^ M)SQS<&%N/CPO&5R8VES92!0'!I&5R8VES960\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^)SQS<&%N/CPO&5R8VES92!0'!I&5R8VES960\+W1D/@T*("`@("`@ M("`\=&0@8VQA&5R8VES92!0'0^)S,@>65A'0^)S(P,38M,#@M M,#<\'!I&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA&5R8VES92!0 M'0^)S4@>65A'0^)S(P,3@M,3(M,S$\&5R8VES92!0'0^ M)S,@>65A'0^)S(P,3'0^ M)SQS<&%N/CPO'!I M&5R8VES960\+W1D/@T*("`@("`@("`\ M=&0@8VQA&5R8VES92!0'!I&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA&5R8VES M92!07,\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5R8VES92!0&5R8VES M960\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'!I'0^)SQS<&%N M/CPO&EM=6T@6TUE;6)E'0^)S4@>65A'0^1F5B(#$X+`T* M"0DR,#(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&5R8VES92!0'!I'0^)S,@ M>65A&5R8VES92!0'!I2`R-2P-"@D),C`Q-3QS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S,@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)S,@>65A'0^1&5C(#$S M+`T*"0DR,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$&5R8VES960\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^)SQS<&%N M/CPO'0^)S,@>65A'0^)SQS<&%N/CPO&EM=6T@6TUE;6)E'0^36%R(#(P+`T*"0DR,#$Y/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES960\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&EM=6T@6TUE;6)E'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&EM=6T@6TUE;6)E'0^)S4@>65A'0^36%Y(#$V+`T*"0DR,#(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\T864S,&(W85\R9#EB7S0V,#9?8CED,U]D8F$W M,C4U,#1F,S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&%E,S!B M-V%?,F0Y8E\T-C`V7V(Y9#-?9&)A-S(U-3`T9C,R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T864S,&(W85\R M9#EB7S0V,#9?8CED,U]D8F$W,C4U,#1F,S(-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO-&%E,S!B-V%?,F0Y8E\T-C`V7V(Y9#-?9&)A-S(U-3`T M9C,R+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T864S,&(W85\R9#EB7S0V M,#9?8CED,U]D8F$W,C4U,#1F,S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-&%E,S!B-V%?,F0Y8E\T-C`V7V(Y9#-?9&)A-S(U-3`T9C,R+U=O M&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M M;#L@8VAA&UL;G,Z;STS1")U'1087)T7S1A93,P8C=A7S)D =.6)?-#8P-E]B.60S7V1B83 XML 18 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2014

Notes to Financial Statements

Note 3. Summary of Significant Accounting Policies
Use of Estimates

The preparation of financial statements in conformity with US generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

Principles of Consolidation

The accompanying condensed consolidated financial statements for the period ended September 30, 2014 include the accounts of the Company and its wholly-owned subsidiaries, Singapore Volition Pte Ltd, Belgian Volition SA, and Hypergenomics Pte. Ltd. All significant intercompany balances and transactions have been eliminated in consolidation.

Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As at September 30, 2014 and December 31, 2013, the Company had $2,419,667 and $888,704, respectively in cash and cash equivalents.

Basic and Diluted Net Loss Per Share

The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. For the three months ended September 30, 2014, 543,275 dilutive warrants and 2,357,275 potentially dilutive warrants and options were excluded from the Diluted EPS calculation as their effect is anti dilutive. For the nine months ended September 30, 2014, 592,204 dilutive warrants and 2,112,995 potentially dilutive warrants and options were excluded from the Diluted EPS calculation as their effect is anti dilutive.

Foreign Currency Translation

The Company’s functional currency is the Euro and its reporting currency is the United States dollar. Management has adopted ASC 830-20, “Foreign Currency Matters – Foreign Currency Transactions”. All assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. For revenues and expenses, the weighted average exchange rate for the period is used. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in other comprehensive loss.

Recent Accounting Pronouncements

Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s consolidated financial statements.

The Company has limited operations and is considered to be in the development stage. In the quarterly period ended September 30, 2014, the Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the Company to remove the inception to date information and all references to the development stage.

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: VNRX_NotesToFinancialStatementsAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Balance Sheets (USD $)

Sep. 30, 2014

Dec. 31, 2013

ASSETS

Cash $ 2,419,667 $ 888,704

Prepaid expenses 133,848 82,135

Other current assets 117,409 34,612

Total Current Assets 2,670,924 1,005,451

Property and equipment, net 315,777 63,265

Intangible assets, net 862,753 1,002,043

Total Assets 3,849,454 2,070,759

LIABILITIES

Accounts payable and accrued liabilities 693,646 518,086

Management and directors' fees payable 240,978 222,294

Derivative liability 6,446,068

Deferred grant income 199,862 216,894

Total Current Liabilities 7,580,554 957,274

Grant repayable 367,112 432,811

Total Liabilities 7,947,666 1,390,085

STOCKHOLDERS' (DEFICIT) EQUITY

Preferred Stock Authorized: 1,000,000 shares of preferred stock, at $0.001 par value Issued and outstanding: Nil shares and Nil shares, respectively

Common Stock Authorized: 100,000,000 shares of common stock, at $0.001 par value Issued and outstanding: 14,308,960 shares and 11,679,757 shares, respectively 14,309 11,680

Additional paid-in capital 14,548,494 12,024,711

Accumulated other comprehensive loss (93,526) (59,795)

Accumulated Deficit (18,567,489) (11,295,922)

Total Stockholders' (Deficit) Equity (4,098,212) 680,674

Total Liabilities and Stockholders' (Deficit) Equity $ 3,849,454 $ 2,070,759

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669686-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e681-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13495-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=20225523&loc=SL20225862-175312

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of the unpaid portion of the fee payable to the managing member or general partner for management of the fund or trust.

+ References

No definition available.

+ Details

Name: us-gaap_ManagementFeePayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of unearned revenue or income not otherwise specified in the taxonomy which is expected to be taken into income within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherDeferredCreditsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6386993&loc=d3e5879-108316

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Grant repayable

+ References

No definition available.

+ Details

Name: VNRX_GrantRepayable

Namespace Prefix: VNRX_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 20 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Financial Statements
9 Months Ended

Sep. 30, 2014

Notes to Financial Statements

Note 1. Condensed Financial Statements
The accompanying unaudited financial statements have been prepared by VolitionRX Limited (the “Company”) without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2014, and for all periods presented herein, have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed unaudited financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2013 audited financial statements. The results of operations for the periods ended September 30, 2014 and 2013 are not necessarily indicative of the operating results for the full years.

X

- Definition

The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.

+ References

No definition available.

+ Details

Name: us-gaap_AdditionalFinancialInformationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: VNRX_NotesToFinancialStatementsAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets (Details 1) (USD $)

Sep. 30, 2014

Intangible Assets Details 1

2014 - Remaining $ 22,721

2015 90,882

2016 90,882

2017 90,882

2018 $ 90,882

X

- Definition

Amount of amortization expense expected to be recognized during the next fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the fifth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the fourth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the third fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the second fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: VNRX_IntangibleAssetsDetails1Abstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Warrants And Options (Details) (Warrant [Member], USD $)
9 Months Ended

Sep. 30, 2014

On 03/15/11 [Member]

Number Outstanding 200,000

Exercise Price $ 0.50

Contractual Life (Years) 5 years

Expiration Date 2016-03-15

Value if Exercised $ 100,000

On 03/24/11 [Member]

Number Outstanding 100,000

Exercise Price $ 0.50

Contractual Life (Years) 5 years

Expiration Date 2016-03-24

Value if Exercised 50,000

On 04/01/11 [Member]

Number Outstanding 100,000

Exercise Price $ 0.50

Contractual Life (Years) 5 years

Expiration Date 2016-04-01

Value if Exercised 50,000

On 06/21/11 [Member]

Number Outstanding 100,000

Exercise Price $ 0.50

Contractual Life (Years) 5 years

Expiration Date 2016-06-21

Value if Exercised 50,000

On 07/13/11 [Member]

Number Outstanding 250,000

Exercise Price $ 1.05

Contractual Life (Years) 5 years

Expiration Date 2016-07-13

Value if Exercised 262,500

On 05/11/12 [Member]

Number Outstanding 344,059

Exercise Price $ 2.60

Contractual Life (Years) 4 years

Expiration Date 2016-05-10

Value if Exercised 894,553

On 05/11/12 One [Member]

Number Outstanding 26,685

Exercise Price $ 1.75

Contractual Life (Years) 3 years

Expiration Date 2015-05-10

Value if Exercised 46,699

On 03/20/13 [Member] | Minimum [Member]

Number Outstanding 200,000

Exercise Price $ 2.47

Contractual Life (Years) 3 years

Expiration Date 2016-03-20

Value if Exercised 494,000

On 03/20/13 [Member] | Maximum [Member]

Expiration Date 2019-12-20

On 06/10/13 [Member]

Number Outstanding 29,750

Exercise Price $ 2.00

Contractual Life (Years) 5 years 6 months

Expiration Date 2018-12-10

Value if Exercised 59,500

On 08/07/13 [Member]

Number Outstanding 45,000

Exercise Price $ 2.40

Contractual Life (Years) 3 years

Expiration Date 2016-08-07

Value if Exercised 108,000

On 11/25/13 [Member]

Number Outstanding 456,063

Exercise Price $ 2.40

Contractual Life (Years) 5 years

Expiration Date 2018-11-25

Value if Exercised 1,094,551

On 12/31/13 [Member]

Number Outstanding 64,392

Exercise Price $ 2.40

Contractual Life (Years) 5 years

Expiration Date 2018-12-31

Value if Exercised 154,541

On 01/28/14 [Member]

Number Outstanding 10,000

Exercise Price $ 2.40

Contractual Life (Years) 3 years

Expiration Date 2017-01-28

Value if Exercised 24,000

On 02/26/14 [Member]

Number Outstanding 1,530,975

Exercise Price $ 2.20

Contractual Life (Years) 5 years

Expiration Date 2019-02-26

Value if Exercised 3,368,145

On 09/05/14 [Member]

Number Outstanding 10,000

Exercise Price $ 2.40

Contractual Life (Years) 3 years

Expiration Date 2017-09-05

Value if Exercised 24,000

On 09/26/14 [Member]

Number Outstanding 24,000

Exercise Price $ 3.00

Contractual Life (Years) 3 years

Expiration Date 2017-09-26

Value if Exercised 72,000

On 09/30/14 [Member]

Number Outstanding 3,490,924

Exercise Price $ 1.96

Contractual Life (Years) 4 years 8 months 12 days

Value if Exercised $ 6,852,489

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: VNRX_ContractualLifeYears1

Namespace Prefix: VNRX_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: VNRX_ExpirationDate1

Namespace Prefix: VNRX_

Data Type: xbrli:dateTimeItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: VNRX_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableIntrinsicValue1

Namespace Prefix: VNRX_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: VNRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber

Namespace Prefix: VNRX_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: VNRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice

Namespace Prefix: VNRX_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 23 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 24 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Going Concern
9 Months Ended

Sep. 30, 2014

Notes to Financial Statements

Note 2. Going Concern
The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred losses since inception of $18,661,015 and currently has very limited revenues, which creates substantial doubt about its ability to continue as a going concern.

The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions and/or financing as may be required to sustain its operations. Management's plan to address this need includes, (a) continued exercise of tight cost controls to conserve cash, (b) receiving additional grant funds, and (c) obtaining additional financing through debt or equity financing.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

X

- Definition

Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.

+ References

No definition available.

+ Details

Name: us-gaap_LiquidityDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: VNRX_NotesToFinancialStatementsAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)

Sep. 30, 2014

Dec. 31, 2013

STOCKHOLDERS' (DEFICIT) EQUITY

Preferred Stock, par value $ 0.001 $ 0.001

Peferred Stock, shares authorized 1,000,000 1,000,000

Preferred Stock, shares issued

Preferred Stock, shares outstanding

Common Stock, par value $ 0.001 $ 0.001

Common Stock, shares authorized 100,000,000 100,000,000

Common Stock, shares issued 14,308,960 11,679,757

Common Stock, shares outstanding 14,308,960 11,679,757

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Warrants and Options (Tables)
9 Months Ended

Sep. 30, 2014

Warrants And Options Tables

Summary of Warrants Issued And Outstanding
Below is a table summarizing the warrants issued and outstanding as of September 30, 2014.

Date Number Exercise Contractual Expiration Value if

Issued Outstanding Price $ Life (Years) Date Exercised $

03/15/11 200,000 0.50 5 3/15/2016 100,000

03/24/11 100,000 0.50 5 3/24/2016 50,000

04/01/11 100,000 0.50 5 4/1/2016 50,000

06/21/11 100,000 0.50 5 6/21/2016 50,000

07/13/11 250,000 1.05 5 07/13/16 262,500

05/11/12 344,059 2.60 4 05/10/16 894,553

05/11/12 26,685 1.75 3 05/10/15 46,699

03/20/13 200,000 2.47 3 03/20/16 494,000

-12/20/19

06/10/13 29,750 2.00 5.5 12/10/18 59,500

08/07/13 45,000 2.40 3 08/07/16 108,000

11/25/13 456,063 2.40 5 11/25/18 1,094,551

12/31/13 64,392 2.40 5 12/31/18 154,541

01/28/14 10,000 2.40 3 01/28/17 24,000

02/26/14 1,530,975 2.20 5 02/26/19 3,368,145

09/05/14 10,000 2.40 3 09/05/17 24,000

09/26/14 24,000 3.00 3 09/26/17 72,000

09/30/14 3,490,924 1.96 4.7 – $ 6,852,489

Summary of options issued and outstanding
Below is a table summarizing the options issued and outstanding as of September 30, 2014.

Date Number Exercise Contractual Expiration Value if

Issued Outstanding Price $ Life (Years) Date Exercised $

11/25/11 680,000 3.00-5.00 3 05/25/15-11/25/17 2,710,000

09/01/12 30,000 4.31-6.31 3 03/01/16-09/01/18 159,300

12/13/12 100,000 3.01 3 12/13/15 301,000

03/20/13 37,000 2.35-4.35 3 09/20/16-03/20/19 123,950

09/02/13 16,300 2.35-4.35 3 03/02/14-09/02/16 54,605

05/16/14 25,000 3.00-5.00 3-5.5 11/16/17-05/16/20 100,000

08/18/14 670,000 2.50-3.00 4.5-5.5 02/18/19-02/18/20 1,842,500

08/18/14 60,000 3.00-5.00 3.5-6.0 02/18/18-08/18/20 240,000

09/30/14 1,618,300 $ 3.89 3 – $ 5,531,355

X

- Definition

Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: VNRX_WarrantsAndOptionsTableAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
9 Months Ended

Sep. 30, 2014

Nov. 06, 2014

Document And Entity Information

Entity Registrant Name VOLITIONRX LTD

Entity Central Index Key 0000093314

Document Type 10-Q

Document Period End Date Sep. 30, 2014

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity Well-known Seasoned Issuer No

Entity Voluntary Filers No

Entity Current Reporting Status Yes

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 14,450,717

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2014

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Details

Name: VNRX_DocumentAndEntityInformationAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies (Tables)
9 Months Ended

Sep. 30, 2014

Commitments And Contingencies Tables

Operating lease payments
The annual non-cancelable operating lease payments on these leases are as follows:

2014 $ 84,251

2015 $ 2,458

Thereafter Nil

X

- Definition

Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12069-110248

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6452660&loc=d3e36991-112694

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 1,3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

+ Details

Name: us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: VNRX_CommitmentsAndContingenciesTablesAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Condensed Consolidated Statements Of Operations And Comprehensive Loss

Revenue $ 14,785 $ 14,785

Expenses

General and administrative 129,318 67,961 249,986 242,660

Professional fees 119,510 153,226 412,532 310,585

Salaries and office administrative fees 457,355 179,846 670,518 569,238

Research and development 1,071,984 524,534 2,733,742 1,758,372

Total Operating Expenses 1,778,167 925,567 4,066,778 2,880,855

Net Operating Loss (1,763,382) (925,567) (4,051,993) (2,880,855)

Other Income

Grants received 143,987

Loss on derivative remeasurement (4,130,562) (3,363,561)

Net Other Expenses (4,130,562) (3,219,574)

Provision for income taxes

Net Loss (5,893,944) (925,567) (7,271,567) (2,880,855)

Other Comprehensive Loss

Foreign currency translation adjustments (19,893) (6,478) (33,731) (18,336)

Total Other Comprehensive Loss (19,893) (6,478) (33,731) (18,336)

Net Comprehensive Loss $ (5,913,837) $ (932,045) $ (7,305,298) $ (2,899,191)

Net Loss per Share - Basic and Diluted $ (0.44) $ (0.08) $ (0.56) $ (0.27)

Weighted Average Shares Outstanding - Basic and Diluted 13,524,998 11,086,237 13,057,866 10,649,152

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=16317811

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OfficersCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax of other comprehensive income (loss) attributable to parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OtherComprehensiveIncomeLossTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Reflects the sum of all other revenue and income recognized by the entity in the period not otherwise specified in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.4)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 4

-Article 7

+ Details

Name: us-gaap_OtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.6-07.2(a),(b),(c),(d))

-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section 45

-Paragraph 3

-Subparagraph (k)

-URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849

+ Details

Name: us-gaap_ProfessionalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e2646-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesIssuedBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: VNRX_CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Gain on derivative remeasurement.

+ References

No definition available.

+ Details

Name: VNRX_GainOnDerivativeRemeasurement

Namespace Prefix: VNRX_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Grants Received

+ References

No definition available.

+ Details

Name: VNRX_GrantsReceived

Namespace Prefix: VNRX_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 30 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Warrants And Options
9 Months Ended

Sep. 30, 2014

Notes to Financial Statements

Note 7. Warrants And Options

a) Warrants

On January 28, 2014, the Company issued 10,000 warrants to a consultant for services at an exercise price of $2.40, exercisable immediately for three years. The warrants were valued at $21,500 using the Black-Scholes Option Pricing model using the following assumptions: Three-year term, $2.26 stock price, $2.40 exercise price, 229% volatility, 0.75% risk free rate.

On February 26, 2014, the Company issued 1,500,000 warrants attached to the issue of 1,500,000 shares for cash totaling $3,000,000. The Company has valued these warrants at $3,995,546 and treated this amount as a derivative liability, in accordance with ASC 815. The warrants are exercisable immediately for five years at an exercise price of $2.20.

On February 26, 2014, the Company issued 30,975 warrants to agents as part remuneration in respect of the issuance of 1,500,000 shares for cash totaling $3,000,000. The warrants were valued at $82,507 using the Black-Scholes Option Pricing model using the following assumptions: Five-year term, $2.68 stock price, $2.20 exercise price, 241% volatility, 1.5% risk free rate. The Company has treated this amount as a derivative liability, in accordance with ASC 815. Each warrant is exercisable immediately for five years at an exercise price of $2.20 per share.

On September 5, 2014, the Company issued 10,000 warrants to a consultant for services. These warrants were valued at $20,092 using the Black-Scholes Option Pricing model using the following assumptions: Three year term, $2.10 stock price, $2.40 exercise price, 236% volatility, 0.99% risk free rate. Each warrant is exercisable immediately for three years at an exercise price of $2.40 per share.

On September 26, 2014, the Company issued 24,000 warrants to an agent as part remuneration in respect of the issuance of 300,000 shares for net proceeds of $688,970. These warrants were valued at $103,223 using the Black-Scholes Option Pricing model using the following assumptions: Three year term, $4.45 stock price, $3 exercise price, 235% volatility, 1.08% risk free rate. Each warrant is exercisable immediately for three years at an exercise price of $3 per share.

All of the 1,530,975 warrants issued on February 26, 2014, have been treated as a derivative liability, in accordance with ASC 815, owing to a ratchet provision in the warrant agreement being effective for the twelve months to February 26, 2015. The derivative liability was measured at $4,078,054 as at February 26, 2014. It was re-measured as of March 31, 2014, and revalued at $4,182,748. The derivative liability was further re-measured as of June 30, 2014, and revalued at $2,315,506, resulting in a gain of $1,867,241 for the three months ended June 30, 2014. At September 30, 2014, the derivative liability was re-measured and revalued at $6,446,068, resulting in a loss of $4,130,562 for the three months ended September 30, 2014.

Below is a table summarizing the warrants issued and outstanding as of September 30, 2014.

Date Number Exercise Contractual Expiration Value if

Issued Outstanding Price $ Life (Years) Date Exercised $

03/15/11 200,000 0.50 5 3/15/2016 100,000

03/24/11 100,000 0.50 5 3/24/2016 50,000

04/01/11 100,000 0.50 5 4/1/2016 50,000

06/21/11 100,000 0.50 5 6/21/2016 50,000

07/13/11 250,000 1.05 5 07/13/16 262,500

05/11/12 344,059 2.60 4 05/10/16 894,553

05/11/12 26,685 1.75 3 05/10/15 46,699

03/20/13 200,000 2.47 3 03/20/16 494,000

-12/20/19

06/10/13 29,750 2.00 5.5 12/10/18 59,500

08/07/13 45,000 2.40 3 08/07/16 108,000

11/25/13 456,063 2.40 5 11/25/18 1,094,551

12/31/13 64,392 2.40 5 12/31/18 154,541

01/28/14 10,000 2.40 3 01/28/17 24,000

02/26/14 1,530,975 2.20 5 02/26/19 3,368,145

09/05/14 10,000 2.40 3 09/05/17 24,000

09/26/14 24,000 3.00 3 09/26/17 72,000

09/30/14 3,490,924 1.96 4.7 – $ 6,852,489

b) Options

On November 17, 2011, the Company adopted and approved the 2011 Equity Incentive Plan for the directors, officers, employees and key consultants of the Company. Pursuant to the Plan, the Company was authorized to issue 900,000 restricted shares, $0.001 par value, of the Company’s common stock.

Options to purchase 25,000 shares were granted on May 16, 2014. These options vest in equal six monthly installments over three years from the date of grant, and expire three years after the vesting dates. The exercise prices are $3.00 for options vesting in the first year, $4.00 for options vesting in the second year, and $5.00 for options vesting in the third year. The Company has calculated the estimated fair market value of these options using the Black-Scholes Option Pricing model and the following assumptions: term 3 to 5.5 years, stock price $2.01, exercise prices $3.00-$5.00, 235% volatility, 0.80% risk free rate.

On August 5, 2014, it was approved at the Company’s Annual General Meeting to increase the number of restricted shares that the Company is authorized to issue under the 2011 Equity Incentive Plan to 2,000,000.

On August 18, 2014, The Company granted options to purchase 670,000 shares. These options vest in two equal tranches, the first tranche vests on February 18, 2015. The second tranche vests on February 18, 2016. All the options expire four years after their vesting dates. The exercise prices are $2.50 for options vesting in the first year and $3.00 for options vesting in the second year. The Company has calculated the estimated fair market value of these options using the Black-Scholes Option Pricing model and the following assumptions: term 4.5 to 5.5 years, stock price $1.85, exercise prices $2.50-$3.00, 237% volatility, 1.58% risk free rate.

On August 18, 2014, The Company granted options to purchase 60,000 shares. These options vest in six equal monthly installments over three years, starting six months after the date of grant, and expire three years after the vesting dates. The exercise prices are $3.00 for options vesting in the first year, $4.00 for options vesting in the second year, and $5.00 for options vesting in the third year. The Company has calculated the estimated fair market value of these options using the Black-Scholes Option Pricing model and the following assumptions: term 3.5 to 6 years, stock price $1.85, exercise prices $3.00-$5.00, 237% volatility, 0.89% risk free rate.

During the nine month period ended September 30, 2014, 10,000 options expired following the cessation of a consultant’s contract.

Below is a table summarizing the options issued and outstanding as of September 30, 2014.

Date Number Exercise Contractual Expiration Value if

Issued Outstanding Price $ Life (Years) Date Exercised $

11/25/11 680,000 3.00-5.00 3 05/25/15-11/25/17 2,710,000

09/01/12 30,000 4.31-6.31 3 03/01/16-09/01/18 159,300

12/13/12 100,000 3.01 3 12/13/15 301,000

03/20/13 37,000 2.35-4.35 3 09/20/16-03/20/19 123,950

09/02/13 16,300 2.35-4.35 3 03/02/14-09/02/16 54,605

05/16/14 25,000 3.00-5.00 3-5.5 11/16/17-05/16/20 100,000

08/18/14 670,000 2.50-3.00 4.5-5.5 02/18/19-02/18/20 1,842,500

08/18/14 60,000 3.00-5.00 3.5-6.0 02/18/18-08/18/20 240,000

09/30/14 1,618,300 $ 3.89 3 – $ 5,531,355

Total remaining unrecognized compensation cost related to non-vested stock options is approximately $1,209,924 and is expected to be recognized over a period of three years.

X

- Details

Name: VNRX_NotesToFinancialStatementsAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrants And Options {1}

+ References

No definition available.

+ Details

Name: VNRX_WarrantsAndOptionsTextBlock

Namespace Prefix: VNRX_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Common Stock
9 Months Ended

Sep. 30, 2014

Notes to Financial Statements

Note 6. Common Stock
On February 26, 2014, the Company issued 1,500,000 shares of common stock for a total of $3,000,000 at a price of $2.00 per share. Attached to these share issuances were 1,500,000 warrants, immediately exercisable for a period of five years at $2.20 per share. The warrants were valued at $3,955,546 using the Black-Scholes Option Pricing model using the following assumptions: Five year term, $2.68 stock price, $2.20 exercise price, 239% volatility, 1.50% risk free rate. Agents received 30,975 warrants, exercisable on the same terms as the warrants issued for cash subscriptions, and valued at $82,507 on the same basis as above. Due to a ratchet provision in the warrant agreement effective for the twelve months to February 26, 2015, all the foregoing warrants have been treated as a derivative liability in accordance with ASC 815. Other fees and expenses directly attributable to agents in respect of these issuances were $147,186 in cash, and $25,900 settled by the issue of shares of common stock. Legal expenses directly attributable to the issuances amounted to $84,879.

On February 26, 2014, the Company issued 16,667 shares of common stock to settle liabilities for services valued at $35,000, at a price of $2.10 per share.

On March 25, 2014, the Company issued 12,334 shares of common stock to settle liabilities for services valued at $25,900, at a price of $2.10 per share.

On March 26, 2014, the Company issued 99,178 shares of common stock to the subscribers for the 297,500 shares of common stock issued on June 10, 2013. These additional shares were issued for no additional consideration under the terms of the Private Placement Memorandum because certain subsequent fundraising targets had not been met.

On June 5, 2014, the Company issued 160,228 shares of common stock for cash of $352,500, at a price of $2.20 per share.

On September 24, 2014, the Company issued 21,250 shares of common stock at a price of $2.20 per share to settle liabilities for services valued at $46,748. In addition, on that date, the Company issued 492,316 shares of common stock at a price of $2.20 for cash of $1,083,094 and 27,230 shares of common stock at a price of $2.20 to an agent in settlement of their debt of $59,906.

On September 26, 2014, the Company issued 300,000 shares of common stock at a price of $2.50 per share for cash of $688,970. The amount received was the net proceeds, after fees of $60,000 had been paid to an agent and $1,030 paid in other fees and bank charges.

In addition, on that date, the Company issued 24,000 warrants to the same agent, immediately exercisable over a period of three years at $3 per share. The warrants were valued at $103,223 using the Black-Scholes Option Pricing model using the following assumptions: Three year term, $4.45 stock price, $3 exercise price, 235% volatility, 1.08% risk free rate.

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: VNRX_NotesToFinancialStatementsAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets (Details Narrative) (USD $)
9 Months Ended 12 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Amortization expense $ 72,646 $ 114,879

Impairment loss $ 0 $ 350,000

Minimum [Member]

Intangible Assets Remaining amortized life 9 years

Amortization of long-lived asset on straight line basis 13 years

Maximum [Member]

Intangible Assets Remaining amortized life 17 years

Amortization of long-lived asset on straight line basis 20 years

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13854-109267

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13777-109266

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Grant repayable

+ References

No definition available.

+ Details

Name: VNRX_AmortizationOfLonglivedAssetOnStraightLineBasis

Namespace Prefix: VNRX_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: VNRX_IntangibleAssetsRemainingAmortizedLife

Namespace Prefix: VNRX_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 33 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Going Concern (Details Narrative) (USD $)
3 Months Ended 9 Months Ended 50 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Going Concern Details Narrative

Net Loss $ (5,893,944) $ (925,567) $ (7,271,567) $ (2,880,855) $ (18,661,015)

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: VNRX_GoingConcernDetailsNarrativeAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2014

Summary Of Significant Accounting Policies Policies

Use of Estimates
The preparation of financial statements in conformity with US generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

Principles of Consolidation
The accompanying condensed consolidated financial statements for the period ended September 30, 2014 include the accounts of the Company and its wholly-owned subsidiaries, Singapore Volition Pte Ltd, Belgian Volition SA, and Hypergenomics Pte. Ltd. All significant intercompany balances and transactions have been eliminated in consolidation.

Cash and Cash Equivalents
The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As at September 30, 2014 and December 31, 2013, the Company had $2,419,667 and $888,704, respectively in cash and cash equivalents.

Basic and Diluted Net Income (Loss) Per Share
The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. For the three months ended September 30, 2014, 543,275 dilutive warrants and 2,357,275 potentially dilutive warrants and options were excluded from the Diluted EPS calculation as their effect is anti dilutive. For the nine months ended September 30, 2014, 592,204 dilutive warrants and 2,112,995 potentially dilutive warrants and options were excluded from the Diluted EPS calculation as their effect is anti dilutive.

Foreign Currency Translation
The Company’s functional currency is the Euro and its reporting currency is the United States dollar. Management has adopted ASC 830-20, “Foreign Currency Matters – Foreign Currency Transactions”. All assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. For revenues and expenses, the weighted average exchange rate for the period is used. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in other comprehensive loss.

Recent Accounting Pronouncements
Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s consolidated financial statements.

The Company has limited operations and is considered to be in the development stage. In the quarterly period ended September 30, 2014, the Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the Company to remove the inception to date information and all references to the development stage.

X

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122427

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02, 03

-Article 3A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 860

-SubTopic 40

-Section 45

-URI http://asc.fasb.org/section&trid=2197723

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2196966

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 325

-SubTopic 20

-URI http://asc.fasb.org/subtopic&trid=2197087

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02)

-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=16385135&loc=d3e33801-111570

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144384

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-URI http://asc.fasb.org/subtopic&trid=2175856

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2175826

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2175892

+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: VNRX_SummaryOfSignificantAccountingPoliciesPoliciesAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies
9 Months Ended

Sep. 30, 2014

Notes to Financial Statements

Note 8. Commitments and Contingencies

a) Walloon Region Grant

On March 16, 2010, the Company entered into an agreement with the Walloon Region government in Belgium wherein the Walloon Region would fund up to a maximum of $1,329,413 (€1,048,020) to help fund the research endeavors of the Company in the area of colorectal cancer. The Company had received the entirety of these funds in respect of approved expenditures as of March 31, 2014. Under the terms of the agreement, the Company is due to repay $398,824 (€314,406) of this amount by installments over the period June 30, 2014 to June 30, 2023. The Company has recorded the balance of $1,009,610 (€733,614) to other income as there is no obligation to repay this amount. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 6 percent royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of $398,824 (€314,406) and the 6 percent royalty on revenue, is twice the amount of funding received.

b) Administrative Support Agreement

On August 6, 2010, the Company entered into an agreement with a related party to rent office space, contract for office support staff, and have consulting services provided on behalf of the Company. The agreement requires the Company to pay $6,270 per month for office space and staff services as well as approximately $16.000 per month in fees for two senior executives. The Company is also required to pay for all reasonable expenses incurred. The contract is in force for 12 months with automatic extensions of 12 months with a 3 month notice required for termination of the contract.

c) Leases

The Company leases premises and facilities under operating leases with terms ranging from 12 months to 24 months. The annual non-cancelable operating lease payments on these leases are as follows:

2014 $ 84,251

2015 $ 2,458

Thereafter Nil

d) Bonn University Agreement



On July 11, 2012, the Company entered into an agreement with Bonn University, Germany, relating to a program of samples testing. The agreement was for a period of two years from June 1, 2012 to May 31, 2014. The total payments made by the Company in accordance with the agreement were $494,715 (€390,000). On April 16, 2014, the Company entered into an extension of this agreement, for a period of a further two years from June 1, 2014 to May 31, 2016. The total payments to be made by the Company in accordance with the extension of the agreement are $494,715 (€390,000).

e) Hvidovre Hospital, Denmark Agreement

On August 8, 2014, Belgium Volition SA entered into an agreement with Hvidovre Hospital, University of Copenhagen in Denmark, relating to a program of samples testing associated with colorectal cancer. It will run for a period of two years to August 8, 2016. Total payments (inclusive of local taxes) to be made under the agreement are $1,745,920 (DKR 10,245,000).

f) Legal Proceedings

There are no legal proceedings which the Company believes will have a material adverse effect on its financial position.

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: VNRX_NotesToFinancialStatementsAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events
9 Months Ended

Sep. 30, 2014

Notes to Financial Statements

Note 9. Subsequent Events

a) Common Stock

On October 3, 2014, 50,000 warrants were exercised for total proceeds of $123,500. As a result, an aggregate total of 50,000 shares of common stock were issued.

On October 9, 2014, the Company issued 91,757 shares of common stock for a total of $229,393

b) Warrants

On October 31, 2014, the Company amended the terms of 1,121,225 warrants of the 1,530,975 that had been issued on February 26, 2014 (See note 6). The aforementioned warrants had a ratchet provision effective until February 26, 2015 and have been treated as a derivative liability. As a result of the amendment, the ratchet provision is now effective until October 31, 2014.

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: VNRX_NotesToFinancialStatementsAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets (Tables)
9 Months Ended

Sep. 30, 2014

Intangible Assets Tables

Patents amortized over their remaining lives

December 31,

2013

Accumulated Net Carrying

Cost Amortization Value

$ $ $

Patents 1,314,559 312,516 1,002,043

1,314,559 312,516 1,002,043

September 30,

2014

Accumulated Net Carrying

Cost Amortization Value

$ $ $

Patents 1,219,969 357,216 862,753

1,219,969 357,216 862,753

Annual estimated amortization schedule
The annual estimated amortization schedule over the next five years is as follows:

2014 - remaining $ 22,721

2015 $ 90,882

2016 $ 90,882

2017 $ 90,882

2018 $ 90,882

X

- Definition

Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of activity in the balance of servicing assets subsequently measured at amortized cost. Includes, but is not limited to, beginning and ending balances, additions, disposals, and amortization.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 860

-SubTopic 50

-Section 50

-Paragraph 4

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7882072&loc=d3e122739-111746

+ Details

Name: us-gaap_ScheduleOfServicingAssetsAtAmortizedValueTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: VNRX_IntangibleAssetsTablesAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Cost $ 1,219,969 $ 1,314,559

Accumulated Amortization 357,216 312,516

Net Carrying Value 862,753 1,002,043

Patents [Member]

Cost 1,219,969 1,314,559

Accumulated Amortization 357,216 312,516

Net Carrying Value $ 862,753 $ 1,002,043

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 39 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Warrants And Options (Details Narrative) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2014

Notes to Financial Statements

Derivative liability restated $ 6,446,068 $ 6,446,068

Loss on derivative liability 4,130,562

Options expired $ 10,000

X

- Definition

Derivative liability restated.

+ References

No definition available.

+ Details

Name: VNRX_DerivativeLiabilityRestated

Namespace Prefix: VNRX_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Gain in derivative liability.

+ References

No definition available.

+ Details

Name: VNRX_GainInDerivativeLiability

Namespace Prefix: VNRX_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: VNRX_NotesToFinancialStatementsAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Options expired.

+ References

No definition available.

+ Details

Name: VNRX_OptionsExpired

Namespace Prefix: VNRX_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 40 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Statements of Cash Flows (unaudited) (USD $)
9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Operating Activities

Net loss $ (7,271,567) $ (2,880,855)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 99,904 109,044

Stock based compensation 311,907 236,966

Common stock and warrants issued to settle liabilities for services 403,483 348,172

Amortization of stock issued in advance of services 52,500

Non-operating income - grants received (143,987)

Loss on derivative re-measurement 3,363,561

Changes in operating assets and liabilities:

Prepaid expenses (61,483) (81,965)

Other current assets (88,422) 7,292

Accounts payable and accrued liabilities 238,446 (166,093)

Net Cash Used In Operating Activities (3,148,158) (2,374,939)

Investing Activities

Purchases of property and equipment (297,607) (713)

Net Cash Used in Investing Activities (297,607) (713)

Financing Activities

Proceeds from issuance of common shares 4,893,529 1,871,500

Grants received 143,987 605,154

Grants repaid (33,166)

Repayment of notes payable (1,321)

Net Cash Provided By Financing Activities 5,004,350 2,475,333

Effect of foreign exchange on cash (27,622) (2,627)

Increase in Cash 1,530,963 97,054

Cash - Beginning of Period 888,704 376,421

Cash - End of Period 2,419,667 473,475

Supplemental Disclosures of Cash Flow Information

Interest paid 10,274

Income tax paid

Non Cash Financing Activities::

Common stock issued for debt $ 77,333

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrants And Options {1}

+ References

No definition available.

+ Details

Name: VNRX_AmortizationOfStockIssuedInAdvanceOfServices

Namespace Prefix: VNRX_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: VNRX_CommonStockIssuedForDebt

Namespace Prefix: VNRX_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Grants repaid.

+ References

No definition available.

+ Details

Name: VNRX_GrantsRepaid

Namespace Prefix: VNRX_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Loss on derivative remeasurement.

+ References

No definition available.

+ Details

Name: VNRX_LossOnDerivativeRemeasurement

Namespace Prefix: VNRX_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Nonoperating income grants received.

+ References

No definition available.

+ Details

Name: VNRX_NonoperatingIncomeGrantsReceived

Namespace Prefix: VNRX_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Grants received.

+ References

No definition available.

+ Details

Name: VNRX_ProceedsFromGrantsReceived

Namespace Prefix: VNRX_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 41 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party Transactions
9 Months Ended

Sep. 30, 2014

Notes to Financial Statements

Note 5. Related Party Transactions
The Company contracts with a related party to rent office space, be provided with office support staff, and have consultancy services provided on behalf of the Company. See Note 8 for obligation under the contract.

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: VNRX_NotesToFinancialStatementsAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies (Details) (USD $)

Sep. 30, 2014

Commitments And Contingencies Details

2014 $ 84,251

2015 2,458

Thereafter

X

- Definition

Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of required minimum rental payments maturing in the second rolling twelve months following the latest balance sheet presented for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of required minimum rental payments maturing after the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: VNRX_CommitmentsAndContingenciesDetailsAbstract

Namespace Prefix: VNRX_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

ZIP 43 0001078782-14-001938-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001078782-14-001938-xbrl.zip M4$L#!!0````(``1L9D4?MB<%/UL``"#Z!0`1`!P`=FYR>"TR,#$T,#DS,"YX M;6Q55`D``ZB^6U2HOEM4=7@+``$$)0X```0Y`0``[%W['_GS\QVC$74+@V*?-KMR)]X&[-J?@E/L)N,`W0\__P'TW MG3G^Q?O]R]U7]+]Q^:>_^O=U;*PYS" MB_GJ^7\'QY9'5MR]-_@[\!3_FT.J=X/310`_ M'64J]RH=>_[3B6\]@:HZ@&X2F:X&C]"L'NG\7?2<8AG$2/4U? MW7@3"T]E2"?X\:,9K$K&`'>\OX$$/;7#Y0?9EY63^&'N55CXJAJ_"M-7;;#V M7@"LXR?OY00]0.\+TH@71I*0ONZ#R5;(Z@EZFKX(`T\6!6U7_>(WT@_FP>C) M-&?+#R9F\!B]G#PH`(.>^)X#@L)OHB<%'[F>Z\ZGQ;CLT#\)WV;@!+TT0F\! M'UK+[\H_RG^`,."?B]%%3PK0?;^^^WWYP8OGP!#U9W^!^M_T).U'1VGOP(PZ M#2+>WH$)%Y'Q]#EJ(MSQ1ND'QXO`/DH>8\&?C@(XG3F(62=I47%OL3PW!(N0 M@_:GHW%P,XGP"2+&E[RX?!6X(0S?EK\N?XJLA28+\\63]XY6XDT)YB;094KAG%Z"(^D[X>56!I8CDR7KYN9+2'Q-];%?2 MI>]-TT;DA=![MPI#2O%#;)4_KZJ3EK1ZMO$9&CQ6'^7TG#YAH^<\&?],3,*? MMTB"&P;?P/01^'O3^$J)X&D*,MQ:/K(1F,7,@18,8ZR<#=&;\5P@J,@`&'PY>V;^9?GGSEF$(P7,#CZG'Z4T\#'DT)A6:`G MQ4C?12^3,[T,_=T8K4SA>^QEEM2[F5Z6Z)D?\?J(5[JBYZ0Z!Z3GQ)J] M3]UF.OV:DMAV^KR2!I-_<":_T=;?;O*73/B&E#>=3[O!A#O4^"#?SKGZM=W. M[V.DVDD/<]%M>F3K-]"C:.P0W^52+&-BQ29GU5L&V-],WT="8@+]:9-9YZ+A]1\!\LIHKR#T2`X\X&)-W:P6F.A M>-_G-*?EKH[LU+1[]@$8B-<\\59Z'J@74^_2F_L#\QIGWDK-`_$2XJ$5X4"\ MYHFW5/-`O)AX]W`Q\*YQWBVU/-`NH1UX`>Y`O.:)M]+S0+V8>A?PZ3DV#IN,#N1U\S]OXATK]:^@."YSF6;Y2\T"\=!,;.,/: MNI5][)6B!_(ET,]ETAH7.IA\%^B$8Z->**R6KZH&`*V_*0,#6/"H# M`3>]*I.!?RTY5B8#_0I\*P/]VO*O](Y^&:)=!<$<'QR\ZRXZFWJCKT-P= MW4YF2X)A4[._#H5QGHI`)R-6W6.!=S=W;08V"!,.@UA#E M>C:HM4BY85"+%-Z=,PXD].K^28/5^42M6QD+M(,\Z">]2]WFTF?LA8Q+6P2= M>0A?0+)=UY'3]6-4KIW4[!Y8P,129,&;+]>.]3E8Q(H6<5V#^Z;D@24J(,AC,=C&3MK&`R-B M^1JU.X>A"9:HO3N2O+/!>[OW2D.#8?.U*=+U;/>U3=(-VZ\`:[PSZ19*Z)6O M[-#@/1W::&DP#&U-D:Y'0UO;I!N&-JSQSB1T(6!7W]*J[&KNWHYK%"08AK6& M*->S4:U%R@V#&EXA]R==U,;F0`\R.!'X1(87R'^3ODGV]KV;K'_/,=YN^0PKY%-_D^4]AWF,-# M%OQ6O>4#AQOG\)!BOW]8'!]`P>$OT/C&''F&YZ``\KMST;HON2DK5;O.W,N6X2A@ZG MJ]ERIK]C=$\2PW:>MWT;HWN26[93O.UWOE*S/_E*N\[:GAG;GJ0\/7#6KF5* M)'OA(7CL7U4#B M[IO4`^%+IE8LL5ORZWJ.#T>4X+11I-!\>;&<8.W:)P>=%+N+TY&UAP:CK!IR-DTT8RKPB&(7T\V2&H.A:-"HN@ MJ9*DBTU@*1HX=V(Q1$51M8:@;(PM.Z&(NL[KBE(-R\5BAJ9>@`E99%Y5-4TO M`))*J0J#BB<"PB`4MDTM&+04VS.90`OX`5YYHN=13!4+QJD:&L6R=JE`3@TL5/22%4W*]4>&6&BY)&B(Z&IC M6*B8HZB&*%&VT:WO34"`-PY,YQ(P&L0$49$R!%Z741$#G0D2#$7@V6*@Y@;2 M@J@RQT#%"4G@%5TAQ_`3<-'@YB!;,[;1C!H&(1[J7@#+P4LV##VCEA*1;!#2 MD4.I"Y]-1Z,_!$7="67Q9>VXK/MK$_@D'@@=WP`*H$6TFZV1!E@P= MS?8+RJ<77=9<-2M7HW7()51MH+3]X[7K@[E(.MD7U`M/G@&3MU7D`L_]+S`7QRS^:^#USK[0%Q*#`M/*M#9C7Z M/R>:XXWMO^9!B!<)UR"\F2#8MYX?/0A#'S[.0_/1`0_>K8F*JZT]ZFU$5<[ME_5=>70;GX(N2>J!:P]OOAZ8(2.$ MU$X-&S$VAU/#A@S"056PD4Y;L88%):6E,.EBFL0KHI%IH1T"ZV.CZQR*(4BZ MI+6!C=Y=)HF\K+0$C=9]9AB"(53"=F'Z+G2?@M2+_<4,H%6!:!D_>`;=U?4E MPL+U!6+NHM1N6J%'"^@U$1\?M\0OP MS2=P/3..X#A^`!NR+=DM"1=9`"LFV:KF;(1@J!,?0=E-P*78DV9O<+ M?3=MMT$7>%T5LV9[3]!W4'L;=%Z5#4$1ZT-']I5QW(HF:D+._9X302V?'_'Z MB%3C@.`A`R&2]T71;%73`WQ;*"2FW:--%@#G5L6=[<#8-;\PTOKS&W++G'Z8ES09S7-8(%]>KC6Y M#SWK;]1.2<:PX-+S[X'_`BT0W/AGC@FGC,)EI;SYI@'`'#UU;`ZB3#;0KQ+Z MR)V<'463K^.E`NH[]DM29E(`8_[(,: M][2^:_<%Q`T8#9%0U-YK=3V%(AG"YQ^!B%(+%"C$0U[RX(' M;VS]9PY]@,I`K1Z^W3JHL9$%P.=(HWA?)E.'-6V32V>+FU;;.657!XW;*``ELUM=RRZP<%FDY9,%1:)9?G:Q3R-`)*B`I*FR*%0KGZ2-9$V2 M-:6\?-1`^#^XD5Y,!S?D;71R;WW6Q\3Z*A)OJ%(>%"D`UN!I26]HO"*S@7XQ MF0`KO)E<+*QG?"C\S@S!C5M<(ANSKJG9M2"-?-;8Z>?#:L[/4`/ZEF'A$KIH M5L)\+$4S(EE2^-)1J4`\6^#TH<*:(DGEPRD!\#LP2T:'F\FU%X)TQ=A0R".- M..I],REKK;=)RDT9D<(L`.P`2VQX*KM=5`U$M"I2>47`)I(04>8(Q/+-U9+K MS)M./3=:/C!9F>J&I(B9576I5"8PJ5FF:T*TE**&&2D]\WN\YD(+U7/PR#K$ MF%H6]013BPS03CE;8X)Q9X0V,EI-!U;O%,0D7CP$/EJQ8"E,+`8O:G)V7V]5 M/*UH!K4K'K/':*CQ_34%!C5$-`;#$'S%9A4U&9H0 M0;P?&^V0_^2O.QXI]"=(@JPH&7-9)H@AL&4FJELTMT,J2#)1'1Q5Y$"TTBH$@,,U!5K$O;4(G#V;IZF2;`85 M>/9!Y2EG_2I@Z?4K<>G-_;W5`0MG4`7T[OZJ@-[-+<77O[L#4Q/B<.RD`!R8 M,2'==-N6U?C6^"-9D9.):P-A/E7MK:!5@Y@V1=YUO5Y&^3J88+069%W+S*]W M2ZR/CW:+0!/5;"P3';R?/,]^A8YS-9V9T,>[HV2QKP23?06GMLQDKRB45!T/ MK9J(H11$1'SUW"<']_9(B3?N?>B;.,3\*W2C4Q.D`+?V4T'ZHS`4HU1PJZ#7 MNJ[(UP2]._IWC.-VGJ),T%_>5J\DONOQJ^G;-S/\8G`S#W%"4QO9BCC6G\S, M;SM/H`JZE&4N M:0=/6HF9H_5'-P#K!HT.Q,11^V.,L6[NX8)4-3B"LR^J6;N`AV"DTGIF<-8N MYRQ7T/O5S]H!SXL%\"T8@%L?6J1+_!W'I*5CW6A$+[M@'YZV=LX4MZQD2!7< M$/$ZJ>##@G]D7PP$RQ4/.SR[$G+[]HB/Y:+?=PB-BD<:!`T=%M650& M716'#12=?VV;6?%%7R9TK]QSX,.7Z+Z[-&/A&XL,Q3+.-ZZ*Z95IVT1MW&&1 MYA7[BI/%!)?S<.Z#9)649EJWGX M1I25HCNXZ817K,/#,_"!.0E)(X'+,R<44.(.H*52N):&@T)!JHP&-%5/F+=# M0#X=B(?/GD'3<=[.H3/''Z09#L=NVK$(.\9RX7DQG3G>&P!1QH:X#.(8-'SH M$B>M(D?'K#Y;(]7KU$<01,.H5)\E27'FVSCC!)N\J*)@*-DL$!D!]++I\KM/M\N3RP5%<-*SNYMK3V"6.T8[1-$9C=FCS`R.QW[ M1+':1=@CBC(_]F%!6SO0I_RA?ML7N%+OZ>=;^<#@'9CVRKQVF'H'AW!-ARIQ MY[A8S*`?[3=@,2R&DVUJ0Y\K(UX9B>GXGQ?=#*JR,&6,2AWQ>,:[7U3Y!D2? MZ_CS=E%EA\&HM7`V9ZE%!*7$1I]K(T%HET.EL:T)B8R1R.\9UH:V#,SM=F&5 M15%^CK]'74[<,ZP-;46-V"JLTGE.RGB+JGQN$S,>62U] MW[B*]+4/7"3#LGXPT(JTIA-!6[I"T!N,DDS'3IJ"TC?3(VCFPK(K`R"JMR3ILDZ)(-I1C%/CU*R_)*O"^CYIKN!JHHEJ+F@R;]#(9E)C M1#1%SOJGZHDD:U,C=J$JBFJ/Y=A%UX1#M*`N*IFG5\!1D M(+Q86,X<1_^E*9*8I;@D$<8*()%K=2TS8Q5\!3F\*%0D\AJO91,@;TD@ME4( M$3]TV9"5C0ZS(83@=L":UD(1=%[/YBDC%\D8+9%SUI#R6=6JH_UFNF8<#G$) M0-'M%C2<07^,3&L6E5U5/IE3GS[$IG*?(.T8JA<]"1""L?W5 M0HU2BB-J0$/6U.P]Y#O$H>5$S.PHJ.36]&_\^R@\)XI82\]G$%9\QX$._IC/ MGM8G$\L.+%VJG`;`QF[M\3Q\]GR<])5,HUN,KG:3)$%5LQ/KI&PJH34J90-X M>N&&4:#Y$PQ"+.G:)(]9_OS]YNO5P]4-@LE]?3C_>+*MP$V!9P!'=SA7K@T6 M/X-MYS@V)4:VT$"*D[/2UDK+BCOWK#GFP\/;C+Q>`C_Z)2X_^WE1L?'5P1>N M3>%62OW(^.]Y*;G2LN+&Z*D=;;(XYA.QF`DB&H@EY`K(EIRL4B]A8)D.#K*A MKJWN/^JSG`CNRTSZQV&LO2X`MI6V*_>XY\N+52"N@=ZP'U6IP6WWW"\YHYN;0_0)"C=V%IFU(C-&=(W4^> M3]ZE[I$]0M]QR^(Y?);+=-^R$')%%]27>MP2$!"59-R2%5X3M)PZ"$:N;*^* MV1CWK4OT&WD[_"+E^^=&2=O%Q;?6T`C#?R\2MRQI]R*&]N9-NB42[:V9%&NB M6E>&HNF67CRI*;XM&6,#8X/GH$;H&E3`7 M5?4T4@S-4'(N'!JQ#:`F.G&%[[Q6F:$^!R_`\2(/,!HWG@"RH<"?^3``YV`" M+1AFRC^?^\B&KG]1O6^*!CZ+DG6>U,723NV(R*\KJB9G\X2SKUUD49X]QT:3 M#.S'7SOP3!.TH/-JUDFR67(UV61'"'E#%[.A,>72,]OP8]=FIX<-EWN9(!;` M*KGI:8&M3.\E=$W7@G@]-/'\:1QUAJ82CH<7QP$W!?'*[[YOG!B\H,3?IAQ M0?CF@$]'$_31*2?PLY![@%,0<-?@E;OSIJ;[8_S#C]P]FA]-/G!3TW^"[BG' M?^"PF)'IP"?TOW_-@Q!.WHY^>`H_X))Q@;2%1Q\_/(,?_BE('TS+BN>K>*XY M=\TYT@.PN4FJ!2XZ0QT=#.>>S1?`/0+@S#/P59^Y#,B-,?]`__R[W"\-F;AUPD[SA".>CB&!/TE>N\_7][7_KDMI'D^_U%[/]0 MH97C21$@&P`)'O+,1+2N&>VS)85;MG<^38!`L8DQ"-`XNM7SU[_,K,+!LWD# M(&MC1V:30%56YJ_RK(,%*"^?1=P!EQ_'4WKA-0NXP^,8P@Z6A#B`&/,<8]N+ MX,U$G/O0(!(5B^WP8`"O!8V:.'4_8V`\?8V8GP-Q90BL8 M64?7&&)`/`4P(O)GY/G&6=_`)]QF[T$7.6.)B*GM\C8*]P8EFDGZ9D:?\`'Q M3SUQ)87\2BQ/2$*K]`!4I1A$H00W[NY1H@E[`!%$HPN?%@]@?)I M`P_@Q(M<7!1+DX'^AK`880M6#UZ=^3PF(NYY`+###N`9Q!B]CW/EUX"F&^7] M":"W4QB&8Y=F*J@I%]=ON@Q0&,+TA!?:[%/"O)C%Z?T]C[&%9`+XA19C7GHA MUP8+4Z,TH!&'Z6$3/?#>O]/`(5;1@)#`E2\A(Y&),3X2<9B-9<;A:U)A_-^8 MO8=)BU.*2.@8-*TZ;).6:C-0;:LG+HHXTIHK#\]_ MDL!P@<^8-\4NA-Z21VOD?6>]C5.8_$^X`VO=K%X5`FQIAY8M+-@W:./I@FU6 M`8_5^`*9Y3,MC5$D*Z;0ROGV[,2R9S,?_COR!26`79O=AS)/X_`(L$]VB3@] MG?FVA#E.$S^[M!W:L\6J1,293Q++?_%+RS(D-=*N`;U13'@;X:@`C$P?BMF M#$Q\?`OM'Y`/XH^A%7@6E`S^,\LZ>6D,M%[/T'3#$H9,Y,A\T<`#!R/I2UL> MX9+]%`4A1P8CP4'%Z0C31GBX!U'AAND([/D(K;J'0Y-G#"7B!!P/VH!1+[)+ MV;G*9].8#@'*U%@&)!154%)J&>08+1IV^0QT)WA=BZ(.1V@[`1QCC-FHDE3* MDD3>*!6:&$!W`^I1SM_@7OBB,0SZ21@5F!,(86@RA@%CF]A3HRTL#QJ%8BP0EC4?R*0C^6 MV(UYA#=?@Z\';8Q>HW_)O0?A7V;:FMUCM094?>!*W_"5\UIR8^')?,Q`9!2F M]Q/@)LPF`26,P0_A190`,G`VPFTT(;ZBF<;LW-!9C``3` M1O>*Q6`U'&'$"N3A"W9"TVH6A6.8H+C$L3R[T*B48\/U/J`;DH>416*D/$J! M&KF64YQ@.+&+(,R;YR:P"_Q-I.(Y@T&QXH:7I0J"(.K/E$IQ0@%IP'\TH;Z+ M=(!+Y0CUXN!):.6A/^NC;7*QEO)``$D/5"'N)LD=CJ\0,8-RC"_&,<.74_SP M:RRF#(#M`[0]14^!6)CFS&RP(A!.9>ZIK9P-(A)"CQVG.05"O]YM[W]*PQ>7 M1#B<6)+&C*>V\6/(Z"S<3_RX" M6GQ03,![['WU.T(QBIY)O8:@4RC!6WJ)V$11FU!- M64J)R/#C$!Z[3WT;*YWA@=S"E:@;E_?'30A/6PVMIT$P`7N21)B1.'3H",/SZ>E]QX@ MR`S36&IO?#R,I'0]5*&^!QPCUT0$WW$8Y.$(>!]R]%1_X\M6A'$24)D2U\`YR$3*3(;=SE`X,D M3,7)@I@%9F6(C8D$#V?(#",W9!4HPGDCEIDEM'/Y>`K^43HRF0\2R:-T/9@7 M.+H$GA33$"7D0J`3<_B+>BH9E"Q3V?NQ)%7H/*2'0,70M,3D!5&?M2O[05(P M-9(\9AD]>FL.'I6&"?07[]%/B:NPM]^\]"!3S7^YN1;#VCR>@$,Q= M./6<&)]OXPMM=@N3+BY<..F'PVQW<@O@DXH5DQIBP-AVQ(0M4K`<4RF!+?.V M3ADB9YO%'L4A\'?;\@(ULY^;V>\@V,\!AW\P+!N"Y4-47\Z\SFPD8M+#XBC5 MJ280K/E/,B\)D(V3*!73610JT-Z!?Y9%Q!$'"PB]3V+,8?B8?9&.(1@\<@P] M>?J'=%JH:L8+?HJ0[G9-#8UF5E8&8%D)0)N+_R:VRUZ:6M<8:KU>G]YX.1@, MM+[>I?K=#$RF]\"I1".ZSZMW@BOJY#./CE\%M8D'/.`J'?85 M($"K%B]Q#DYG*;J'`0P6,_=H-%E,&X=6E`MO[]XQLP=SY(,=88:QQ)LL4Y_' MDK+@G`>N(W"JR>DO..U*3O.LM:+S5Q^^WKW&$(;B.]O)8ST9,.7FOLU(>@R> MQXR,'!`YY:[WX%'.*A^<_6![?KF.XM`J0-&G7*K!7@6@>,`##J/7TK5GC_): M+6B`[M5B\`@J!J")7@4E5%H\^\HEFQZ()DI1919+2H01$4CWO8?!%9=A=$CZ MT)6'`+-9=IKY'+'S/2[U(2M0I`\CVF'Q!"S#I,^4)Q/XG511&,!P$B_CQRQ; M/BH?+=KPQBWY,/PH6FBS3X'D-CZ531H8CM"2&:=$4S.Z;VW!,<,$6BS\$Y># M>S.EK'4>NRSQF();$3^#0I]!<#;!.RJ*0*J<71?]AEDL'+%'>9IRFWV49,Q9 MD04O491^\Q455K>CF7VKD$K6FBC::AVK3[_/BJ/GUSR;4?2(<1S_+DO0^1!* M?!2E`=MW_Y!&(Z*V5.5DMMP9+)GB^ MG]6FI\7@3E MY#L5:XM$,M$I+P$G8I1FJUZS_0(AGLRP%)4R]C4*`_CLB'Q2\[5;H6J(2E0W M6?"-$\JGU:M4=BF7A\H\H&@:'4-:U8,3S;=CN9"6]E%3EPZ$^'^-4""0[SDK*Y`Z#-#MR8_;KC(J6G\,V$_LIH=72=A)&^TE$4(B;)M'*OOH6 MSB"X'1K6ZS?L@TSIRH!:+AEF^9K-TG;07T047EJ;2G3)-VF=TNW=KZ+$&"\L M,"$*X-WP@6<1MUS#AX5+','B`F6A0?(B5!*NX?FJ=0W;K55X[I#)RUQWND)Q M9<4`.?K,AR/3)XMJ6;F?`KB9C<$<+AESY(HW.4WH;[$% M`9OZ#<;TU@O9W:W`D'Q/Y&\B+#207S=%T.&I*8"82$9S@!^Y",W'Y$:6'<*W MAF)9,B''Z&]>HWS:DL39%:U8\>2`?.*9C6NBBYR00? MU7]X472*_4598Y3H@;@[@^DH3))P6CR-LXO><$_*$]E\U3W"?$$)!']]89X6 M`ZM[#\+'R)[]]87X;R[PLAI!;X='51!7*V)*+*U1L!MD<B0IC@3C1OBW5?-?25Q)7$F\$99I0PQ[32BJK=/6 MP%A4X>8Z<7-81*E0&K1'#+JI6%H/1-2*&*5AE`B5"*LFIH+=M%UE&VH(A%H1 MHQ2+$J':3:O$JG;3UAX0M2)&[:95\CS(B*C=M!2G61- MH&D,M6%/[8:].!I.A!BZ+E3M9KT\&DZ$ET'/U/J6VHMZ;1%(/4+\:]JG5C7_ ME<25Q)7$&V&9U%[4]3E7LVU:T*T;IB.?5^B6/4]<+2-"A9_KQL]A\:%"SW6C MY[!HL2(+?(8=JNJR[34C>)]&N!03*<1;@`,OX&P*#4S8L_=AXR6^^`[>XBL? M*U_`B$]UYF_-CK@3W@=T7_#+OJGUNCUJY*4!S0WZ0Z+""[);A6VZBYA_G_&` M;H&/9]Q)O`?N/[69(/O9[N=ZM_TX+)/@P==>1'=4^V$<`Z/",9'PLF/IFJ[K M;?8Y7/'4(X]XN1VWH&5[]E5TOWPM=F_7[=!MO/X>.(AO5-O-1[",[]@`<'L@^X=$T9A%>U`W`&$?AE"$60Y"\O/-: MW,L>!'A1-XK=H&*&?'[PE`.]2UP@'3;.%Z!5(&T(CW:5Q!5$*V['ATH MD"J0SH'T-$E#E2!<&D&9[L4TB4ARH8;P,;OWX/''F'E)3!D3-I_>.=7HZYDW"\7+.4.1F(AZG M?H(/)!,OSEISPF",R4!7)DS%0`2%8@CT`F._OO@8A5-,*+1T`_X_"<7G8:NCO_A;35&Z M"$P<3@3#E0DYA`/Q`@0#S$`P1IC1#<=C#V"!:22NL1'(+0H?/)07O9;]G,YF M882$V>.QR'M/[`>.G2!(`%E/+.;1`SP;$Q5Y*V$`C4YL?YSA0M+7!M(Y^QPF MG`W8.(Q8.`*&B)P?&%69Z\L&L2Y77(!C!TDO@N0N@2\GH0^=QA_^3+WD"C*.F15D!FK9'X0/'RA='!-A(-L`A$2HK1JYZ0;E_9M_#Z*APQ<=C M43HC6O"9Y)'[#[)41;9Y<5I8FL"D[PL+%T;\/D2AY*,C%3CB'#J-..E6))*! M'O$>;.K,]^P1\7R=%1X85IM]@?;!R'-`!W)$UOMBYGH@A\1_DG,CB;Q1*C+_ M.'R2%K8KZX)2P<9+\^&ET>UKQJ"'SZ(4!-]?FI8VQ(G*D\0'TD=/-$R2&#:U M.(&)"`);F_W$[[%JLT@G6Z0Q:U`08T\A7$K$]'TYH'IG135`Y=5N,`9LE5[O M:;U>?YU2!WD*%.5X]WA,$RWS">94I$4Z'S_;TEW%@.-G.X)( M`A3%!F286J?3/0XRA$82R!"V*S/)"AEU&<$\,C;IC.%0,_J##<@@`R\<`HC] MXMPRF\,^>G#KWA3-"V0$['_2`#P^O12X@@'$&CBZ&&"D9"-D"$O>2!"6'\(P M!J*5:#'\$$Z-#%R^DE6'_X([1TZ%8`2?AN`-N.D4/`''3F,LRT>)#;86Q\;_ M3-']&$.;D>T)+P\DQ,E[<"G2)P=BRM?&.+6'Q,6`FK"T4=GU=,TTUV(Z=W,I MLK%,BD/84E!C*DU6AQ%(H1<+T\SN!M&;AF9::W721AEO806)DI(E[/:T?G?0 M9I^"7$UI(MR"7UW00BMI[`[!&!N]78@L058L_#,T?0!!^;!+08+9U\S.3J/& MR"00P0G&&V+<4Y%IDBE`EX_HKY?6$.Q][VQ30"V'W6]:;#+RGX.!-NSK9,*S98`0+K(\%?$HDPN!B/@QJXPIA'&2Q<[4BB`';2O9U9GM MN7.8%*MM-1U03;\!1L/Y\'MD!W\P9X)6.E;JN;(1?!(XW$']@?XN)_UR%Q-S M2"3\]6E`6ER:Y0&%IL*\&"4!L\SDR\[664!#[X"?T-DS!\A6Y_]DR2>C*TL" M=MM=:R$)V%F1`;06,X#Z8"D#^&R2?>M,>99B_^WS+__[YG?)IMO`%0./]\NH M[[3H=8^EK$DXVV*Q:G+!6K%ZQ1JPN-'*=(.<(/]NO2W)_7`J.E M:N;SM?;]!GK4VBN1G8%HBX&%DZBLN9_1TB85BDZEI%OSE1JSMU2IZ:ZHU)@+E1J] MW;>VU=.UA\S%@'[+I/E2'1(+).4*9E%M62JSE1H(+W#D%AU#.;4` MERL=7W@B.-;^ZP2%/Y:02L14:S[PZK%E-N8'96E/4WO M#S3=ZM(@DV5^M-FGA%Z+>*MXDW2$6'4A%\G+\TU(%@L4D`>8=R8?>X[@'GI:$->GT-_-U2 M7H;+*2V9*L+E_BN/&@EV320N0$LTMK3NMV>IO<&FES8.DK9[(-M*HS3&JNA]YR,&M$($9)3!0,P,!!O]Y_,FNYJ),0,F&:Q.#RNL(D M(B)J(^NK/UOD)!LJ\[K">[`W.Q='3BJ2>EPP]SE%\.]>-KK&T_C.+9L/T@]6 MTJFC=-Z%8L]::OL-%-"9`#SS1.RL5.\R=^AN3^:-&X$>?_?#$S8MLMA\A]T1 MF?Q)K")O)OPJO>GO2^$K-P*A2H`+`OR:[ZQ!(IMQ<:,2XH(0?_+&A0Q?_1.S MI*\;*,E:\++!,6"E?,OB$+=ARF0/GV75@4_1_>B5J7EP*"\K@4"I3'5=#2O3&4PU4#.5R+PW7"O%;OQE1> M5O6C5UZ6`H+RLA0*E)=5T$*F2;E9U8_^6MRL\^2U^C=&1WEK#VJ%1#. MXWJW=65NKQX%"@*%;5(.5]6VJ4?W9-08DD?RN$Z8V,+=`#?&UM<7*RB?:'%" MMZOIUK#&4%9`.(].:_?JK-`4"LY3.5,0$+9)5VY6Y:,?#+N:975J#,DCN5GG M26PICZL6J#9[6F^@PMFKQX'1[BL47#T*ZFS=SNUP;3T=%!A/Y/V#:1K6.1=P M)'_KM/L0`0X]*XDKBURSQ$W*C99CD+6V;#5'@NWSP'8PH'9KG7$IU!PEM%;;57RA9?!MT+C-*B>DBN'XU`M M8S_0S1KK\M'WNEIGN/6FS4M6K]>-`^5G*10H/ZMLFI2?5;4< M+/"RNE?@99UGQ19$#X,;8^L36!2J3Y6OK7FZ5N%`.5P*!:J4>,92HC!-6V^D M56`\D4I2&PR.G7.KV!9G3K#,HCN5KG26T-;_"(-^5U5>UUJ=26PL&]2FTI%)"5 M4Q#(39-*;56MDE1JZW`D-S6UE?4R"B.71RW!/>"B#^QC!O09A[[GUI:P']DU M3@@%IR;!J:/.GU!@4I[C<3U'M+=-]!P5II=I[9LUM[='-0TZ7ITR67<$?K#G5M:.XAXDNV#@IDQP29T1[V%+X4ODZ%KVZ[WV!X M56[_.XT3;_PDO_0"EV.#>MOR@M..=U8,*`\-<)S,X;X?SVS'"^[_ M^D)_07_/;-?-_MYYY(^>FTSP4?V'%W-<7!^*).%L58R1/2Y;[`YFWT^+W='K M$@OGF;D+D(]'T)=9XH5!O`4%%0'Y[*"MX0B^!$3=Y_"!3T<\8D9?8Z9N&!I+ M)IR]"Z)Z$7>2,()NP_'87&<]\9R#F9^$_P99S8OC_E!$I0_H"-B'/VQ.U(4#".PJE`NIUP M!`_UJ=%DX=]G`/_R*\P>)US,#.P4+!6]%Q-%\#R/'`\(FP%2<7;`RR^QMD'3 MJ4PMO@@$0SN"""^"$6`/@.KNYA=8S&&FN?)I)/.E]X3M?CH./3]\!&_MV&23T538(QY-"4J.CC_K;8EF*Z)*2NX MREZ:;1T4W"*OB<\M8@6`I&/]P!Y"&);G@W+3P,T9Z#^`T8[_8&,49@3#4RJ@ M:KMUF]Y#B\P2LUIC7B+,0&:C[&2=*K\-`ISJ?^$>K$3@11W6" M;P8IF44`[9+Y@-_M)(=\-B.\U48H!6\Y>LYDPM.4IED:`B'C.2)EM:Z,%*0R4 ML#C/&+6RC:)>B8C59H>=V>00*4MFAW7!VFPP.D9[8*TP.LBW%G$#C4Y_WN@8 M;6N@C$YM1G"P8MA&+Z#S*?3"6A=4&IW@MX]29\2PDD=5%!J=$"45_/6%^>*D MA&4L^TP!^L'UNGHQL5;$G%NB'Z3[HV1Z.3)])YT1"&N46/>8$>`%DL.GC,-. MC/N-`CMOW'3,^;NOC=ZT)N%LJX`^D?]Z>:#=98W2T4']I8@$FHYK)?;MQ8[I M)IX3NV_W[W[\.'CQRW6AW8Z/QP^,'E!T]8GUL^38/QPF@6J^^J"G*P:T'`BWO0& MAYQ854=&*0R=&T-4'+3V/_Z@CJQ2*#H[BBX(/2=BD6Z1=;5:TLSN>C*"`G=5 MDC.U_D%'0U;#JB/YH(^G/)%+-VZ,K2_O6Q$IJ;/ECJ&[U;&G"@?WN,N[8[1Z M\(^"PK5#09U@A?:I0_:IUY*&2EVH6/'H#6NH=6IMJ8[DS1.U"@?*ZU)04%Y7!25%L$_=EC14O>I) MNFY46EVMI]=9.QW)Z3IAHLL"&#?S7L6+0K(XO+;&2%8X.%KZM$;VJ!K:E:MU=21W*\3 MIKV:ZWQEO:BK3DL^G'+A%)Q4$DXAJKZ(LEJ]ML)3X5`.6L(&-]*A5!!?$3YW MZVZ$C^25GC(IB"^/:)8,;SIZYJ".L-?^BN&]A8OM$8,2GMA?@Q6]I$'$GO`_H;FDGG,YX("\"=,(X M81&7-UV&@)6@A5=EXFW5=,-D<:6;=X`2FSLYL,Z=+,_`[1=1?0_>7FM\^__.^;W^T(;R"-;P-7W*$9 M?P/.O?6!OK_]U_]!I/\EC5OWMCU[\RZ<3KV$KCR%I_'Z(!@_#QR/Q^^]V/'# M.(UX_C9==@A__,+'?WWQ,0JG>!M>2S?@_Y-0?!ZV.OJ+O\W).I?@K)C@!]]! MM\?-3'SSW;D3)C1H]LP=7&=>G89,-UL`.K+ M"T"KV0&S[T%KH7YACUXRH4?G,<'N4=,%](@7L+?4YP/3-)B1]S&GRA%!>I;V@['#AR^="^R"^TZ MW'O(;D4&[1KQY*FX`AG[C[%IZ!^-`5TTBV8#7T'[$+A>`AHXEG>1"LZ#8R/N M(66_`K5TES01@1%`&X!1*C&J8W2UKMY[ M+9I"2S8-4Q#/:,4=V=2X-%+_DP:"D.RB5.P&OY0WIYJ=Y8NCT>)%KF30R/:1 MCU*$.IC+GJ&7*>MW.O!5EP08PAL1$`3VF2-[\$^.XPO@MQ$@GRRV8$PVVM)H MVNR3D"A_0.@E$SN98Y24'%((#P#+QF#O&(C&31T<.Y@9'CW0Q='0N@\MLGT<(3N/(F=V!"J33!2IQ3$J2U0"H#RSR^5A2D;Y3Q(^8(C' M8TVH5-#$$_N!9U?4HU+-K1-Z$QY:6-#*(SZQ_?&":R-L2D%?Q/],/?0YRL.1 MANME3S/[.BI\-@7:)D@8D5"FFRP#D3=G(Q]!F>%_%^/B7EO7RTV"#1US>`7' MG#R&T$;@P4?^G3LI3J1XWHM`B^['H;1Q1+J;D8M-@#6$(=EQ&)"*):\JYNAU M.6D$SXK6%3#S^@PA_#=/6]Q(,_4PI+0U#I-MDB^;C(`%"0&MG!/?Y"056A M8D%M0[`A_I!F*0A2VZ<\*\78/H&`+,Y\\ZCO95@:R.A:=@LA.YJ=<0AAT6/\ MYEPR:)`>W7Z0)8V[Q3KRS:KX&/=T!!I>[M?UX#07 M20VZFFGM>]AW-1):8;#VN3K^&%BVML7R^9%[=IR>Y):SKK7U%2?UJ"77;?'E M-TS5VF-P!>H+U55W/)\`39\]OUE8.HT;?NG.TBG"TU,&G>YQ@L[C$?0V#`+V M:^`!PV(O>:IG\G0.Q:=?<:,^7?:GAB8+O@3L?U+_B4@T1*G:W"DWOC#7-?9W M'D%7\(%RYACR4\5_%H7WD4T5_QBXYF/*FL?X^T)*6^1D;9%2GEM3]1B*%54B M$4&U:DDQ=O&S_50JMF.3":X6*U(-4]OE6!9?6"A@.UC4IE)VMNI!Y.F+<6*M M^F5WV-7ZX*^7JZM#VMSSNLV`C;>SR/.SA1;=S3S,T]%%U;XH0I?'+=/U\/B6\;E[)/QX\-WP`N/XC MC&<>3`J-O>CHHUY#M7AS5[`@(G*_W#C)]G"U6^RW$Q#>HLKO;YVS; M"L24O%I0A>_"&0\F]CT/4'M*-!66+UO/M,GZ,3N.0\>CZC)U6BQ68]E"M4]( M#U9&TV"#582.YL:,^C]?+YWK_U=>X/AI#*/`M_T0-`=+[.\\?ETV#6FV5FU1 MTQM:OVMI0U-GK][_OU]`))K9MM^# M=VT7M3EG?#RFY9:@QT%'CKT`-"_^/@MC,A9;*+?5W%N_G^(O-_OMZUC<%7*7 MCF+^9PIO?\#%L<7VD9TV@*BE')>WGP-QA7X.[G52VJYIVDZZL5^<)!R!+];) M_%B+XFKV*/>-B>P$_\XCQXNSY6HBY!=Z,18K],T.GH[79K:<'FS MI>7B+7A8]A!/0,W&60;"$6`2&^<>Q>K].+WN=>#U1\UP539*"(X-P9>W^E+, M;%'$(L[(,?'2-(=:9[CBPINKD;8RD9>WZC_;?:O,8\,579;YG]=T]A2W"(J= M3_F&.T,S3$,S3:NPH3*K;6A61]>&?:M@#VTUP\V!(XY)'J$Y04E^Y*,HM:,G M9O;$LGY*P+^ZXQB8@#'MO99E#="CE#Z!(`(S/%F/V"3883MQ)CP1R_XIORX" M$&O/\"[RUF"PK;,[-0TSA`\CH,UG[CMAZZ99V(Z[B2;[71>S8729) M;CH4'>0;/=PTHI)A_A*QB;*=\SM)=%P;#2 M<1`N'_-(9']I6VIB?Q=C9J(M%#CNSGS$+.S"/I81+5;&7,%ZV>`)%+AI198T MQ[:3`/@F'OA7$=I]&G3D\4!NPGFP891I+/?*XN.XLYDD["5%'D-D:4N;9(I< MK>-%3CH%&2#!6K97&N8\,ES452D_@B"5>WAC3Q1:`6?(Z7^G[KV`M#T*4R%I M!W36$_Z(;.'/P8E4B^-$J?`;\0R.>1&+I#CAEK(XN(?)=CV<(3.8:(@\JFP* M-L1A&N76Y'NP`)20R/K+D33V57I2*O]O[ ML219S*.+W<=8!DWDYF6D/L\CB;Z0E!BDDSR2:IXLSMQD:0S"=HQ3W#=>DE6V M'!]A1'FK$9>S/`NX%E3LO.9 M]X)A]20$R+3"1S3;,5@PS_5@@M+(@$8;=)-0MWD]Z2LHQ)\25U::(+0N59HT M:OXD@\!YB@!`A M`[T`(H$\`=`/M$=-;&QWRB)?"9E-H%@"D!U/,#4)__D`9@H4`?*]GDC*!(D< M\$`SQK2I<`*A#V@`WP/R73H9(4H%>.3V/Y@X8'J2IRS?(4[PD5M=`%]@HW/; M!].,;!^Z@[180NAD!]C#>,$?X78EJY"(LGS/'?FM\*0Z<[XKT8%>XDM3ZQI# MK=?KTULO!X.!UM>[6G8,!7AF/BW>H.[QD24Z5HI_&Y$NXN"#'>&92_%7'MUA MVJ!^"#BTP#"W`3(T9I MLC*1>WDS/,0D2'*W<@3FCLRQDSM.8!-3G,T\:ZWH_-6'KW>OY=XI]!1R3TRZ M,KEN;+.WV":#Y]&?EP,B<^EZ#QZ=Z)`/SGZPO6++%F`Z2PAAGZ`.:3*]"F#> M@&T*H]>9T7WDF%=`[PY,*_BN#!Y!7&.Q6R:7T@2]$NKNE4L*,!!-E/R]S,M[ M+\9-1"#=]W2RAZS08#7=]P5O,":9A6B2T027B9WO<:D/EL;9%Q@_@>_[)+-> M4YY,X'>:16%`&9J,'R`QZ2^*1XLVO'%+/@P_BA;HP!+!;7Q*#@G%("9YQBG1 M%(0!<@-SB4805QH+9>YRL0$Y7U(P6<%C&4.*C"+ALWTE]Z:K3'G@ORI""B^J@L[RC8F3`QW4#8Z5!#4W- MU+MK!V48IC8<6@(;1QP8VVE0SP;?SZCL10T//(+9'+RCP`6>*_D;8"WH3T%: MO:U_V8\?IP$-`'6$'!8==`-/?TBC,/?X\GA30&OAT5\##P5TEY`W[X)S:$=M M]G,1K.,!2;8;4HB/EF#0T5LFH"DCI?^CY"W+F`MO)PGJU.*T4[;X#-%2ED+6 MW.!'X3>N"<5R)2LTR%@V*T?ER9VVB90G+ZM$0.?$#NXI)43I#S0+&5ND!Y0= M_A1/.%@/=,_%]%H9U&NKK<1\/ZNU7YO]W09G30P/;)0,'\$1)W+1`A:0%.<\ M)8DO!(+)FOEA/\VQ9K-\D/,@!*Z:3='_CW(U'X-#A('1XU5P.KE\B[`X)8Q_@-3([K[Z%,P@WAH;U M^@W[(#,2V1DETZ[PC> M"Q]X%@-Q\1HF>9%ZC]+R!2&4!R1EDB?MY'%\RSQ_UL':541%E M7#JTBK_"HSWJ0EUPL0M2)& M*1@E0B7"JHDYMXW`PJ2R#34$0JV(48I%B7#7`]<=)YVF5'QHNGY18BW$^IDG M[)U<,=ATN2J[<6GH?!?&VYSQ46M4*GF6C(C(D(O4OI+KQJZ=Q\"R-)SDLQ=#P#E[+&A[H M(]9*VG6@02%N#=D=P]0LHZ?PIO!V)@VGZZ:F=U><#59CQ!W)4UBX1.^Z8JAZ M)"F.=:I9$_S;JOFO)*XDKB3>",MTRCL!&X2BVCIM#8Q%%6ZN$S>'190*-=>) MFD/CPHILK;HS=>M!JLVTC2[(U*OB7RMBU'X&)<(=5XC,G;Y!=#5X:=`>,>BF M8FD]$%$K8I2&42)4(JR:F`IVTW:5;:@A$&I%C%(L2H1J-ZT2J]I-6WM`U(H8 MM9M6R?,@(Z)VTUZD7-5NVKHBH5;$7-Z>NWKQMU;$*&$K83=8V`VR..>7=[4( MJZ#W:UQQI#BN.%X_!:AVTQ[@+-2(!MQ+=I(U@:8QU(8]M1OVXF@X$6+H[D"U MF_7R:#@17@8]4^M;:B_JM44@]0CQKVF?6M7\5Q)7$E<2;X1E4GM1U^=-GL.BQ8HL\&7L4"UNT-W]!MQU M=^B&XX]>`$'P3]X#=S\%B1W<>\`JT=K'-$DC7E[C]$%<4/\-V7DQM^MFET_; M09#B!>/0[)1N.K=+(V>QY!@+P8NCJX\#((:-@7'LB=L17J3.[)B-0[IN^(3T%2*>M?!^;1NFEER%W,B$XS%H>+E?UR?*=9I@ MO$QC3^.E4IWK\&[5UI4[.WY/`-JAK@T&9K,\KKKE/`"DVT8\"J0*I!7IT;Z" MJ()HW?7H0(%4@71->F4Y17&,!,.ZY,67\=W$COA;.^;NNW"*;U(CMT[B/7C) M4^W2%&^Y'SY2GH")P#E.I_":]Q\($RFE\&A'D1TDF$N(4^[*M(3+PC2)@748 M4&..(1RSN<-S&)+?/F&2857*91XJ#<@-[*(06['W'R[HR6?5"#^\MY/=-X:M MX-R5ZF6+850]W`_?>>1X\>$;^)HRX'?P8V0[26K[9QOS M<04V\R)[KTVT5;.>TNS,&Y^0[WNXA9MRG7N>N+J6`Y^$J3JGX(ZX%6OML+X4 M)K<1>N00YG1]J+=@'\^,D;<_;JGUC]>7UVQ7N.`9[=VSG'H#+WP#TI MDO?0VH<5KSJ#]06)15[HG1O#NC&VKH0L5C[6%F=VP.]"&66/-_6=BD2+/#!U M7=-U?4_!'V\4%\%,O6TI3AZ%D]O6TD['QL/H)\VR0[GE(H5HG$VW',G,[%S6 M6&%1S.[N%F5_4>\JV*J$>20Z:\61`[3]);)C7Y5]/@IIAVZ1*G6AJE6<'J49JU"LQ[NLO9N3*57KT21*+W:,+U*DU,I MUH:ZK/T;HW.9JM4\D?":RQ&CK5>L3FK%COJK5CD[+U&SFCU3L^JK6@_W6;%J M=V-LO4"T0:+K=+N:?MA-VQ>F2TK=I1,;U,TZ]9":Q#SNS`YA\=W>VKCL79N3)#WW<-Z#>QH@%X5L_,2/=8N>*PUSK+^OE&Q'I&3YYM8IU[F MKT9ROI$(X/I[KQ!W=(S+5*V]KM89'G1TWH6I$J59FZ99Q>2\2,UJ M@5[MUE:O'C7S"O9Q<&-LO5RM25)4!6^E8IN=(!"3<^M5"@UBOMG@>OY?S<>B5C@YC?T3J]@69TCR^$.KJOPQM< M;7N1>E:YK\I];;;[*B:G$$XKC&IQ[V#^U='ONI-?>H'+L4&];7G!*BKI_KOEZP]WNZ)PUXL.[Q)X MZIAL32;H;;DT,!0?DI8ELMPL3YS!ZY-L3#Q__`LJ> M([;)5RYNSQ/_D-N)5JGX9VX2.HJT5A-SV*UTN[/L2#=!UHN)M2+FW!(]VF67 M]6)CK8@YMTR/>9]GO3AYGAFQ]VVB]6+6N6%WM+M,*V;CBE"A@@M3=^?_GC>I MUAZT1[S4<7>F'O,>UWIQNE;$U$WL=%5M3N3A%WW6B]NU(J9NHL=;>7,:CW4[ M;[U87@%$O.D-3G"K:K7"4A@Z,X9P,53+VG]%5!U9I5!T=A1=$'I.Q"+=(NMJM:29 MW749F@)W59(SM?Y!&R6J8=61?-"=SSO??D(,Z1K?(]TO<5;@U2/#<2S=??`F MH$OAQ'7CH-ON&*T>_*.@<.U0.&@M_Z4P0>^0?>JUI*$ZTBDT"I5[YZ>LH=:I MM:4ZDL^UQ^5=VS/1I+LNE==5-9@/OROG4EAQW4#HM'7E<2D4*`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`,6@Y M=N!PGVYH"S,^,!\9P6;VTY0'2+E? MUX/3G)XZZ&JFM>\)-]5(:(\\STF2.8!E:ULLGQ^Y9\?I28[V[5I;G^M7#P>J M;AE',.P1M\<)C^H+U>=NCCL2FCY[?K.P5#CCA9.[O4N:.;._??[E?]^4KFC$ M^X;HEB%C2Z?U7[+O?_UN1Y$=)#_3O<3_]QH2Q1]XD)/5K0M9'U!)YF1UZD+6 MMXQ7^:,_>X$W3:?U(_6S%Y3G0._GFM#U[9'[I=E9&WY]\.=F0FTFZ+>)%R6\ MCI2A[I^CK#:RG*=LWC*,Z\E,,`[UY"49B'J21D:"SYFOP<^&^7YK\HK+JK&Y MDWB0\!J>>]4R+$G50I_GH:?L/&84F=T**2K[C8(@;*9*@DHNHR"HUS*K)*CD M+0IZ^BVC4R4]9?,H*+):AEXA17,^(J:O*J?H6?@ZE2KW!4\5WNUC M.^:@-D1M<%)I.NHP'7O5FJ-E#@)956)MR37-J-J*4U16'RV6U6^QKWN.!>&W M3\4C7T6-^/;1CEQ)3RPOC,:LYB?P-+T@]IS?;#]=&.%M_&6\G_/(TL`3;?QZ M]_X%<[GC36T_Q@+LWPP=_T\.\X1#:0;+2O[M)J99BF>K/'#%LIUC!,6R7:.8 M31PS>Z:E6+8BT-K$M,&P:UD=Q;2E6'`3T[J]WG"H>+95M+J1C\.N4G(K0M6- M=F&HE-S*8'JSGSM00%L9[V_F&AH'0[%M54YB(^.LKM55?%N9-MGHP2ESL"9] MLXEKG4YO8'0MQ;<5*2:%MOV28)OXUC<5W]84CS>QK3>PS.Z@DK!A:=O/.J! M=W"5;-H^?:C*IC5IP;5\ZNF]SE4R:FTB M<`VK>MW.T+Q*3JU-_6UR/J^34VNR?>L8975T4.A7R:IU"3Z%J:US>NM\A,6$ MZ-6P:FT:;VU<,]2'^=:'!O'J=TXC=6\?>&3?K&6&S8.S]G_W+S?13YWAO\%_[\_U!+`P04````"``$ M;&9%\`KNCRH+``#K@0``%0`<`'9N`L``00E#@``!#D!``#M76UOVS@2_G[`_@>>%P=D/SBVXK2[ MR3:W2/-2&,@FWB3M]5O!2'3,JTRZI.0X^^N/E.472J)(V9;%`%>@B6-S1L^\ M<(8WX@_YY<[!<>'70C:;0MF7Q`)*/M\WU\R&T71Y+33>7EY.21T"E\H M^\X/?6K'[H'&S$=+7E/"9M^.NMYQ]Z37_>9U_^H=SH8"]R6,Q*?R@W\=77J> M^-%]_]CU3KVCT^/WEE>*8!3SY96ZLV[Z;T[^(<3D^ZG\\00Y`L(8A)_..#YK MK\ MPQD/6@OE)QID-$3W:`CD;^$ERZM.:8@E##83OC'NR(\[PD3Q&)'HG`17),+1 MJ[07&R=PA0@)OQ%#P[.6](OVPB_D17^VH8U>)V*6<#R>A$(EG8UQ?H2AU.K# M"*&(FX`5#JX%R0`RH8`1BK`/PTJP"BEWA5%.-"1-P^^&=Q,9><0`+NQT0<<3 MAD:(<#Q%-Y0;55F=4QTR7$`^N@[I2R6X.:)=(;O&1-@1PW!U-1.N$I)=H?I$ M19JZH,+!F''F%HW=F=WB\1BRU[OA`WXF>"C<6T0(WZ>Q"!'D>2`H?(S,AJS$ M95?8^T3$[F?\%*)SSBT"C6[\KO#[WQE658+MN-8UX]+K59UR&;*:T7D;PO/V MA,_:!VSIZXMAEO8V$M:.T&AS,V7M&*WM;L]A#]G!T@7L.91A%AMW/PZ3'?&- M^%NA0+,(D0`%"SX2^-:%&/&VY)(6S3S0!@NJ]9>0!&#.`B@\:@1?7'!1T!X) MB,O-KW@ME!X@PE$@7W'!,Y`[%I!R`BFK%/("=$A]!6@H"VN4J>9.<2;5LR'D M3TD)+>;M9P@G'>$&O0X*([YX1SI&K]WUTDK:S^G;W^9![")FLDRSN$`(GU"8 M7/9;.BXSK-,<8%GNT..$$_9'1J_1 M/S3#[0QQU+`A2F5USC)WT0@QRVE;--;.)KV&;:*7TCF#J#4Q7>QT)RII-/XV ME#U@=()8]#H(X7P1\2/&$YEK;U%I>"JCDL6CFX_YUB8K M$]4.P^8+BE]O[K]\^R3KHO=@RZP*O')4=Y%2*S+I"$>`J MIF\T>6C\^@W%GZ1;8D1#H34N-S?1J]ZKB\8V68U4TM&\9=-E/Z,WB;]&>!`X?Q+K4TF&WP519'PV$["U64`'8+5A9*^ M&N520%X+',0$QF*=B8)?&FQ727&2Y_1F?4G]HV!H@V%T_LW(4-;;@S$FF$?S MIK$4G%X,(V'S051KE$Q,L=2!MAC'$&LN:W M:+;&LI+?.:LMI5N5%2S2ZOK@1EUNBDA<%I17(QQ*E7E5YUQ)E;'L@CUFR^]%IMYS&@6EG4+:-S.[-NUL4V>2@S+#F7;\0MR[\ M%8QT-+9;B57@B,XM<"QNH`PH2S0;10P_Q9%L`GBD\[*/(05LP]A!I5Q3)HQ& MYDT#_OIS%<2J-ODK]<'@OS&/TC[DW:NP)AC-QXH=.6/1--RW-9V;Z`4*,-]% M+B5JWE\L9++TA:H>YFA6JJZ0XCSFU'V,\B-=*A(L*)CV&: M%,_',C3^;2@KEQ(U'R.W-IV%4IPSY,-(Y*^/4$AJ=VM`-[[YFP-;FZ]<%>-%+=# M\VM*;NOA(H4FD4K9SH-I"CA%IZG`56/1?//7YJ:L+NV^S'A+"56K5E:E:3.9 MG;G>.VLN6\6X5V$5:!F"LF-T_KM/U*=?E`17(Z6=57]UTJK60KX=P\[+`//O M_IB>46%';6?@W]Z6@?5J>@M&MOD^=Q6SV_&SU"H\ MG*V1E1@WVW99667NI26-$M+3`+;R\$(>S?8"^P@%_%HXPFKS7?#4]\+F8!.I ML_Y<8LI\&[&=@NI/H>M0K#:N903.UG0M3&.2S='$F3R-(;TG=DLCQ(W/^M%3 M.%O3M9]9)G7LHY4N=1RY(]9USBE#G"VQ6LZ:(H'=R[]20/D%,?%+KA:F,)1> M,A#K9!ID]SDE?1"5N#2?JC:1.G^#LNIVQ-6FB-J44;:4W4(9=8;:^I11%C:< MZB%Z7@O;7+-J$!"QIZOQ> M;K6CNA38OV5AI\QD9\X:.[#B!U8,:Y1)>["7@OXDBWY%!K*EX1I`&D_Y6@?K M=;-@4W*0T`.508VHBW8\"E`O/_$D!D5)3#NDWVQ4>M<8+S2%B"N#C?&18D($%7>-!K32X>>\V#V[@8/&J MWF=[EMMTV)DB6"X3 M%\SXE$$CJ+UBV+GTK(<-O$:`&QPJEZQ+!-B3WY@/35,DR&7OHA72GIS'XC`U M!7LN;9=BK]N#*AROIDB1R];E4NS)C2H`L``00E#@``!#D!``#M76USFSH6_KXS M^Q]8W]F9[@?')D[2)K?9.WGM9"9-LDEO;_<3HX"<:(M1KH#$OK]^)0(V,@@$ M02!:]T/K)N=(SWG.T=OA"'_\;3YSC6=(?(2]PX&Y-1X8T+.Q@[R'P\'O=\.C MNY.+BX'A!\!S@(L]>#CP\."W?__];P;]\_$?PZ%QCJ#K'!BGV!Y>>%/\JW$% M9O#`^`0]2$"`R:_&5^"&["?XV_'M)?WO:W<'QL[6&!C#H41C7Z'G8/+[[<6R ML<<@>#H8C5Y>7K8\_`Q>,/GN;]E8KKD['!(;+MMZ]LC?C^,^K^D<7 M>=\/V%_WP(<&=8;G'\Q]=#A(V?0^"DBFV`7WL*IP?ZE M`;7L]1F[B,$@CY[A)?9+J:S>D@H; M3H#_>.[BETIP,TI-(3M''O4C`NZJMS)'SA7!X@L!G@_L:/R5X2K3:PH?G01FV+L+L/V]#%*.:%,H M_@"$VABP6>GZ28H?L4:3S*`@&NC19!F%+=UW2H2^A&IS8_7>AW^&M*NS9YEI M3"3?[MS1[!S2UESR!="/E6<47DO=B)%#5Z;7PNB1`RK=@(K5]Q0&`+G^%2,K MH+NC*JNQ2+?=$5;5@K>UJFK$Q?U5'7)K:HK1F37AF2WADXX!67UU,J.@HEAGE-J`>][*SH8-G`%4$G=5N`7'4 MTW`&9_>05(3+JZK'"ERW&L)(03TN#P='5:$E.JW&))R"T`UJ!V6BSF.F/T9> M-#M=TO]RN.$\@)X#G00Y:_#->5CZ8]9*G%XWC:&1:*4_`L\Q7ILPN#;48<]/ MMW)@MRG"9>J+?J93KD/)A0[[Y-,V'9:O,.*6C*2IEC#GYV(Y`R9U###><2W_ M2Z5!-1*UG($[<@:NNC'PU%AU%(4=UY7!^C+>A1X('4156[,^F_?E#-VM8RAK MTX@:;&_S(MUWLAP1R!BW;,-*-J,.L(''-`=Q>!Y@H&E336*JJI;`LBMZ-BN:,=Z_Z2B&79L@YT)GE<#E,P6J8MH);/F'.&9!9&0M';2N62&73 M.2,R*R2W*3'>Q:T8RV;4;F7?EDM/6[:=64^K#/$!;\$[%AN'?(JR(Y(`C[.54@FA%X3)`XT((TP13(P,#$@>1P8(Y76&AH0N=P$)`P MQ^06O71$P]]!;L@"_0[:(:%,0_]L;KLA';WGE!-VN@V#Z+A[/3T#Q*/#Q;^! MY.Z1'O*/%_D-',U10:0J[;31^,E-*Y?%"Q\&N#W3A8&G88BQ*MK3..M=+4[2 MFHTZ.YN.%WBZ#2?*A$V6PZSOM\<_J/,M,\>RIOR?9+YK+AWZ!4C$EBA&)G5C M)/N(\>O5[3?K-`:2;.L_QT^,,JYFTOG"5E["Q)J5OON_&E M]+%'WHJF]Z62@TIR$.E+M!"M<%EIEM`;'%!XB!ZB%^+1*F!92E=OZN5-$"X; MJ8S9*"=EUEH*>;V\BTN791[KY.20XP8VN;!-+NR'S86=,V[A)1WFSOKX.5Y\ M!O_#Y,0%?DENJU(C>N>J:O"A6^ZIP(25`3+9B,H-=9.9JN,R::<7,:9=XJDK MS^NV'<["J*#M:(9)@/[BRKLK^5'05I\]6V12T^=\Y;Z^@D$M MOU*]/OLP@=^7/,#J/AV7",B43XH3`8;9:@F<7-U/IIBR`/^FO&>3TOCQ4QJW M-/QA<<(B):)W.B)CBVY[H`A@V7F"$^HF29`E,H=HW@[MCO=5N=;Y6%[!'SH? MJ#]3+F?AK,PIG%A791YY(8Y+8`I'0K>SSF1L=IBVGK.\1IZ(-(I]T7&N8.CY?3T77!',J#0OU M]'6:/'P]]TN?,'9>D.M>S)X`(I&IA?F]?'GM_5,`N^G\CF!JXR/D$GL/+LMB M1`%R[=T%!*"'Q\B.8^#GGA58,Q5;T=J]I_,"U:"' MV[TA2KO]\H*++[NE93I:<"H-#5R`O:5,3]0OE1`'_A+=2DI!@*LG=PV^<'%7 M0/`Y#DDIORNAKIYQO87>-?3"Z%7!+GHNC]Z54%>/LM[$+H]>..DJ8/<.S4O) M7,Z+6>9 M/3R&Y%@@9%K)803-I9CFY"RSCR>2K`5"IE6<2J(3D1S7O*1E]O!XDFN#D&\5 MAY3H@"1#-R]HF3T\K^29("2[]K%E<]6HQE6C2?=D;ZX::T9F"+:/]2E7;"->7W),_!A]"UU=&B#5RH(P\S& M[_%B)7(#%M$W)+X`XB0%V]=AX`?`^_$)#5:T#6XB!75G.G%6`6[BN;9?AL_H3(LAI+Q.V:E.:LYJ)M^DA4 M-!G>EP_#>]$PC`<;.^==T.!`=`MM1R^E%OE&88^:^UFYY:*8V='N[IS@W4B9 MKPTLO#S'7H^DP>VFC,\WU^Q[%9D MAHCX/87$2]TOR0KWL2!78(7P^8UE_)[!"R+K*V5TZW'EA:]+#(E.1&<)5M?8K'26(EPUW3M::]+`R3V"%D/5= ME:Q+5:[G2%N3CAY@-\+\NAU"[C]H\.KDGZ=X3(-*O4WQF)9$S)JQ`Z+![3]_7@&9C"":A;VC=O.I1^TV&WQ96;-QUNWG38W=JN^9L. ME9[PNKJ')?4VPU+@PN5>98HZ0E'E&1BO8)D=O=^@/N5KV(6L[W=[D*Y=NQI7 M,,E4EB=31M-=63O:ULBI-5D43-TN>0T:6[$6O7FV"\NP?Z:P*R=".+.IKT<7 MK"-YHAH[K1ARTRE!J6)T`;&\D.:4YH'5\R17NY@Z'JZ5ZM;34X22/C4.BY9L M%T69?K7K)=^/NU>MACWU%;DK0QLWAOILAH+HP19%P29.NDQ!ST:P^-MLWJ\; MDVK(H(N=P365^EJ;R);88>PO%A;T)_\'4$L#!!0````(``1L9D5"=!,9-"P` M`$N!`@`5`!P`=FYR>"TR,#$T,#DS,%]L86(N>&UL550)``.HOEM4J+Y;5'5X M"P`!!"4.```$.0$``-U]^V_E-I+N[Q?8_X';>Q>3`';;ISOII'LGNSCM1]88 MM^VUG60&P2"0)1Z;&UDZT<):3-/GAS>SMX1N$DS"-2'+_PYN?;O;G-T=G9V]07@1)%,1I@G]X MDZ1O_N/?_^G_(/K?G_]Y?Q^=$AQ'G]!Q&NZ?)8OTW]!%\(@_H1]Q@K.@2+-_ M0S\'<'`=K?MS#V,TZB-/OI^JPU]E`4RT\'!\_/ MSV^3]"EX3K/?\[=A:F?N)BVS$+>VGI+LY;=WA[-O#C^^/_QM=OA?[]^^+"CN MXZ"@3]F#?WUW/)O1/PX_W![./LW>??KF@^6;BJ`H\_9-AR^']7^5^I]CDOS^ MB?UQ%^08T<9(\D\O.?GA3:]\S^_?IMG]P;O#P]G!7[^[./'CP?\:2,J2+[<97'SCO<'#9S6,GU*-/(])#GYE'-XYVD8%)Q3 MQM<@I03[UWXCML]^M3][M_]^]O8EC]XTE<]K,$MC?(T7B!?S4[%:4I[FY'$9 M,U#\=P\97LC!Q%EVP/0/$GQ/&SQB+_K(7C3[P%[T+_6OSX,['+]!3)+R4%FN MCP-;M=*!:[!7."-I=)*LAWJL[0D^[3M9L4$!^OK.BW";%D&\%OB^IG/8%WB] M&N_TW-C7=TQS"CMDOS^E/`^#XI:#S$(X:Z,R69H#CK^+C;FV[M9Z& M`[LQ&RS33%HCW.0BR.^XW3+?OP^");4_>W^`XR)O?K//?K-_.*M'QW^I?_W; M%2UG4N1?\.,=;E_`2_?#&X7,P1@MDYYG#>0@"PWEKB4.PI1."LMB/ZYJN%)? M9.FC\M5UI:0*@=_BN]9.57/T50K``[$,YWS&G]1P?=2Z&JM1/<94BGE-.-G_ MZ>;-O]/#*4E(@<_)$X[.$CIKWY.[&,_S'!?YY]67X+_3 M["@.\GS^0G)%V2=9<,FE-8K69]H$=3`\G(YYS-+*PCXW@3H;J#*"[E:(FT'< M#OJ56=J8R1)=+ID/*1^]+'5< M,'`2?,8Y*P7O+)N"L#&P7E2D*C&>(/#,B,%P?G)2QB7=((_I>]A M[LHX[I]]!=1IH.:=B+4YZKT5I0O4O!?1%R/^YCTV0ZAL;6>VV$Y_/Z%+CG2% M\4V1AK]7`YC6)];(N^QK1MC]GJ(4!L-S$T+!ATZ9#TV".%ZAEF'/S8P2)!%* MJ[D(V.SRA7I5C^6CEF$C&9>LDL+K,VD@`(8],E1CQM0RP/AP32%BC6_0>^Z2 M!P*L/@?:AV#:?XQHW/;\.:A9YTOP8AX'AC).QP$9O,$XT!<`PP,9*F$M" M7OVGWMM;"6GCZ5P(:^WQ=QV_M%<,/^WSWWWL@:4/(QX-TWVQP#-$U\ M2LNG;^&^A-,&%J$-VK=[#*=Y!4RRUOWFX'#FJG7)DZ'_]B7UI#&;?SL`3><"*.(3I;$E22=J;S\+MO7?7G!Y(5V#@7CZ086'TLYCV\96GPH`J?%I;AD8SGMX]\? MS+YQ$^M:6#3X4,AQQ$L"7%.PJ(-.N.&!(F@%Q[H-R@(4O!X8-JPT/&`C0>N8JCL!KB*%5`S6J*&#Z.ZHMXUG8=PG M)Y/TXUGH]\V)8O#&".,^NM["P^%'WV:"LW,SQY)>_`H+-Q/[!70O4W3 M9CR)H!]/4[LY3Y""-3C(H&EX\.W!S%5$NAFZ+%<=@JB7J<)FU1%X7'5831:3 MEAO?'\Q\Q=\?^O`$K+]9CJ7] M^0-V7R^'HG#G`AE,./X!\V^9G@^5U>9$%82,MEI>>.*Q.*T1''0@D(B^R1"N'+6A51 M750IHY[V-L_YYSA\>Y\^'4285$?\Z0_CD_WT5[]5**[Q/6'(DX)=)3`JM5K, M!:5,(!F#5#+>"6,`)F3VJ"C1R?*;'?S1XHAR-0OBLR3"+W_!*V7A!#FWQ%#` M'#)C)`2(&G)D"F[4PHA+(RKN@QW-.'9+S4J*-7SLB@LR4`T%^L]`M+P$D'*R M8#(^6[F]HH/Y3YJRC.11C$?\-!IAX, MU**N&&`"VY!!)0>"%P9P8XK4XJB21TS!Z^!0.2N_X#C^2Y(^)SGG-"Z3(LA6IR3& MV3C_G$;.+7T4,(>T&0D!HHLYX MX:H%/5J_2F4!$4<+4+6:K>>M5JF^Q-(?CSB/C^BT>9]FZH#'2,HM:Z00AV09 MB`#BB`R7@AI<%#6R'@>6]/$Q3?@M$OP:DORR+/@5M92MZKZ@57(\R%@48#34 M:#0`D,"YRW5?D*=K.OB5/+U+[1=E>U3NW MUL,K!($:`ZAO`=4F4&4#1B[YZLI/!1M50DXO'I0"'-P5.)#P3B$M+"&B?'-S MM\18$4LDXO!]?!'5P2+A,$0PT=.N'"PTH6X4H8R,QP63S@K!K$]*21";ID MC!IHGRZB%!BN**$)>Z>9(`KK4%W`-6"0Q88G'BEB9(<_8A1I$<3G1C]"3XQ; M9J2-X,J2Y0@36[G)+@C M,;_WWA!!D4JZY($&:I\4$C$P0X8:VY@IYV?SSV?G9[=G)T!"*_,P3,NDR*^" M5<"&O"2BO\E*'/7*9'">IUAP.L!,+]I@%+)7!T/$Z9B%L%]M`2TK$]RQ"BHC M*.ZLP&#OER`)[OG=N*<8UX565(UMS3J[@DE@WX/L%T\F"(9@%2^)C:JK0C MU58W!6T8L3S&"TSA1T?T?V(5NE1I.(]AZJ$+P4RY.!AJF3&*S*J$T3T_<4F2 M,-WNF/IZ1OD>I>S&)L\CDG$=:#T8#0.?Y]OSG!0;.WYDS+S&2ZD3))5P MMD%##JW=A#%\['V44&,:-S$70AD&YK$R!(-T"BZ98@;>)XY:VOM@8@UQS*B;V\NCO_SGY?GQR?7- MG]!7QR>G9T=GMU^CD__ZZ>SV;S#H=975;A$OW<]!7*H6WU))QWLW5%!'.S?& M8F`HI,8FV;51NZM<%,W+XB'-R/_@Z!.:[1T>'K+_45YM:4\7:-G*Y]5N]Z!` M__?P[>'AC"[2,_3$7H7J5$=L)9]VN^`_H0L2-Z;8L^Z?>W1FS)=TR4_78S&0 M=5CO.(".KJ*8TPUF"I"#S68C&3`L50`3]Z%VIRN&_*S8.6)H6(FO0<_9-WOO M#[_?^_CAL,_2V6SOPWW+#;R/^V*F+X?6!3JVYZQL>J9R3XGB'1K>"W5B)=GZE-P>@BXH+3>F7J M>ZEOM\2'%2)2XI-'BOKB;'5?,8>N[KDJ#`;U-[4DD36?S&J^-A?I"J'::233 M@<4\2[3&B"5?%^V6EVL?2;T*V$>4!UR0,(@W.Y^J,`7HL*JVL!-.KDKM>'=9 MMP!^K3.M:&`1Q@@[C.A1@)<92VV#(QXYN<(9SSIA%0Y4*_N+LIH*I`Z\JC2] MLWBLZH14 M7-950=T)E=$H^&;;$+B):94T:)8-(!H'M)IBA"O!I9UEF^B*?)T6:J` MIIPY4Y>*=^ENLG1MY;/C1"_/2M/3Q\DI_IV%&A@RVF/5?=4$Y]8)J?",/IU6 MPQ/I;+PYC3A$DEGZ<4-R`?7BA&)I73BEM%=RJ9TWA2A<4FG=-BFA(/EL$]*J MVJEXI97!50.=4'4"2"N6;=%#FQ)4YC,Y^Z277RXNESCC-ZJQL/G@@SG[5/Y3 M$I01H2J3H\T;O<-O&'H+U:./3V_P`N]=8)>ELHQH=R]"EPO4O8I?%3AX&3H' MLU?CFMVL6BH/(W2/70[.8U#]@;AYYIUQ"D!CLM2/8;1V3LC1!'MPQ%$E#(8Q)H1"RG-0Z?U^Q`F%'[/D!=$C2?@UEVQ?;HU246:CEDL^ M61:ASRJ#"AANV>$4CLI56E4VB8$>#,Y=9>D"YSG?P7N*E;.5*.8XZ9L4Y"C1 MVT`&#&\4P"0)W5HQGB<"!C\N%PL2XBQG7A:E.?>[5(.O5-3I;*8!.YC()')@ M^*(!)YR5"^(@:[8PI5QO-,@`8M(USC&MT@$)B3-JQX#('")97!&SBJ?0%8`XP,FFR(@;/BT258H(0W?>^TU78^ M.]D729BYS*I@!J9I>.7K(:@[+51E.TTS3.Z3*A5IN+JE?G].RTC'VWD2\7_% M/+H^C_Z[S(OZOAV>*.0JS?B#HLC(75FP))>W:760J;5<+RCW`1]M*%<)0Z+C&:@LA4!5(*=!%E"DON\ M.2KV.&;VE`JQU MV(591=PLC'&9SB$,$H]<1[0'KWZB!3A+VBT:LL/"B7GOVU>A(F6;B:J7L7O/>1]DOV4_ MAVP"+]DL3Q+4;D9#0?NB3S!ZZS%>TD*0H`XDSQ]9%.Q_=.<]M!INDX$;H0^S M?"O%P3#9C%&\J;'3J$Z;]71@4*P)4.#(XC212MAIBFXMX$&:;JDD&#IIX0FG MBOC=-'=,FE^$T(C#(!&+'+#TMI<+CI-VCE^"C._H/$VS&YP]D1#GE]E1')!' MU9Z5B3:<[H5:IWB#'5)3#(`AZ#JH%0E7^%U)?`1\KDW4N7W8C)SCHHAQ_SYW MOO4JK]^PH^A1?_BN2U@%P,Z2>?14E[N&((L]3--W%A]:IUAM0&B*LG>:KHM8 M\!I[)MCU7A57:WH2]DF=V^&/=DM)\62$^4""6<<9]6SAMW0S*8#:JFX)5EC^ MI\E^M\*HMY/N5U=W[_R\`UM<33KO8%!P1B4KX"V/M-(PQBD;B%8''?;!G72@ MG2&CF/`QKO[NK=SK:^H,@:(I!AQO@9]8L-&N>$MM[PQ=&[+@[3W0?[&\C8.H M2IZS*R^8\]=S\8!$6,0B7[$KU$FDSX%@5O-+5'DA]/0R?BE63E9D(( M0SL/-.YH?`\^C$E7/PZ2R,(8!4M"#ST(E9OEV_6K3;E$/BE#9 M.`_#M$S8Q4 MQNH)I9!<0LE5T;+2K>+>E7;?`8#!??L/ZAM_D8>Z56*S+1*P=N].QBW=S,N^ M#C)%=):@J1LEO%/W+'G"^39V_6@-`:"R14$M**VQ`F9=MC;T,;M;#7!DIA-- MO45@'OY1D@S3PM*>5ZRN:`$*.O^P2S^7DK#5.@:\F3D MPLJ-@GJ@SDC.`N_+6ID[$[C1A$%=^]ZY&.NYN-MZ^"A="C5OO0I`$P1UU M%64])4F0A%MP(;2&`%#9HJ`6E-98@>Y"F*$+IX\;#7!DIF4+,8[R4]KRW=:% MWB4QJIG*K.8\*-(._J0 MVD=M_B:ODW;V"=4,N?U^JA;U3AL[?)ZR"=90V`<&&>SA<^>9(ONPA#R1["&4 M)8,*F+)5F0R,.8?A7=5GS2[2`C7=O8WX/JB&_F@+^*-:4:MW)-V9A`GU<(KBM^LEC@L+A< MG+R$?$?(->V^EPDK`+N(CO[%@C]/0&,I-'X2ZFBMJ:9<)JV9XW"#?+X M3-"'-0:O@5S\?%(]9D&](P-?=]R&JK9Q?#QZR:OOI@BRPE3WR@/2?%[;1Y_Q M/4E8VAPV0E3-`K%^WWNHWY-$Z_L.<"EJ]X1?1F51KPY/'I;+9W\6U^; M707U[,&@[%E28(JRN!(C/G(1M[O:1'##O6K=62<(>LGB+P"5)O!OI0#Q0P%-XIO5B?H!\:09&"]H2]$?NV_(2219 M^W?CH&'NV]RLZR7'-BIA[(IM8A,,O[=4$,FIPWH>E<2(/FU\]D:9D*_]BE<= MPCU-LV-\I\BVIY)UF$I/#[>7)T\NZ)U%-NBT)_+K4\[LN'U$579VKKG`^6U: M(K&'';:*R-8LYS$(VT8AW^FZ*7$9H-'N+NB2@ M<)E]3OXH"2WVRI[$>A67?+4!WZ>F3AX,"RU`2@GW[BWZ,64>VA&KN`Q(J..& MW"=D04*V6;LZT44A7J4Q":D':6*:K;+3V-RD`@U"_?HIOR M\3'(5BP>U[.'.H.HL0B#KF=)08M!V%E%?K+6?E2TTG0L'MO[A(2)N;D\(Z@H9A9W%@2R`-U&?S2RWOEB"5!* MC^_>HD834554Z\(8QAAQ294`G&WU2;FGBI-P$#HWC653C3B^=6V-`HXN8IM@ MP3M5-X(M)?#WU?A6&^,'B@?F8##YIKS+\1\EA7CRQ(]1FR9@M;S;#3`&V,,M M+PIA,*PS(902["-;/3=ZJ%+ MV#*NMX'V#0!AF?P(@1W=['0!G`6Q(*"-(APF3D`KW3W/EPCLAYXZ#$*.+QJV MHZ)1R^>5SQ;T,ZB`(9X=SC'EA-MS$3O\66]O_8KEA/^:'>.HKMZ%0+:X' MMG84'AI_9K]E"2ZT82"3AK-PCQWT-JRC%_=.)WN,DL-/PWT.J%*#,0#>A`\X M*N/VCBUV6(&CG!?UK5HX^CF(2_/WXS4,.8UKKUW00%GP&/R!(WDZ>*48BOP.4LI-N[,IV7!3N7TKI*K M[R7AW=66_MMYA8^.L; M._@M$AK'PZCB;) M#UFCP`I?9((E[VS>"GS5M]!TT>UMJHY25LPOBYR.S1'U2UX'[?G&O;J_;K4+ MV!B&U!WL*V)*US!;?37=Q+HHFBZ3UA-#?9:81:[3[?48S5%SQ7XPVWOA%T;LG#Y8WN+6,P3"#;)BG>5F9R=)ZV/DQ[C(B!Q?L$< M&W:'M&Y@M--SE\E\0C&Z#.<62MZ)-16ID`J]?V`8U-[6P M!#^X$4*_:(;2^BD\4-#LN,)P8[>0GC,L(1NV>%K1++@B\2+Q?CG4R?5W(#\Q".AWT*],",B;)]V'.BR/JM:QH#?#/AY/V<`JZ M_G?/*HICWCT[4H1&ZBF@G6VB5:Q^CNN.T,1R9;ZW*.-L5:."UZY@Q@+>YSH= MJG%C-V+HN9;;U8UL*=M'0((X7HV1=1^Y9.6P5'1W3]N4@G17MMEHP2#.%*C" M;I%.%T5C9E6A9DCGSS6?\W_,>FOB\&?B1*!BT#D' MUU$'PV97N[J.-M@[L*OG*+ M^UC!.VVFH#1O!O.,ANG].M5%MK"R[E1\5=G^FUH5=* M\"%Z":^_?;5T7K=6294Q MV)SN%W@S2C-+KYC1/?@20G_W:@E-9;=71]P8<$+W"KPAH:GL:R9T!U]"Z.\= MQ2%:G[T]%WM.%F-&3M+T%I/0%T49F9"K>2?6=*SF*$6KWCO/'%,#,`;/?C^Y M7(R+KMJ^8E!R>J^550$&.XVT&MXY.`FF$,?O'^'%U;@'@V@_IFGT3.+X['$9 MD(SOAE-_[50)NR26'G"?4')),$32PA/&KU8(Q5O8P*R8$(?Y;,(>+4 MODQNBBP@]P]\NR1+=2;=HS'9A+,I4@LG]/C>$ M`F8)\5M)*UMT$DTPNF/6=I4Z6WYLF.TLN>?;=#^O.I&KZKC._#G(HF;O2N]4 M\$7Y>(?'J^B=O<5=RNV=55&7CGOKKX#18W96+N%S*W^XS2/J#OK++YCU<3J` M/.$LN,ZDQ^E>_(_7#RU*.^Z=C0SB0CL[ M"I_P3^ME$+.U*XN$Y#-992@$'1YQUP#M'6>72,%@DPZ:N&.PE45,&'W%Q;_> M$0E.7I8DJZX[#@HL;7Y!Q%G#*\"U33YZ#J.QY:#$'MY((2:VR\GWSCR,W:F& ML7H@8B<4SR@O29*3D&_.DC)EIZ]S.\7NMM*&L^INW@6C-^R^@..>Q1\BLD#- M)!K!B'6M[5+4)QU,Z\8=OL?IP=Y=5=/@7/"V7P+MV-VN"KC[922XSC9AT>G\ M[:^T8]HN/!V_^A^X$[^F-:CM"LKS"M1J`0J%4B:`H%:AYE65MS6H80D*JKFE MT':\#MWB[+W.HJ$>^*Q7K2Y>Z'R.WFG%"=/R3MX&I1\Y*^GN%[&JG!Y(3(K5-&-VL'T\;$M$)&')CLC1CG+4 MEY"/&V,)9S200VO;?O@81H-+,8F)8:ODV;B2:2FS:QLPE@RC3,O5)3A?2$(>R\?:(*I]]>#MAX^T7+#WL,GH. MJ\KEX`!2G`.-\1-.=-7<$P!8SR(ZH!7-4BIHJKE[#*^2!6Q0JY@67U?%[6.` M53S&!K2*V>3-?"D#FT4Q>%6NQ`B\ZB\3FYIOI>!6_!@B\'KG:UELF+ MKHZ;IP!K>`0-:/W>:CE\"Y?!8VA0Z]?@=H!V-UZ-FZ%W+P"[%:_!G5!>5:6J M-*J MK@51)>GQ2Y>AO@<2\.I;!D]:W[6@Y_KN]E(8QW"Y*+P6T.)4C#*EOS&=)0*X M["4"N,:/.,C+C`<11==?)PVK+6R@"@L#JC/*2?Q'A>RV+(Y%(-9_5*,ANHG$,)RVGTH@A3O`\\-A'1 M0!IL!%;]C[^GD?65/12!5]=2?`"K>N#IVIUV&XK"JWHM3J!-P-9Z MIC/X$CF8E2\'":SFIV7F!%7/4FR&#)U>ZICE@K4/&6NE8;6`#52+Q+C^0\;- M9HME0-3;=]A#6/4O0:;<'L5DO(_MZ^P3?.\]XYH5/)G3+I%_?6$!*/6O1Z<* M"0S%??-_^O<0*+6O1Z;UN,;U74GMH5K.:R6K:Q=%$.-PZQJFSKV5+7'=!*(TR5;T=T4[/K'I,#9 M,B,Y/L8+$I)B'M+U7AFSS>''94:2^[&&K$4VMPJH(;=8&'$O?BN(N"3JC.^A MVCSJV4?5"Y"@Z(D^/)'M0QI'.,M/_BA'>QK44H":5P-NW%Q]T3^A2AC-BR(C M=V7!3M:C(D57`8R1RN0LEV&2BU?PT[Q@+.J`TJ'F^XQI&%&@DH8 M7IA,,[3\2CW5H(P+=,X,_=UG7;-+>#/\0*<:RH!NF+S`Q>7B-GBY8AEXTJ3O ML]VFE<>F;)_U34)KTRV41,Z#@>'AA+.'J'F4+A!]P1ZJ7P'+:9942U,E,E)H MQ`$UN`U*R:6.=LT(HOEVE((!R!QHC5.7?D&FZ*F342@9NQ/L&%=_GR57U??_ M>F$@ZVDF'4#=S1KJN+D:1?15H_HU.RI1:S?+)C"-5LTC5318_5G!1@]TXVG@ M6C9@/3%6)I#7[Q9B\>9AF)9T3+BJ$D+.DXC^)BM99D)MI'T]2Z!;>E(!+-N^ ML8EJHSSD5)M%_F/^="8_"O*'JRQ](A&./J]^RMGM<&W$8![2Y9.2`_;:@-I] M#=#"O$K]'V8#-4;0W0I]Q>S0)O\:=?&6SI:G]FTNVKQ-Y^$?)5:`-JWC5`3^R^K2E_W7?BIE\@ZQ0I)E64E`EYZC4\1S;OX)>+B[3` MS80OZR,J64`]P@AQW`2=`EO%&,I-'8#Y?&V2;H`VKCM6`+D3C6PLS9X#_T[%!/ MA%M"DJ4'J':>4Z9GV8HR\><@+B9Y"#)V MJSN.6"08)SD_Y#-GAQ7N^5>TSZM.I/:7Y\]!UN1CORR+O*!%I.6X*,>;JG?V M$D`,V5W9A*U(S,S^';.#^N]"O9>QF:$O5[\0\3?N-0GQZ0_=6_=0]=[73\!? M,#_E';1N9/V>KI/RT+,H, M?R$)>2P?FZ#O<4EKZSJ-J?H]&ZYNGU/I?J#U3`&BUZ8E4&\SK0SNH`L``00E#@``!#D!``#M75ESXSB2?M^(_0_7+;NZ MNJNF>R=UE%GD+E*28Q#^_&;T]>N.A."`ACJ<_O_GE_N#T_NSJZHV7 M9GX<^A&)T<]O8O+F;__[G__AT?_]]%\'!]XE1E'XT3LGP<%5/"%_]6[\&?KH M?48Q2OR,)'_U?O6CG/V&_/[I[IK^Y^IS'[UW;X]\[^``T-BO*`Y)\LO=U::Q MIRR;?SP\?'Y^?AN3A?],DG^E;P,":^Z>Y$F`-FTMXN3EZ_'1Z-W1AY.CKZ.C M_SMY^S*A/13Y%'R8C3CR\I_OE-1;_GD['QV-#G__4KDJ3X M8UJ(=TT"/RML2OD93UB"_=?!NM@!^]7!Z/C@9/3V)0W?K,$O$$Q(A.[0Q&/_ MIE:R^>J"1)B)D;Q0VY@=LC\?4HKR&8JSTSB\B#.<+1E?R:P0EZI0M/>4H,G/ M;YA='*SM@GWT+Y"ZV7).O23%LWE$(3EL+>4X<"/M,3BUNQ*1N9HB%&3CB?C.>MY:(&4\G1&9O,$/:$XQ0MT35(EE/HM MF=#AS$^?+B/RK"5NHU)7DEWBF/*(_>CU:RJY)%6ZDNHSHV M,][RV$+-F_8004!RVD7$TUM:(\!(3:16*UW)?A73OGN*'R-T MFJ:`CD94OBMY[E!$S26D?46V?$C\./6#PO]4#]X#$Q3<@(G1]QQE/H[2 M&P961F='.J.QJ&Z_'J:KP6ZMFO*X\GNZ+E>K9EBZ44OQ1CW)![8!:'US?1B0 M;V5%XQ(J.5?7-"XCF'=X"SV,#D`3@+<@DYFN?U/:1+$DOJ:_V*J"7C(4ARA< M-\0DWSD20W_-6BFC9B/OP%O7JO[HQZ&W:L*KME'*OI8^(L&6P!$+4I%$!=VO M-W>_?Y7)>OJ89@E=;ZP;BOQ'%!7-?V5U854/VPA;@EN$S5(4O)V2Q6&(\"&5 M_X3]P!0Y.3@:E4&SO]!??5W)<(>FF'TZSEB@DB,Y+T:A.G2>"1)$0) M96S=II\$6Y;0C/.5)0[G18#H('C"T<:()@F9Z4)9PD84BE31I2+T3L$9523Q MHROJ,R]_1TL9!XVB0!)&[K$@T-HL]'FBS?/2W2P!!/W8)=)Z.-K&^10DF M5(.0;:[(0:\5!:)_XB+Z7*UMT'!*I0F91)>1/^7#7RL"A/V=2[!SM;0!]UF> M,!4O<1KXT3^0GT@-7UP:2,+W+I&@TMW>P/L;BJ*_Q^0YOD=^2F(47J5ICA+9 M`"RL`F3FO4O,@%"P1\^O),HI@LGR$D-X6-G-'.=$H2Z<*A5A#(Q`?WF.!J;-$Y M7O?V[I^HYNDXSXHD*6HD4A>1U@.OZMSC!P*(S77':AJRFH=?TM\).C))<2@Y M3JVYE>K;YX1-#<&,5`I#^7!R.2Y0G"5M1:NU>%!K*0;)`#Q;P=]]R%;'>A5J%.A)XC^,;Q>J2L4K9`K(YD? M%24M=V%DCI)L>1OYJZGA'SF>LSG2#9+V9+):UF*_>AV:6G$W7*J>M$,%O'@) MHIPM5#\3$C[C*!)3!:MM+2BL0YD.$&Y0MYUQ+NH&+0:!]?N_;Z7CN\;^(V9+ M2018K'`+6PT2[[QDD>COB.^LSQ2]N+.6OS)%/7#4+.48(710:HCEO):]F+ M.VL3!%'?#:**A=]Y.=">T?]CZ#)75,E>.%J;)H#R;K"DXT2[N(ZQ(`2<$Y## M]#PU%,3>/[,4VCLT%XXWK%2]$)0*8T$)`!4\N1UU!Y`?P%$W%CQHY0#V+;\; MOHK=\"<248Q3%A#)ENJUD:P.E$TSR68[KY'4<+CA9K=K6RL$+FYND>Y"-`M# MB3(6@0!`W=B0$.GL!BF5_!(%(\V24#JZCRVTI4.DK1M M//@OTH"/7D/@W5=W"&V'E1M$GZ,%BDBQT7*?^5-T$6@(8; MQ/5M9T'N&(!0`>,BF:MC+Z=Y]D02_._7CEE%8K.>[=3)'$N:<7)5TW" MUG5L)UMV0M8V`.X2)3]E)U&PS3$[8YLBG5!F^'Q=)Y%:_?$-5-EV?M\NX=QA MC&R-TYR084U:R5IZ7P>^0PL4Y[(IUBSWQJ$3,#6)7[TI%+$D_G.&XN-&391R74HOI55:T'3-3$T#T%'*)MMN$ M3%":%ID3ETC6>39+VHZ'Z1(CTM4-)L:3"0[HM(UU%%2;K=N6.9TBM[3MH)$M1U(I.W0 M\R(VBKVF>@&(K!:V>N5DWW/#)DI#-X`;$I-M[4H35R\8`%7=.]7QZ_'0>^HQ?EI MGA2&)V)(7L=ZR+,=8Q`@AI\I6F1.KT"1C)[50M9/-6O3R=/BVQ@"5]H\^"\E M`I]0C"98,O`)*]B]D[.G\4X!EQO+DQN406:TM6+V#DSW.5_A03-T'Y:=7:&F M"HA^0QNP=Z:XSP6/'IQN^+Q(Z$N2(#R-5_<*!-7GD2E$Q7]%*_;"?^9I5M[: M5IQVNF77WM,_9%F"'_.,'8E_(*N\7'U+,B2&O5/1+6T%9FE&27/;7JOG[3JU M0'##U@]PF[$I36"'/B9R$%`?>956LGZ2?#>[```R=,XO_"2F*[ITG5?YR4]Q M(&9;4-SZN?3=>):"X$;?_QL=W)[8/&Q!IVM3=)//'E$RGE33^!34P5NP?BA] M-S9UH7(NC8Y=-7\9D6=!QMSW;3+F6)M>T:BUU+B-6IUEP_=JF+:>3Z-16T`P_M$33C9[;;&3)6+BW/>IZ MT2.K]_*LEX+I`[E#`8D#'*$M@1](9YYLYFNVD_`ZLQ.39+AA;N>(DA-@OXQ) MG,[8BO+?BGPR:27;B7Y&.:O?,Z,$SPV6UPL(%,(2!D7E;:<,]LBM'#(W:&7K M!G;5`EU'L#,YU`1_\Y,BO>"2)/
``I>/D+/+Q3#+*:S9C.Q^Q1R-H!;"A M#)EJ[U+*LUHW7L6GX:*4LA1)L';1:\)V>F,?/.NC8I3C9CX#*"]*7N^ MN(0"Z&"Z%<-`-]U*4>V^6`=!Y\B0'0<)E0V=H]6_*[J6MY"J%VTZ;=A. MD>QSL-:&UE63N-UZ65+'$.HUK2='G7W*@*K8<5B])J-Y-@]6V MGK%IP![$*'V+-@%YYTK'2F#M67\8QX#=Z"#9>D=]@9)'DB+[E@2/B7:Q[^/` MLSU=;A9H(C?T_`N!QE?Q`J4=[15*V[+WSE"ONX4`/-V8H=(>LIS!GP9_Y#A! MPI>"Q7:@TX;U%X]V((RTUOI;F;/`P>NBUW`@=[@S:]%'[AL=:2YQ[,=!-R.- MM"U[.<*]CC0`/!T9:1(2(!2FEQ2GU\V7RKUSD@%&7=5ZYN\.]#1NIX'A9&BC MHOI]T!:%K(+U1-W=:5&I:)2,]<=85$P`_W81Z[FTW0#.TWOXTZ?BW=*R_[\A M&4J5;X*+:UA_NJFS#D^%RO!YAT/5Q13(@8>=.K,-?>2&/FV^F$Q0D(TG%R_! MDQ]/T1TUX7',0&#G9>F_V+)RX4?,7\36HM>*O0>BNK:7-NBY,3WFRWB+$DS" M>H!;S+M>*U#>C27]=<9[&_2&WE,P9>66`&>X[W!;.X9W9FY>&`1=AB?9$/C[ M>@QGL.\06#L&F4:=<'@1.S"ON\_G\Z@(Z/C1.IYS%4](,EO1HW[\#=H`U`J& M$LS21,Z-(?J*O36+TNR6OQC?[$972T&),_>PBB;2]:WUILJND%'>\L36BSBD MO90T-:)1%DJ,N==4=B1&I+X;]*PUNB%Q0']\W>>(0\[(<8[3("(LK5/=9^[> M,O@8TT`ZTZZP-A3#K(2N5\GWER0Y1X_B4]BBXE#>C(6\.@.:0-05DM+_;0&E M=G[T:J<;^;;N"GCO'7BO>F]=%K!IHW)30)?W`12APP?"$55Q[!]2T>JIX;#@ MPX\V$E:&B5>P'RBKGR+I/EJ+IFR>[8:_M>9L&]\ZD#H/(&`&X%;3^ M(!U,#QPG7(TN^OUXBEGB_/:9BRVG^E!WJM=J7EEO[SN0F-(6UEKC$:CR(+U& M`Q8G7.8.16P9?^LG6?4J6+[KC([JKE-6]XKZWE8#>Q\"I-7PP=?R):U&!NE3 M+6!RPK=XJ8];[C1J!AU8#6]59>]`Z@EW491 M/"Q1K+-0+`P*C$YXHT;90OG*>[6-;]KX.[O/742!UEBBV\ZPG*JED@ZYVGW^ MF*(_N?,0=!QA$=^\CZ84%AU:S>7=\^L#EYN M4%Q_\09,KK*BM3O).Z<5B)$;A(J?OTNWW[^#^_$.35J[O+QS(]@95S?,XP8] M5R!(2$Q_#%:S_97<8*O0;\G:)>:=&T-;%)U8$-6W1-MK()?"^ M6]7O='7#%U&QBE%5LADL")Y0F$>;2\U9.G(AXVE6WH2.PE_]*`=MZ+1HR^:J M!\9E/;30&C`WNMFU_&1RB6.UD)5VB[$07S=G;D732C:SCS2:A_[I):*2?%LBIZ*B5M1QPW/*9R,9C-.4I MDJ6NB^JV9[/'!K(J[K);(.=6MRW2H4@V*#'IVA(@;5OMHLV8!1Q2)WIFR>Z@ MK(MN)+I+][2-]-5*R96/L(+K6_3@S0W1U^Q&D70\N49T%J"7,J73AMTG5C49 MK;]VKXV5$RY8/89UCC(?1^D-ZYK8*S1\[VMDQ&\=R_*^*UOQ-LUTZG@R>14^ M!ZOZK;YI:\1I=-C0?,&VBU<*7-T?!SG:<2-_7F>?W*P7ME.SDXUS)SUWD^7Q M(+_HLEY.Y;L-K[`5RM5T[KJ>U5>:7*").CJZHC]*>EE>635:'5--YCNP8-`9E-%YG6:V>7!A//R MF^MPR1T2)8`(A*FS]07>@058/),@5'_YK7A>S>426"%4B5D)NUYDCXBK6 MGW779%BM43>!7*!7O08AM?RK6)H(##>"ZORLN-/LC$J_I)U\L8^K MFT78J&XM-"Z9O7(]2`L.F[TFT!.!GF!(8$A M[8;\U35MDP=>L4)!<)ZRTR#(9WEQV58U'[@5B<*VW%_F[J#<0(B6/CJAJN?^ M>AFHB/MKY1%_L=RX]4J\6/9&?2R71^W6RR,G%LPR/V^>BKBAW#X\HVB!OI`X M>VHWPH':=>E0DHAGC2X3#J7SW2='EW\@/WEX)EU9PZ8YIPX=&;&"&G*#)9]^ M7A)M:]V@U=L?^C.`*GI#-8%+DDN6IFW;LWI/1&\&4,5NL/Q7\GX[X;]HS^H5 M$?WQ7\V9=GA&KDCP;MS-*9F9F\GC5LG=;J:^S\TVZU#[+&P'8NM#W^NZ8P_' MRW>R*D4&A'E%:C=VH0J!5'L16X7<0+MA(3R@UR([L>_SA7H;2UNK#_!UB^WOLEI[U[3S7>,*; MN?#F"*+*M@*$6GEK>DBXX0'5-$SCJ*K MV=S'2:&==.-95'XP^Y)RA0UU:-L6<4WB:<16]X5!C.-[NF;!TZ="]$]^RIV! MLF:T6[$]D,/ZN);@.!'G:"812_-T&X\C\![<,9.J*Y14^SJM?;JNH0N/]@F[ MUI=X0P]B;$1;/5;&3KV2N#@!)`UL**H-D1N^)FX$0&JRJ9)M!<4=8T5F*V9[;2*UJ!KZ7`W=6(V<):B`[)S:E+S':I9TS!UDG513 M^,KRR"+\YVCBYU'&>:N)2:IR"5AM-V@2&5J-*)A*AFYZH%]X>";R`^C;96SW M0CKVLW4JEJ>JJ:/^[%LL7T8-;+64[?C&3M`VU34(+LM%46);+60[2K$+M$UE M32*+%VJKK1:RO:NP$[(-90TB>X]?E,!6RMB^U6,77!NJFH05+9#X%IN-1-52 M0&C?.PEM4UV#X%ZPJ*@2W*U20'!_ MQD9793C)$*3CK16$@NSD"H*OM>'U&0CF>D$HS&XN)[A:&UVL36`H;Y>#@NSD MVH*KL]EE&PCC6CDHQFXN,G@ZFU[#P5"NEX3B[.1Z0Z"WZ04=!.AZ02C.3BX_ M^%J[L1WU)SH2<+(_$K`_$E`1O-V1`&,]S/Y(@`CR#W^.(P&"5Q]9)L.TZ.X^ M+5^+W/I+]JO39S\)UVEVXSQ+,S\.<3R]R24#K(D/#>*H@3F$!V`2OZ%B&A*> M+E#B3]'%"TH"G*+;!`>B*-"-9&*=L9`C!`!U>[V*'*W MTJG8*N&*6@*.4QP4KP.(:#'Z1=NI"AI]G%G0W3[6(KA2[WNM%7:9K3+Z,Q(*F& M4];VLG*770.AZ@;W9];?A"3E<\K:GN%V`7>?2?J;;X*2];FEAYSO*%&_!]!! M2?R\PK8W"KJ`O->D?O91Q#X*2>[G%1YT#I]8^PKDSKQ-6!$8^$.MH M8&F;*%=NI4,R6=<]2O>?P-L0*.9-]L]-T//G.T;$?LVK)%W*QCJ M^$5MKR_;9]TZS,IV3JN`CWHAV\O.-NFZ+G#08>_>)D>U[$JT\H*KW9>A;]K. MF]#KPXT"W[%Q.I17K'@8\+U>?K&9MP%O2(;2!\+9IU#D&4,J=KIV1`E>%/I? M8_\14QJ6=RAE'PT%$DIKV)KQ0Z'CK"+5`!A:MG^FZ]JKF/-]`?"2\M;FKNUQ M5VIO"/5-!TI'=*&-UPM9FR^VQY>OIQ,G1NB0-\/92H,X9+-IEG%/)RTZN< MCZ3G.3K+$V:^XMF>;CLV!Q!];FNSNG:@N;&%!93]*KXC$?WXM'A+_IGLS'RS M0:N#65\V(,)Q^&M*(``/3RA!_B23A:1;-&5UI.[+>)K8:8WKY5_8/]CZDO[F M_P%02P,$%`````@`!&QF11UI6^GF"@``"'$``!$`'`!V;G)X+3(P,30P.3,P M+GAS9%54"0`#J+Y;5*B^6U1U>`L``00E#@``!#D!``#M75MOVS@6?MX%]C]H M#2S0Q<*QE;2=22;I(&DN:R"-L[';:>>EH"7:(2J1#DDY]OSZ):F+=:$HV4VV MG'7Z4+@\%W[G'/+P4"+5XU^78>`L(&6(X)..N]?O.!![Q$=X=M+Y..J>CMX/ M!AWGUW=_^ZLC_AS_O=MU+A$,_"/GG'C=`9Z27YP;$,(CYPIB2`$G]!?G$P@B MV4(^G]U=BW_&^H^W_YV!O.16XSP$75$GXQ_ZYZXJ_ M^F_'???(W3]Z_;9E3QSPB&4]]9?]Y$\[\0^(>9GPOQ[(&_;3\@Y]G@WQS]&_ M)Y\';`@>SA_`T%_]?K8:P6]+=N6NIN/P8;'Z\LW[\N'^P^CAX(]E?W_P^\5U MW.4Q\^YA"!P1:P)IJ[@@A1YF5RS4%%`8)#->G2*HD'WZ>;ND\`!@3,5T$1](B MV^9S).:#:/C+L1PX1]*O8X'>D3]$0JC3+LD],9TBB?04^Q>8([Z2X)]B`5&^8N)_GQ!\YU$I1/K?'$U9[>`"LON(4<"K\;O M1;HY"`?;!,%Y5>CBGSL:E,QO;#@=SF5!)!B8R#;O22@LO1=^1`MX35@R.3;@ M-P?M=;N@K?MSR-19]ZBR6*%/1W;JO(HPB'PD1%\B.IR^!^S^,B"/FN"M2>8X MO=DF3E*YH[2_!*1WB;#(.P@$:Q_%X=`1S,%X*]=Q47('A$44%J*1*@H"D-`5\/I",VPJ*(]("I2SR.1 M*"/Q[%9(>`BF2:8=KSD*/Y>CD&B5R26GUUDK=E+-.QJB@;`$S]`D@*>,9;5L MI=7L]L.RV]?R3JQ@1[U[!P.YS(F2D:_&%&`&/%6&Q%ZNI1J][?;+WD[T.$J1 MD]>THVX7!5Y(\(@3[UOLZ7R#V;EN=:F4HHZ2W5%W_@:H&%-6[\:MK- MSMTO.S?5X`@53J)C1YTLQQGBJOY2VR*U.D&\7B!-#&:W'^C&=*(JV1#EE.VH M_T?1A,&'2!ATL5C7VI56LZ=?5^N/5-Z)%>RL=]M4=]M4A.TJ0_?-]I6A\RK] MM:M;T7(Y.`;B9TVIF-#,T:AL2"L%H_,J5K2K+J^NK7FGUU+-;J]L4K/U%ZS7 MWUWWO&&=S8>@F;`5+;1 MF@4^T?3B]8)C7:/;W0:_5W;8]7YWW!?/%WQ;2EB-7.9(5#;=ADCL?`:JUK.% M'%1/-L>@LAW7/6_:^414ZUVWP?M-R:BRYS:Z?W?S4:V#2QFI!9\Y()5MMSD@ M.Y^6#'N\0GYJP6<.3&5CWK`9_/_+6/(O>7KV#DX==>KV2)[E/.DP%,X#>496 MM=U3.#WIR'/-W>QYYUDC##A+6[X33?5$__9PE*XM\+2X MS-!FI.0E;V)!.50.Y5!QWWXGF.V`-*%(;D2H(D?>H?AZCH)(5H354O0##">0 M=A1BD3.:^5`0R$?:)QU.(YERY'69(Y&*$/''*F/Z$4UN-,09-+YBL\.K;-GS<(:^91H=4*G.-'&.AF?*G="JP7@7XZE=JMP#J^1Y1#[5`M4ZS` M*U#X:ZM:66X\?C+^U[S;MBBW#GQ[)V M#Z>E6H,;&F=HA6H5;NT>3T>T!C4PYY4JV2[D=?XN$ZU`K1Q94U552%8@5IMI M+>`*Q0J\A2%K+`8K'-;@EZFBYMF&GOSCD1N^4',J=%+@\D M26S^2<>CT$>\"#XD&')`5_^3:!6^_+)YZ&K$K8NCUI+V'W#YF'ZXHY6'ODNO M=:Y3@YW=00\*T'YA"N1;-X!9F@,^G#SC%+@2J7V(SP60A3KW=2?H0)Y(DFR9 M-0U,MAK7./RR3]ML/X)-*JP;K*Q!X)H7[FMN#;WL1G7L]DSFR=PDDN>M71;PW%#.&1C MHOG@5GEE:,-IW0*@N44,E_PL4)]-B>TRLVR[B>2ICB. M_D1N*;_QJGL3]AU0[P&%["E*2K&$"S>#(%C5GU[-JLN6S#_:J)I+K$WK0H7- MNH%5=S^ZI67NG\^TVJ31GM]Z4\7V$R`L="?/&:!_C::PSM!:[BW-2EN?_-G* M-<&S0&X]%>ZAV`11(-_&7",,SP!#-8]7VHC]>%-K;Z4V%VGVIYF13,3"UU`] MCX:8Q>^9FRC_:NY9-+=_M_(L MJ\U3VO0;5"^+_=,%I&`&+Y:0>HC!6XH\^!P^;.AO4\_*;:X@J^Z?YN&UFA@1 M"&2.^P(!E=?SL\?26N*/SPT7RSF*E>I_.'(+P_79NMCZO>KS/D.K_WI$Z_7!YF)--_=,\]+" M::F?E=\W*9]BZYB]E+A&8(("Q%=WD,GGJMFC<3.+K0<-Y`O4`=9@S[]AK6.P M]O%_,F75(%I'J-)J+?[F;WAL\$3.IL+VN!??"18__PM02P$"'@,4````"``$ M;&9%'[8G!3];```@^@4`$0`8```````!````I($`````=FYR>"TR,#$T,#DS M,"YX;6Q55`4``ZB^6U1U>`L``00E#@``!#D!``!02P$"'@,4````"``$;&9% M\`KNCRH+``#K@0``%0`8```````!````I(&*6P``=FYR>"TR,#$T,#DS,%]C M86PN>&UL550%``.HOEM4=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`!&QF M11OK:H]^#0``,L,``!4`&````````0```*2!`V<``'9N`Q0````(``1L M9D5"=!,9-"P``$N!`@`5`!@```````$```"D@=!T``!V;G)X+3(P,30P.3,P M7VQA8BYX;6Q55`4``ZB^6U1U>`L``00E#@``!#D!``!02P$"'@,4````"``$ M;&9%@%&@^Z,:``!%M`$`%0`8```````!````I(%3H0``=FYR>"TR,#$T,#DS M,%]P&UL550%``.HOEM4=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` M!&QF11UI6^GF"@``"'$``!$`&````````0```*2!1;P``'9N'-D550%``.HOEM4=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(` '`';'```````` ` end XML 44 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 95 132 1 false 34 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://volitionrx.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://volitionrx.com/role/BalanceSheets Condensed Consolidated Balance Sheets false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://volitionrx.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Sheet http://volitionrx.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://volitionrx.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (unaudited) false false R6.htm 00000006 - Disclosure - Condensed Financial Statements Sheet http://volitionrx.com/role/FinancialStatements Condensed Financial Statements false false R7.htm 00000007 - Disclosure - Going Concern Sheet http://volitionrx.com/role/GoingConcern Going Concern false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://volitionrx.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R9.htm 00000009 - Disclosure - Intangible Assets Sheet http://volitionrx.com/role/IntangibleAssets Intangible Assets false false R10.htm 00000010 - Disclosure - Related Party Transactions Sheet http://volitionrx.com/role/RelatedPartyTransactions Related Party Transactions false false R11.htm 00000011 - Disclosure - Common Stock Sheet http://volitionrx.com/role/CommonStock Common Stock false false R12.htm 00000012 - Disclosure - Warrants And Options Sheet http://volitionrx.com/role/WarrantsAndOptions Warrants And Options false false R13.htm 00000013 - Disclosure - Commitments and Contingencies Sheet http://volitionrx.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R14.htm 00000014 - Disclosure - Subsequent Events Sheet http://volitionrx.com/role/SubsequentEvents Subsequent Events false false R15.htm 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://volitionrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) false false R16.htm 00000016 - Disclosure - Intangible Assets (Tables) Sheet http://volitionrx.com/role/IntangibleAssetsTables Intangible Assets (Tables) false false R17.htm 00000017 - Disclosure - Warrants and Options (Tables) Sheet http://volitionrx.com/role/WarrantsAndOptionsTables Warrants and Options (Tables) false false R18.htm 00000018 - Disclosure - Commitments and Contingencies (Tables) Sheet http://volitionrx.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) false false R19.htm 00000019 - Disclosure - Going Concern (Details Narrative) Sheet http://volitionrx.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://volitionrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) false false R21.htm 00000021 - Disclosure - Intangible Assets (Details) Sheet http://volitionrx.com/role/IntangibleAssetsDetails Intangible Assets (Details) false false R22.htm 00000022 - Disclosure - Intangible Assets (Details 1) Sheet http://volitionrx.com/role/IntangibleAssetsDetails1 Intangible Assets (Details 1) false false R23.htm 00000023 - Disclosure - Intangible Assets (Details Narrative) Sheet http://volitionrx.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) false false R24.htm 00000024 - Disclosure - Warrants And Options (Details) Sheet http://volitionrx.com/role/WarrantsAndOptionsDetails Warrants And Options (Details) false false R25.htm 00000025 - Disclosure - Warrants And Options (Details 1) Sheet http://volitionrx.com/role/WarrantsAndOptionsDetails1 Warrants And Options (Details 1) false false R26.htm 00000026 - Disclosure - Warrants And Options (Details Narrative) Sheet http://volitionrx.com/role/WarrantsAndOptionsDetailsNarrative Warrants And Options (Details Narrative) false false R27.htm 00000027 - Disclosure - Commitments and Contingencies (Details) Sheet http://volitionrx.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) false false All Reports Book All Reports Process Flow-Through: 00000002 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Process Flow-Through: Removing column '50 Months Ended Sep. 30, 2014' Process Flow-Through: 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Process Flow-Through: Removing column '50 Months Ended Sep. 30, 2014' vnrx-20140930.xml vnrx-20140930.xsd vnrx-20140930_cal.xml vnrx-20140930_def.xml vnrx-20140930_lab.xml vnrx-20140930_pre.xml true true XML 45 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Details Narrative) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dilutive Warrants [Member]

Sep. 30, 2014

Potentially dilutive warrants and options [Member]

Sep. 30, 2014

Potentially dilutive warrants and options [Member]

Sep. 30, 2014

Dilutive Warrants [Member]

Cash and Cash Equivalents $ 2,419,667 $ 888,704

Dilutive warrants 543,275 592,204

Potentially dilutive warrants and options 2,357,275 2,112,995

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Dilutive warrants.

+ References

No definition available.

+ Details

Name: VNRX_DilutiveWarrants

Namespace Prefix: VNRX_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Potentially dilutive warrants and options.

+ References

No definition available.

+ Details

Name: VNRX_PotentiallyDilutiveWarrantsAndOptions

Namespace Prefix: VNRX_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
ASSETS
Cash	$ 2,419,667	$ 888,704
Prepaid expenses	133,848	82,135
Other current assets	117,409	34,612
Total Current Assets	2,670,924	1,005,451
Property and equipment, net	315,777	63,265
Intangible assets, net	862,753	1,002,043
Total Assets	3,849,454	2,070,759
LIABILITIES
Accounts payable and accrued liabilities	693,646	518,086
Management and directors' fees payable	240,978	222,294
Derivative liability	6,446,068
Deferred grant income	199,862	216,894
Total Current Liabilities	7,580,554	957,274
Grant repayable	367,112	432,811
Total Liabilities	7,947,666	1,390,085
STOCKHOLDERS' (DEFICIT) EQUITY
Preferred Stock Authorized: 1,000,000 shares of preferred stock, at $0.001 par value Issued and outstanding: Nil shares and Nil shares, respectively
Common Stock Authorized: 100,000,000 shares of common stock, at $0.001 par value Issued and outstanding: 14,308,960 shares and 11,679,757 shares, respectively	14,309	11,680
Additional paid-in capital	14,548,494	12,024,711
Accumulated other comprehensive loss	(93,526)	(59,795)
Accumulated Deficit	(18,567,489)	(11,295,922)
Total Stockholders' (Deficit) Equity	(4,098,212)	680,674
Total Liabilities and Stockholders' (Deficit) Equity	$ 3,849,454	$ 2,070,759

Intangible Assets (Details 1) (USD $)	Sep. 30, 2014
Intangible Assets Details 1
2014 - Remaining	$ 22,721
2015	90,882
2016	90,882
2017	90,882
2018	$ 90,882

Warrants And Options (Details) (Warrant [Member], USD $)	9 Months Ended
	Sep. 30, 2014
On 03/15/11 [Member]
Number Outstanding	200,000
Exercise Price	$ 0.50
Contractual Life (Years)	5 years
Expiration Date	2016-03-15
Value if Exercised	$ 100,000
On 03/24/11 [Member]
Number Outstanding	100,000
Exercise Price	$ 0.50
Contractual Life (Years)	5 years
Expiration Date	2016-03-24
Value if Exercised	50,000
On 04/01/11 [Member]
Number Outstanding	100,000
Exercise Price	$ 0.50
Contractual Life (Years)	5 years
Expiration Date	2016-04-01
Value if Exercised	50,000
On 06/21/11 [Member]
Number Outstanding	100,000
Exercise Price	$ 0.50
Contractual Life (Years)	5 years
Expiration Date	2016-06-21
Value if Exercised	50,000
On 07/13/11 [Member]
Number Outstanding	250,000
Exercise Price	$ 1.05
Contractual Life (Years)	5 years
Expiration Date	2016-07-13
Value if Exercised	262,500
On 05/11/12 [Member]
Number Outstanding	344,059
Exercise Price	$ 2.60
Contractual Life (Years)	4 years
Expiration Date	2016-05-10
Value if Exercised	894,553
On 05/11/12 One [Member]
Number Outstanding	26,685
Exercise Price	$ 1.75
Contractual Life (Years)	3 years
Expiration Date	2015-05-10
Value if Exercised	46,699
On 03/20/13 [Member] \| Minimum [Member]
Number Outstanding	200,000
Exercise Price	$ 2.47
Contractual Life (Years)	3 years
Expiration Date	2016-03-20
Value if Exercised	494,000
On 03/20/13 [Member] \| Maximum [Member]
Expiration Date	2019-12-20
On 06/10/13 [Member]
Number Outstanding	29,750
Exercise Price	$ 2.00
Contractual Life (Years)	5 years 6 months
Expiration Date	2018-12-10
Value if Exercised	59,500
On 08/07/13 [Member]
Number Outstanding	45,000
Exercise Price	$ 2.40
Contractual Life (Years)	3 years
Expiration Date	2016-08-07
Value if Exercised	108,000
On 11/25/13 [Member]
Number Outstanding	456,063
Exercise Price	$ 2.40
Contractual Life (Years)	5 years
Expiration Date	2018-11-25
Value if Exercised	1,094,551
On 12/31/13 [Member]
Number Outstanding	64,392
Exercise Price	$ 2.40
Contractual Life (Years)	5 years
Expiration Date	2018-12-31
Value if Exercised	154,541
On 01/28/14 [Member]
Number Outstanding	10,000
Exercise Price	$ 2.40
Contractual Life (Years)	3 years
Expiration Date	2017-01-28
Value if Exercised	24,000
On 02/26/14 [Member]
Number Outstanding	1,530,975
Exercise Price	$ 2.20
Contractual Life (Years)	5 years
Expiration Date	2019-02-26
Value if Exercised	3,368,145
On 09/05/14 [Member]
Number Outstanding	10,000
Exercise Price	$ 2.40
Contractual Life (Years)	3 years
Expiration Date	2017-09-05
Value if Exercised	24,000
On 09/26/14 [Member]
Number Outstanding	24,000
Exercise Price	$ 3.00
Contractual Life (Years)	3 years
Expiration Date	2017-09-26
Value if Exercised	72,000
On 09/30/14 [Member]
Number Outstanding	3,490,924
Exercise Price	$ 1.96
Contractual Life (Years)	4 years 8 months 12 days
Value if Exercised	$ 6,852,489

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
STOCKHOLDERS' (DEFICIT) EQUITY
Preferred Stock, par value	$ 0.001	$ 0.001
Peferred Stock, shares authorized	1,000,000	1,000,000
Preferred Stock, shares issued
Preferred Stock, shares outstanding
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	14,308,960	11,679,757
Common Stock, shares outstanding	14,308,960	11,679,757

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014	Nov. 06, 2014
Document And Entity Information
Entity Registrant Name	VOLITIONRX LTD
Entity Central Index Key	0000093314
Document Type	10-Q
Document Period End Date	Sep. 30, 2014
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		14,450,717
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2014

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Condensed Consolidated Statements Of Operations And Comprehensive Loss
Revenue	$ 14,785		$ 14,785
Expenses
General and administrative	129,318	67,961	249,986	242,660
Professional fees	119,510	153,226	412,532	310,585
Salaries and office administrative fees	457,355	179,846	670,518	569,238
Research and development	1,071,984	524,534	2,733,742	1,758,372
Total Operating Expenses	1,778,167	925,567	4,066,778	2,880,855
Net Operating Loss	(1,763,382)	(925,567)	(4,051,993)	(2,880,855)
Other Income
Grants received			143,987
Loss on derivative remeasurement	(4,130,562)		(3,363,561)
Net Other Expenses	(4,130,562)		(3,219,574)
Provision for income taxes
Net Loss	(5,893,944)	(925,567)	(7,271,567)	(2,880,855)
Other Comprehensive Loss
Foreign currency translation adjustments	(19,893)	(6,478)	(33,731)	(18,336)
Total Other Comprehensive Loss	(19,893)	(6,478)	(33,731)	(18,336)
Net Comprehensive Loss	$ (5,913,837)	$ (932,045)	$ (7,305,298)	$ (2,899,191)
Net Loss per Share - Basic and Diluted	$ (0.44)	$ (0.08)	$ (0.56)	$ (0.27)
Weighted Average Shares Outstanding - Basic and Diluted	13,524,998	11,086,237	13,057,866	10,649,152

Intangible Assets (Details Narrative) (USD $)	9 Months Ended	12 Months Ended
Intangible Assets (Details Narrative) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Amortization expense	$ 72,646	$ 114,879
Impairment loss	$ 0	$ 350,000
Minimum [Member]
Intangible Assets Remaining amortized life	9 years
Amortization of long-lived asset on straight line basis	13 years
Maximum [Member]
Intangible Assets Remaining amortized life	17 years
Amortization of long-lived asset on straight line basis	20 years

Going Concern (Details Narrative) (USD $)	3 Months Ended		9 Months Ended		50 Months Ended
Going Concern (Details Narrative) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
Going Concern Details Narrative
Net Loss	$ (5,893,944)	$ (925,567)	$ (7,271,567)	$ (2,880,855)	$ (18,661,015)

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2014
Summary Of Significant Accounting Policies Policies
Use of Estimates	The preparation of financial statements in conformity with US generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Principles of Consolidation	The accompanying condensed consolidated financial statements for the period ended September 30, 2014 include the accounts of the Company and its wholly-owned subsidiaries, Singapore Volition Pte Ltd, Belgian Volition SA, and Hypergenomics Pte. Ltd. All significant intercompany balances and transactions have been eliminated in consolidation.
Cash and Cash Equivalents	The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As at September 30, 2014 and December 31, 2013, the Company had $2,419,667 and $888,704, respectively in cash and cash equivalents.
Basic and Diluted Net Income (Loss) Per Share	The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. For the three months ended September 30, 2014, 543,275 dilutive warrants and 2,357,275 potentially dilutive warrants and options were excluded from the Diluted EPS calculation as their effect is anti dilutive. For the nine months ended September 30, 2014, 592,204 dilutive warrants and 2,112,995 potentially dilutive warrants and options were excluded from the Diluted EPS calculation as their effect is anti dilutive.
Foreign Currency Translation	The Company’s functional currency is the Euro and its reporting currency is the United States dollar. Management has adopted ASC 830-20, “Foreign Currency Matters – Foreign Currency Transactions”. All assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. For revenues and expenses, the weighted average exchange rate for the period is used. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in other comprehensive loss.
Recent Accounting Pronouncements	Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s consolidated financial statements. The Company has limited operations and is considered to be in the development stage. In the quarterly period ended September 30, 2014, the Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the Company to remove the inception to date information and all references to the development stage.

Intangible Assets (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Cost	$ 1,219,969	$ 1,314,559
Accumulated Amortization	357,216	312,516
Net Carrying Value	862,753	1,002,043
Patents [Member]
Cost	1,219,969	1,314,559
Accumulated Amortization	357,216	312,516
Net Carrying Value	$ 862,753	$ 1,002,043

Warrants And Options (Details Narrative) (USD $)	3 Months Ended	9 Months Ended
Warrants And Options (Details Narrative) (USD $)	Sep. 30, 2014	Sep. 30, 2014
Notes to Financial Statements
Derivative liability restated	$ 6,446,068	$ 6,446,068
Loss on derivative liability	4,130,562
Options expired		$ 10,000

Condensed Consolidated Statements of Cash Flows (unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Operating Activities
Net loss	$ (7,271,567)	$ (2,880,855)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	99,904	109,044
Stock based compensation	311,907	236,966
Common stock and warrants issued to settle liabilities for services	403,483	348,172
Amortization of stock issued in advance of services		52,500
Non-operating income - grants received	(143,987)
Loss on derivative re-measurement	3,363,561
Changes in operating assets and liabilities:
Prepaid expenses	(61,483)	(81,965)
Other current assets	(88,422)	7,292
Accounts payable and accrued liabilities	238,446	(166,093)
Net Cash Used In Operating Activities	(3,148,158)	(2,374,939)
Investing Activities
Purchases of property and equipment	(297,607)	(713)
Net Cash Used in Investing Activities	(297,607)	(713)
Financing Activities
Proceeds from issuance of common shares	4,893,529	1,871,500
Grants received	143,987	605,154
Grants repaid	(33,166)
Repayment of notes payable		(1,321)
Net Cash Provided By Financing Activities	5,004,350	2,475,333
Effect of foreign exchange on cash	(27,622)	(2,627)
Increase in Cash	1,530,963	97,054
Cash - Beginning of Period	888,704	376,421
Cash - End of Period	2,419,667	473,475
Supplemental Disclosures of Cash Flow Information
Interest paid	10,274
Income tax paid
Non Cash Financing Activities::
Common stock issued for debt		$ 77,333

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2014
Notes to Financial Statements
Note 5. Related Party Transactions	The Company contracts with a related party to rent office space, be provided with office support staff, and have consultancy services provided on behalf of the Company. See Note 8 for obligation under the contract.

Commitments and Contingencies (Details) (USD $)	Sep. 30, 2014
Commitments And Contingencies Details
2014	$ 84,251
2015	2,458
Thereafter

Summary of Significant Accounting Policies (Details Narrative) (USD $)			3 Months Ended		9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014 Dilutive Warrants [Member]	Sep. 30, 2014 Potentially dilutive warrants and options [Member]	Sep. 30, 2014 Potentially dilutive warrants and options [Member]	Sep. 30, 2014 Dilutive Warrants [Member]
Cash and Cash Equivalents	$ 2,419,667	$ 888,704
Dilutive warrants			543,275			592,204
Potentially dilutive warrants and options				2,357,275	2,112,995